var title_f41_54_42848="Lymphoblasts FAB L2";
var content_f41_54_42848=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F65474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F65474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lymphoblasts in acute lymphoblastic leukemia FAB L-2 morphologic type",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 239px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADvAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDro1eacyEMsZOcnjj/AA/pVGVbe91+N40AMS+Wsit374x0qjP4gl1C5W0tIzDbkkNJ/F1/T1rb0PRhDHmMiZVJJbHauVRtrI974Vdnc6dcPchI5X/hwc9+O9W0tzE4cHPfntWfYcuGwQAOcHpWvvKv0wBz/nNZ7Hny3LEbGTk9QMk56fXNTg4+b8sc5+gqlZPvLLjgZyCPwqzgMB5mW7/WnsZssLnOByQcdKecFWHJBGOOuKiVfmyP4utKpYcEhiOMgdfemIr65ObfR7uRmJXGPlTPU46Dtz1+tcvp4AYKG+XhRg/17kV2q7WDggGNgQcdSOlcRqdlNo11zlrcn93IemPQn8ae6NqLWqOrsGUg9Bxzj/P+eavzEMCoOQBnGa4q31fywpVjgcZB6f8A16sSa55keEIbkEj60IHSdx+tTrGrHIzjjJ61ueEYfs2iGVlIMpMhHQisLTtKk1ibzLlSluCDk/xY7Cuz8lDamBPlTYUAB6DFHUVWStynnSObq/nlc7izE5znv/hXZaRZqIlJwSeR61xNuGtr+WCY7ZI3II/rXcaPcDygGI3d6dtWaVfhVjQa1iki2uuV7hhkH2rA1m0WLLAKM9gOK6JpUVcsRiuX8Q3Bnh2qxBBB68n/AD6mm9DGjzcxX8ISfZ/EM0IOFliPHTkHj+td0+CCCAR3BrhfBdq8mtSXDtzDFtxjHWu5z83NUnoRifj0MXVtBtZoria3V4pyhJERxuOMDj1/KoNP0HTsp5cskkajAiPAAHQEY4PPQ85z710KsGyVIPUHHr6UuPXNOxCqyStcZBDHAmyGNI1JzhRjJqTNIKMe+aDMM849KM4/CjH0ox+VFgEJ/Kk4YZIGMd6VsDOeOOvpSJ8yBsH5ucUdQM/xBK0GlS7eGchOvrXN6dB5hVgpIJ/E/h+tb3ipN2lYwf8AWKTgfrWZobLvVSOPQ59/84qXuddHSm2dJBBHCigKuehOKSdVMZB6EdCP51PjOCKzdVuxCjIG+bHGT0FM543lI5LUdp837u3oe2K6zw6x/sO03clUxz6dv0rCstNfUpCHLRwDlmxg/St2TUtO0yJLc3CjaMKinJFCWh0VndKK1ZePToR75pM9MisgeJdN6sZcf3tmPxq/ZX1nfKfslykpHUKefyocWYuLW6Js84GaYW5xwQByfTmpWXHBHQVCkAXIBOSMUhGJ4vuDHpiouf3jYIB61k+HbeNpFZgpGBjjAra8XW/naXvxnym3cHtXO6ZM8T+YM+5PShPU6KavDQ6+THG3HA4//XUL7XGJEDDoRiq9vfRyRLukGTzjP41aCCSPdlc4z26fy9fyoMmmjkdd05YW3KuEYenFZXhndH4jHlnCPCwYAcduldD4kmB+TIPXqep/rWb4Qt99/cXTZwq+Wp9c046XNr+5qa+qTx2dtLPMQEQEAe+M4orm/H12zzw2iN8oGWyepoqWx06aauzltG04I6mQDPJBx1/z/Wuz0e3S0l2FsxMASvQf/qqTQLSFcyzrjb0B7fhVyYxSyqYFwu7B44H+eaJb2NalXndi5CEjkk2fMhORRuG8/PuXHABx9ce3vT5YhtUx8noTmkySQoz7/XvWSRzklsNhyFxng4OOa0EweRn5j+J+v51QhUAAj0Jx0zV+IfKM5wT0qrEyFAYyEkLtxxipQBkcfTikIORz17nv7VJjBPQY5x1oSJAZyoyM9s9Py604qroUkVXQj7rcigehHvg8inhedxz8vQk4xVCM1tA02Rt8lum7+Iqdo+mB6U5X0WyOFNsjDngZ4H/6qw9f1WW8na2tdywr8rHoW9qqWmnJ1EeG7nPU9s0Wsbxg2ryZ19tq+mzlUivYAT0XO3P0zWkoI+ZeR6jmuHm0pCnzoOeMkUunapdaJMqOzTWZOGVuSnuD/SmrEyo3Xusu+MNFlmf+0rCLzJQuJEX7xA6EeprA07VwVBU4BxnjHtz6V6ZG6vEkkZDIyhgc9R61laj4e0y+lMksGyXu8R2mi1wp17Llkc42pFgN0oLeh+lRwF7+UR2qNIfboM9z+fWtxfCFgH4knK/3d1X76W30TTx9nhRWPCKOMn1NVZsp1o7QWpBYC20Cx2Sn/SX+ZlByx+ntWDfX13qrNueWKE9I1449zTkEly5dyWYnLMT/AJwK6Gw0pI03Oqhsc554ob6ILRp+9LVnJfYHjYy+bNG7YOQxHI74Her1lreo6Y4N832uz/iIGXQeoPeutazjePbtGKwNZslj3gLheoBxjHf/AD7U7tAqkanutHT280VzAk0DrJE4DK6nIIqQ9a5bwVP5bXViWyqYlQc/KDwf1/rW/DfRTmQQ5by2Kn6ir3V0clSHJJxLNIQM5PX1qFpn+bgAA9z+lQwu8m3zTg45X29aLEpMtSNGdpYA4Ocnt705CrDcDkVVkRVGGB+lMktkdCzblPX5TQo9x2JNStBe6fcWpYp5iFQw6r7j3rjIJjZztFMGRkYLgkjuAOe/t/WuqN9JaybJI3kiH8fcD3qLVtIg1aNbi3kCTbflkXow9DRKn1NaNRQ92WxEdaAi29XHGSf8+9ZbzPcyHjcR6D37+9VZNI1dGKCHcCceYjA45/nW7oejSWqtLe4Mh6IpyF96z1Zu3Tpq6ZnT3Dx2n2WFthPDheufTP8AhUVppHnKWCE55JIzn8f1qvp832nUCmMHftOCOSTx/Kuw0ia3uLCOa1kEkeWTeARkqxU8EZ4INPyCpL2a0Ofm0U+UTtGenA6+gFYd1p0ltJ5kRMUich04K46Y9c+9ejFQTz0rC1yJFiyAMjOOP8/5NDVtUTTrOTsxfDWrNqELwXWFvIcZx/EMcNWtnHt/SuE0acweJbUkbfMzEwPcH/6+Oa711yc+nQ/0oequjOrFQlZEMiJNEySDcjA7ga4LVbSTSLoiQZt2Y+XLjj6V3xIwASMnpz1qG5hSZXFwPMicAeW2Cox1/OoCE+VnBJcbgTuIPXg8j/CpjqDKo2SEp0wTn/Pate48KWDtut5pbcZHy5yP16VHH4VtlIae6mkB/h+7n3zTRt7SDOYY3Oq3YgtUZmJyzY4UdCc/pXYabYRaVapDERkHczd2NWra2trGLyrSFYl6+hz7/wCe9JKRuz+HTtT6WM5z5tEebeMFddffdgBuQT6UVv8AjnTDc2y3sKkyQfeHciioOmm1KJRmmMfymYY6nmp4LzChVJCc8Ada5Ri0TQyOwK7ydmctjI7Vv2hW5Y3B+SBjhVJ4rWURunyo6KxyI1c7uTxzxmpUbEgC7sYHPHWordw0cXzYB6EEdasKR5p2oQSew4J9Kysc5bjX7oUdcdT19auoMDgEAVVtlyc9hz9atgZJ9u/pSaM2xWAkXBX+LIHXpz1qTIPOc59f5GmKABtYYycEetPxjrnPPQdaEIcDg5yOOpPH51S125a10mWRT8x+UHHNXlwQxXJxxnGKr6pbG70yeFM7iuVwR1HNUtBrc4/TEDyDOSQPmz16111nYpgFgN45BNcVZSBoypOMnBI6g/8A667XSrxGVUkIB+lSrm9a/QtS2ysvTcozwPSuV1+ELDIAxHoa7GSRFjLbwB157fWuW1iWOQOQCO2CBVNaEUW7l7wFcSyaRJbynd9mfYjHj5SOPrXSjJP09utcX4Ou5La9aB7S5kgu5Cq3KAMkbqpO2QDlcgcN90njIJAPar6+n0qkZVtJsaCd6gBmBH3uMDpXKeJ5mm1SO3ydqDhRxk9c11oyoOFzj8PwrjfEC41xZGBCuo7de2Pem9h0PjN3RbNEiDlck9/f1rUlcRoWOeTgepqhpU/mWygNzjv2/wA4q9LD5rxkn5VySPWnFEVG+bULaXzo95Uqc8qccVkeIJVMZHB4xV29ukg+RONo54/KsS63XAL/AMKjfj1ptdi6UNeZlHT7v7BcG5IyNpXA7596oP4nsdHi+0KZZmOQ4jPVv8K5nxpqUkwGm6YjEhvnkUfL67c+tWWd7XwdbTXCLbSgCPftyCPr1z7GuunTtFX6nT7JVJcz2NvSvHdxq9wywwLDBgY8z7zH2/rVXxF4tvrWXZAwaVHwQmOB6fzryPVri+t9QMkF4FwwdNvRxwc4/WtvwnfOt3b3FyxBdt0rSdGGeCB26VqqK3Ru8LCOqR6MNfuxBEz3V1JNIDtBQKFI9hXDv8Rtftr+aWaeZ1RmUxCJcEcDJHr9PWus1fW7fVL8rCRBbomCxHLY7/pXEX8a210FsvNuRK+93dSdg9DThBdUFOnB7xPQfD3xAiu/Kt9TUw+YNqu6bSSR0Irs7VE0m4V42kMFywEilsqjHow9B9K8v0BrbXka31Oy2pGSI7oZ4I6c+x/z2rtPD9+1/p3lGUOto5iZ1Gc7fX1qJxS2+ZxYqilrFHdAYGBn+dBpaSuNo4zzTUUbSvEdwjDbG7F1Pqp7fTPFdnpOqJPGodvm9+p+tHiTRU1e2UqdlzF80be/oa4KWW80a5MF6rxvn5SeQR2I9T79Km1tzvi414pPdHqPmKQSWHHXnpXO+ILtXQKrDoeM474rmP8AhJWGPnyzHucZ9MGktjeazcFLSEyYI3seFHfGe3rjr+dDV9hRo+zd5E2ixNdeIbYKWKo5fIHGB3/nXojjke9Zfh7R00q3O4hp3HzMO3sK0254B9jTtZWMas+eWhCVBwT29RUZBZz0/D3/AM9KnYgY55J9KibtgZPaosQR9RuXJGPpUNwY4k8yZlRepJOKnGEDM7YC5YkjnFef+IdSk1W7MUZIgU4wDjP1pPQ0hBzZoaj4utYJDHZwNcEfxKcDP+cVnxeNIPMC3llNFGDjcmGwagt9PDKGUDBzyBweKgu7AhSWXIA6E5wBRfub+zhsdhDNb3lr59tIs0LAr19RjmiuA0m7k0XVI2UsLSVgsqkcAnjI/wA96KJQvqjKUXF2Rx6a3N57+WgkKtggjr6Hn61q3XiGE+XAU2uOCE5JaoNA0Br6MahqbCOJ+UhUYz3Gf8Peult4rdA4gtRGUYx5eIAtgA7lPdTnGfVT6VtKUUz0pzjfY1PCkxuYkkmkBjA4B71tweZPc5t9vk55ZientXLwzy21ws0YBHI2kfezXZaJPBd2xkTAfPzJ6H1rBvU4qqs+YvIoQFRliAOPapgSBxxnHbI/KmoFGNo/THNOwdw9TxipOccihQigHAwOSSePc8k+/frQnU46EDrn88UKOcfmCKkAGQOw9ecUAOUjOV6j9DUiZH3QMcCmbcgA5z246f8A16fgZOce5piOW8QaHJBM19pgLxv80sQGSvuvqPas2xvFLY3EkcEE89f6e9d+pYN6c9DVK80qxvMtJax+YR94fKcfh1o3NoVrK0jnZ7/amfMPA9KpRi41G6SK2yS33u4X1NdMPDmnFgZUdscY3nb1/StW2t4LVNltDHEp/ujBP401uP2yS91DdLsU0+zS3i6AZY9yat9uvHQUwE45605ePf8AnmqRyvXVj1OQOc56Gs3xBpv9p2iiEqlzG26NiPzH4itEZ4/WlGQf50wTcXdHAWeozWNwY7gNHKv3kbvj/I5roE19Sm0jJ/z+nvWtfWFrfqBdQq5HKtjBH41lr4X04PjdORj7pk4xmmlZm7qwmryWpkm7a6uMDGSenU/Sti6sY49IJnLRyN95s5KZ7e9aNlplpZKBBCikc7iMn86j8QRs+lS7BlwQVwcd6qC11M6lXm0jsfONtcawfE90lqZHsIJnkJIwCenX8q6jWZpdU0D7K3mKVAYJgDOOprT8SvPZGHTbVo4o7otJ5zLgk9xn61ATa6RpdnfTziWeIlHJ6556fT1rvc03ex6MJXhFnGp4e/tPw40sMbvc2ztGy7sHHof8965mIanaNG0kKyIpwGU42jOcHtiu60e4jhvNWuw8gM0ZniAbI3H+n6VhR6qmq6Xc6Y9oF1OR/kZOmOv4D/69aK9zdSZBe+I7u3SEyw7Ny4G1T83vXS6HrscumStFICy5iKSAfmK46e51eS+ttKtrKP8Acn5nK8Edj645960EkttJkMs8qSXZX5o0TgkdDj1pvValNI7rTYrj+yDHYSLDLvyzFs7jjn6V13gmCOO0ukSMoxOZH/h3nrj9K8+0HU4o/D9xLaQzi6k2qAwOOfTPf0r1rw1YraaNG06hJJF3N7k+tYVdEcGJdo2Ois3LW6ZOWHBqeorUYt0x1IyfrUtcj3PNCo5oopl2zRo49GGakrM1jWbTSUVrp/mb7qLyTSHFNuyJ002zQnZawqT1IQVOqJEm2NFVB2UYxXG3Pi+5dS1labgBnGMsfpkgZpLLxnNHtOp2ZWM87oxhl+qk0tHobuhUtdnYsMrggNnnpnkGmkdl6ep702wvrXUbUXFlMssR4yvb2PoambAQntii1jLyIX9cn/P+RTDnt06mpHUNtJzwegPBPbP0ppIzxnPJ6/rUlIp6odmm3JHBVG49q87sE3PuBJLHqP8APpXpF5F5llcRjOTGR+NeaQOYZmRuGU4OB05qOp0UNmjrtKtVkg3MMc8jgZ/pVLV7bylXaAR2xS2Op+TGSxATHc/qfXNR6pqIl3BVAGc8jpVSFZ8xyGsRcZ4ABz07j/Jop2puZmVEwC7AY2jnNFXTehu2lubMVv5yhQPlK4BA6D/9dPGmypk4yDxx/KtHRZIpY43HEmMD1rdZVwSu0Htx/T8cVz3uZym4uxxU1oYwSw245LDtVzwxcGDVtoAMcq4I6cipdXnkW6dAtuLPywwYSHzfN3HKlcY2bSOc5znjpiv4QUzasxAJRFzyBgHtQ9i73g2zssABSGwMdR6/SngY45z/AHc0Ack4G08fSlA+XgYH1po5QHUZ7jqf8+1KJFMjRAkkKHK4OMEkA578g/pnqMuAJ9Tx3NVNS1ODTYlMvzSHlI1PJ/wPvRa+wWvsX0HOQOh6D60/B2kN0/P/AD2rjJvEWoTuxtljhTryu/jPGaSPxBq8R3SCBx6FccZ/nT2Zp7GTO0/DGT/Sn55IJY5IrF0fX7fUJBBOotro42rnhvoa3CuMilczlFxdmJ+NOUnoM+vPakx/OlZwkbOxAVeSfp2qkQNnlit4mlmZUQdyetYMniV3kIs7Xcg/jdv6VmX11Jqd1knEIP7sDt6n61sWem7VzJx75zk0J9DdU4xV5EUeu6gADLaQkZ7OR/Sr+na/a3UyQyq9tO3CrLgBj6A96cLZFQArzjjPNZGr6emxt6Bg2cf457fhTDlhLS1jrSv/ANagA4GawPDGoyyM9jeOWlj5jdurqOx9xXQnp/WqSOacXB8rE7+1NdFkjKOMqwwRTuv1oB4qkSct4h0CPU7cQyIgnibdFIRx+Iry11ure6ey1W2W407eSxUkMnPII9D/AI17xIC5BX7w/WuI8U6Fctctdaco3scvA3Af/d963pz6M7MPW5fdkefazJo+miWfTB58ci7QikgJk5II9vWuAubxdTlMFrEINRhjaZViG3dGO/5g161e6bY20YvoYwLhV2yxSrgkH0/H/wCtXj2qwvYasZ4SY7ESblc5wD6evpXRCSPQpu60N/QrdDKt1dPI7ogfAPX65/zzVq78NP4k8UbtPAjglRfu8ngcnPr1/EVsXGgzeIre0l0l44QQFdy3A3dTgd8dvevWfCnh628PaZFb2o3SpnfK3Vj/AJ/lRKqoq/XsZV66hotzmdA8ITW9wqX9xHLZwH93CE+bd1BJ6Zrt5cKVjAyCARxjaPSoEfcpwuyQHcAfrWjbbZmwwPHOD6dvrXPKberPNqTlN3kWbcnyU3dQKlpO4o6VjcyKuq3q2FjLcOM7RwM9TXm6ifU79ricMWY8Z7fl2rrPHcjfYYIsfu3kyx7cetZmiQbUB24j6A4Az/TFQ3dnbh0ow5upNb6YdnTqM8jpUN7YBckr1Xk4yMduK6+BIpEXaUIx0B6VkawojzjBxwf8KGhRqtyscjZXcmh6j9oiz5LNidP7y+uPUc816SjrLEkqHKMAR3rzPVkDE8/MRyf8a7HwZM8nhy13Mflyoz6AnFNNteg8RFWUkbLYAHGP5VGT/eIwacT6dB2ph9zipZzIOQeCT9O1cj4p0F2la+sQGGMyRjrn1HrXV9OOfc00sT8xOT2PUfSixcZOLujyqe9kgiJWMswONpOAPwNRT34EHmSHBI5GCST6ACvS7qxsrolrm2R3z1Iwc/Wq62NlakeTbQggcHbkilY39suxynh/QZZJY7+9BSJTujjIwc9iaK62U8BgSAFxgNxg/wCRRTu+hlJuTuzg7K9NjO8TtsYNtdW46e3+e1akuuEx8YOc4weordv9IsL9t13Evm/3gcE1R/4Q/Ty42y3AA6KHB/WstDf2kHrI58zNqM4ijXfI38IFdpodjHp1kqIcu3LE9T7UWGnWmmx7LaILnPzP346Vbx8x4zn27UbmdSpzaLYemRM2ZRhgNibcbeMHn+LJ59qmHOen48/hUOAWBYjjgnGcVIg3HGCR6Y4p2uZFfV7z+z7CS4blgPkyMZOOP6VyWmWkt5cSzXO5y/UsOp9BWl4wmbzraI/dzu57/hVzQlxCuVBIPrjNN6G8Pdhcmh0+KOMKFUbf4egX/PpT5dOVkHZh09z9f61olTwQCO/TpRnap3Efh/Sgz52cRq9iVIHK4ORgcgjnr+Vdf4Yv31DSIpZTumQ7HPqR3rnPEFyoLBjnPH4f41qeBAw0mVnBG+QsvB9s/wCfrQa1dYXZ0nH5cVm+JpTFosuN2HITI9z/AJFaWeQAKoa/bm40e4RATIAHA+h6fzprc5o7o57QEUzx54DE5wO/+FdpjCjHFcBpNwqlSrfIOMjt/nNdtZzo8PytlV9cflSibYhO9ywFycYGKq6rEGs3J5Ye1WDIgB+cHt7CsfWNTHlmOMHnqTVmMFJvQ59HaDU7ORQAySAcenp+RNegHtXB6TA17rNum0tHGRIxPt/+qu7NNF4ndICcA+3rxSAcgnP0oHPPPtSAkHHQdaZzihgeB1GaZNEkyFZB+Pp9KeeP/r0in8uhzQBzHijQoNUhZb1JWXnZJF1GQRivOtW8HafHbxW8l+XgVslnO1hmvbck54qre2Fpexsl1bRSo3B3Lzj61tCrbRmsa04L3WcP4WsdN0e2L6aI0LAmQ7upA4rZn120WKHMqGJm28NnnP8APmoJ9C8J6XNue3jWQZAjDswz6bc1NBq2kw/LFpjJED1WJSOPaqlOD11f4E2qz1sXo7K5dQxCeRwVTkEfhWrZQGCM7yCzdcdB/Wm2GoWt/GWs50k243Duv1FWuTjqPwrFyvoS7rRiKu0k45PU+tKxwOOT0A96TPzetLyf/wBVIRl+Jo1k0mUsFLphk3f3s1xcdw8sYMzMTjGPat3xTqgjvI7TI8vG5sZzmqv9kLdR+bp82wnGVJ461Dv0O2j7kPeGQzKq5PDZwMd6a103LMcxrycfT1qtNpur2xz9i85DyfLf29KrrPMH2yWsscm7BVkOc07s1Si9mGqAhVBYMrHjC5J56e5/zzXcaHbfYtItoAMFU5Gc8nrXOeH7NJdRU3qDcP3iITwWA+9XYMeCMkr37U0rKxz15XtEa33eOxwPrUXAJ2jAHr/OnM3PJ9/wqInGeflxxx1pGKEOMnr7e/8AnpTS2WPQHjNJk5+XHXB+tIxBOcZGMikhjHzwwwpHTFQPxyQACc8VK/A/DnAzVV+Cc8nPPHT8KYyN2BHbIyRRUNyUjV5XZERVyzMcBR7/AOe9FS0Gh5zN9pvnL3FxcNIxJPzFeD6YPFKsU0PEN5cxoBhfnPGPxrp4NEd4QwIPHHvxVO7sJoJMMqgAZ3d6nc7lOOyLPhHXLn7aum6nJ5ocEQzMeRjnB9a7Rvlbntxg/livLWJt7u0mRsGNwffrzXqRIdQT1YenH+falbUwrxSd0A2qPlGFHAGO1PVcHkNkdjTVP04pykHjgE0GBieLrFprRLyMFmgyGXHUeorF0jVxAMOMgdgOB/jXcKQwIIDIw2kEdQa5vVPCkNwXfS7nyHbP7tuQf8KrobU5xtyyJxrqMuGUY9TVO81vzN2DgehFYd/4W8QRwOsQic4IDI2D9cGs6CyawjSDVb6KOQ9STuyO9NQb0RolSWty7N5+pXiQW6mRpG6Lyceten2NslnZRW8Q+RBgEc81zHg680DcYbCcTXgPzSOvJOOx+hrrM89h9OlEouL10MKtVVNI7DsnI9falB2gHj6dqZkZx+n9KdngHNBiclrejTWdw91p6M9s3LInLJ+Hcfyqna37jAhcbR05Jx/niu6BOe9YPiH+ybZVe5hYTyn5RACC31x2ppOT0N417K0zN+33BUguTnsDx1/z+VVXjnuH2RKWkPQKP5/571KjqYDJDBOSv/PQAZ/+tT7VLoxbjmONj8oxz9DWqpPqN1or4UdJoOmrp1sckNNJy7dce1aWenbvXOabZ3FuDJDcuu7nZnjPfrWvbTsGYTHIxkgjlaTjbZnM25asunqM5FABH8uaA3y569qM46du2akQ1skYGSB0H+NKAQf05pSMnkcdvelHPPfvQFxAOMcisrxNqi6PpMs5cBtu1M92PQ1rL1zjFeY/FWWWbU7S1D7YRGXb6k8nH070XNaEPaTUWVdGZtRuyzktIeQ3fB65+vP5V2cWlYt+flfHBx+n+OK5jwglvaMpkbBByxzgD/PT/JruxdxNCTC6tgdPX2qVsddeTUrROTuo5dNvEurX93PGMdvmBPQj0Ndppt6mo6fHdQjAcfdPY+lefeIr9kuGDDBU55HUf5zzXS/DybzNEkUgDbMx44GDzVxMsRD3FNnSRbjHl8g04fSsa98R2VtIYwJZWGeUTI+maqp4vsUuEiu4p7cP0d0yo9yRWipTeyOFyRzfiNmbxFP5hwoxgH8R+XT6Gr2noyAGCRs9QD1IHcfnUfjCJf7TW5idTHKgYMOQT6mm2FwYpATwoHGQeAfT8qx2Z6kfepqx2dhK724Eq/OOD71javf4mdBEM9OetXItShWPaCenQ9uOlYOq3ZklYpjJ4HGaGc9OHvXsVrW+kXXLFiCitKF2gYznt+oruWxk+h6cVwGiQm71+0VRlUYyH2x7137MMryRnoPXn0/L86fRXFXspaEJUiUsXYggfJxheTk9M85HU9hjHOY9uPmI6nknkH6VO+dpBx7nPeq7IxY578EGk9zNB+H0qLsxxnPWpD0OST0x/wDX9/amuDkDdj3/AJ0LYCvK21tg+9j+Lr9T/n+tV5mWMLk9TgHb25qxKpaLAOD0+oqlKg35fnaOOpx+FHqMJkEiMkkYZSPmVhkH8KKWQevcfhRRe2wDNPkV7eLY3GATVXVsOqA7nJGCcZwP8/pXO2OreWmAxzjjvk/4/wD66ddaqHXrjsO+KxSsdPsmpXKepw4YlcAE7hzmu/0uRLrT7aWJgw2AfQ+n1rgLY3Gqz+VZRGQ5wzHhR9fwrsbLRDY2DxxTOt0+D5g5CnIJwvfjIHuaprqwrWsk9zYxg/Nn6H/PvThndyScjrioEtEjlEkbSAdgzE4/Pmp+ntgce9BzCnB6nHPTHU05RtzjIzQCcdeO+O4oL4VnJBVfmPfNOwjn/Fd9ciB7KxLLI6fMynBAriY9MtrNGa/iZ5jjh2+4OmefWu4vmNusurSlQoUllJ5AxXgXiG91HxJcalIWnRYyDEUOAF7Cu2k2o2RrQoe1ldndwa7LZX1ykdok2nIBvnhPzIM8Zz2r03w5qi3FjF+/E0R6OPvA+hr5f8Faprcc15bRREEjYWdvvHH6967LwXrRaV1tp5ItYiYsLVidk6jsO3X+ftTnT5kdVXCRt7p9Gd+mc+lKPesPwvrY1WwVpI2huBkSRN1Q/wCGQa3foD9Otcji07M89pp2YmcLk4OB0HesC9lttRUYYSyqc57fn+FbN44jhPP3vlA+tZGl6YmnRS/KjPId5yentVQ01EOjtITBudyoC4IDY/z9KfaK2dgLsi8A9/pT5wq7HXG7uDyH9vrU8s8dtAWlkCKoyzk4C+pNaXugIWlC3SLKxRh8o4xke/arcUwLMCSOfT5Sa808V/ECKNxDpMKzu2MzTNtQD29e2K1NO8T3MtiL+xnsbyIj5oNwRwe+D6/WqdN2Rt7Cdr2O8glZi4IGAR+f+f6VaHqO/wCtchp3iuwvLi3huEmsbmX7kU2AGA6gN3711du4IA3AjAA+orOUWt0Yzi47kvbnqDk4FNLYbH6+9KwwPUHtTs8DAyKgkUDBPPH8q84+JkZj1azn5+aIr0z0Oa9GGBk9B69q4DxBG+vXbBdoELZiBzhh3z6Gho6MLpU5uhzVthlKM2I8dMZHpj3/AArSjQW65hleJwOhck9e/wDngVE+nTWzqJU8vOOWGc59Mdfz7VLMsYjZdx3DsuR24+napSZ6LaZE8qXEmxwQ2cE8kn6f4cV0elqLPS5oY5JIjcHiRf4eOtcxaW8k88a/dBbJlYccHtz1/T+VaPj3V7bS/DRtzMYTMdit32nqRW9GLcjnxGq5F1KF/wCING0u5ktId88sRGZkYlUHueme/GBWZN4qvtRkHk6Q1xGigb93OP7wHfiuZ8JaTp13p05u/PZJmxEVXcHA4/D6U0XMXhvxNaWtpd/uThAJycID1H07V32S82VHC00rHcrrdpFBbW97N5McpxGZFx5bf3c+hP8ASrwDRgHJAPTHGff65H864Hxfo8d5oeruoeW3dg6bPmZckcj05pngrxBfWMMVhqbyT2qr+7kmHKDGME9T1x+VZzoKeq3F7N04+7qvxR6Ms3QENkDOSevtVaRpZJFiiQvI55C5Jq5aRC4tfMeAxr0DhgwYY9Pf3rW8OXENnfpby2DJLNnbP97B/u+wrl9jJbmMsTBK6NLwvo39m2xmuFBupQN59B6VrSLuZSyqcHK1I+TjHHv3pjc+/GOtZvU5XJyd2Mb6Ywf8mq5GQMDPHTGeKXULqKxtzNMTjqAo5P0rl7nxFdXalbGLyAP4zgk8cVLLhBy2OnIIz8pyev170xwUznOR/wDrrh5rzWRC269dBjsAMfjVO18R6rpbgzP9utOrBx8+Mfwn8utCsa+xlbQ7yT5c9M4xVdwck8cHjHf6e1R6Tq9lrEBmspGDJw8TcOh96mmABA42jgD/AD/ninaxk1bcgc53ev8AP2oolA6//r/z/jRStcLnDTeEdYt2YxSwSICfmLbDj0q/pfhG7Zt2qXCxRr1jj7j3rsN3IGDtPBOaw/Gd89tp6RQsweXoR6d8e1ZrV6HQq05e6Q32qwabEbPTCoReMr69K5e6N9eSF5Lq4HOQA+PyAq5o2nmZ2LAtk5Zsfhx+FdJHYQxxnKBh0OR3prsjS8afqcnb6jrWmzB7e+llQcGKX5lNd14Z1+LXoGCx+ReRYMkLEd+49qx72yRo8hAMdOMYrm7RxZ67bThUZFlUsGAIODwcHuDyD1B5BosEoxqLTc9YQYHXHPp0qK6AaPymPBHze4qyMHaVrntemd9QWFCemSA2M1UI8z0OFuxwPxo1Z7DSYdNhm2rOMk9CF4GCe1cV4Q1PTbkPaXF2YZCm2TDYDccVoeKhHrHinUoWkaSSwj2qh+YDivHJNQt7LXoFu4maF2I3LkDI/n2/+vXoQhpZHqUIqNNeZ7aW0q3ngtYruBrmRCo28bj9O3rXP6jp10PFkf2hEha3AZJ14DAH7xPrXO6LpaXXiAXV1HchTHvi3E9MdvStnRvGaaQLnTNTs1ubW4Yi0lmyXAyRzkduvpzVctkbWa21PRoZ9c/tEanp4We2iUCRU4I9Qa9T0DUo9Tso54sgFfmUjlD6GvnLUPFd7oka/wBjBhC6gunqe/sP/rV2/wAP/F8uv6hb3UMaw5jEc8cZwM8bW9+9YVaV0cleg2ubsetanceXLFBwWIzx29qISWUJgngY9/Y1X1C1lub2KZQQPLwQDgZ7VFeXDWGl3NyVAaOMkEev/wBeslHRWPPRi+L9fvNMspF0mx+23MYywB+VO/J9a861rxyNR8OSQXhnF2wwyL0J9BmnWniN7+0a2dWi1KWUvnPDDPf1rn7syxarc318qMLaMg7l3KT0PHtxiuynTS0aPRpUFFe8tTnJNQvLnWrCPU0xbOdowuAV9D9K7q70TTJGkttLJWVhuY52kHtj8untXELfG/MV9dSNBIp2xow5Cdj/ADr0PQ7Ge900SrDEtyBwrDO4Y69uP84rSS5UdM5WVyHT5NQ0u4j0bWrQXEBHmQXLA5C+mfxrvvCPiaGfVo9PiYvHsymWJKe30rlEuW0y6RdXBkEaMqKTkHI6An+f0q5Pqlrc21lNp9l9lvgCVYKFLEVlKN9LHPUSqK1j2RSGUEdxmgj2rK8LagdT0a2uGBDMo3Z6571qnrmuJqzszymrOxW1IE6fcYznYe2a5jSIwzc5JJxk9v8AGuvIyCCOCMfWuXaMWGpyRqCE3ZXOORStc3oy0aNiWFEUDg9vm54rmtRvXWXyII4sluCQPl+v41s305a3JVj/APqrn0AjSSebJGBu4yR2C/X/ABpxjzOyNYWinKRUaK3srOXUNWuVRUXmSU7Rj2rxDxx4yg11Ly8u3Y2UMR+znb1PZsdx6Vf+MrSeJYbm1tbkp9mkUbcnY56kbew/+tXlMkFzr9wNPupfs7bVWSJzhNoPGPXn8f516VOlGCOihGU37Rr0PQPDHim91Dw7D9gPlBAQxXHGBz/nqc1R1fVZvE1zBIsyuIZNrqU67ew9/U+9ZXhu8t9Nsb9LeSOOY/JDFEPvsODwPX/PrXonhGy0+28Pw/abWKSUzEySDqueoJ9O3PX3q3bc63ob0l/eWnhuGfTAsjTYjOMMOnOPpjrXn2pT6ndi4jUvxncW4Kg88foP8iuik+1ReIYrbR7eRtMj5RlBI3Htnoe9aE2h3WraO0UBW1QyMGHAYnPepaS1FFqJ6P8ACMNP4WsprhmlVYwBnqMcYI7/AP1q7N4g+owEBSEBIx61z/g7TY9H8N6ZaNkGNQGOcbjjvXVRAHc/TPAx1FcVWV5OR4s9ZOxKQRxkcUx3CIWbIABJ9uKU9PSobpQ9rMp4+Q5welYCRx+q366vfbIiPs8R4P8AePY1btNPyo4HHJxWDpdoE1OUlsgNkAnrzXYRFY4wu/nH5+9LQ6ZPlVkZc1sqIdyn9M59K53VLdY3Z1GfXv8AjnvXYalJiI7guAOCvcelctq86FNoHIHAA6fh/jUjpybOZ0S5k0fxPBdxt+4lYROq9CD0OPUcfnXqUzYDcADGSDzj8K8pjiN1q9rBHk5kUnZ2Hc16nL8qgEtwOAOlX0QYhe8QzNgdATjriimSAktg5IH40Uml1MC+gUPuPB/p64rkvE0bXOspHtyqKP1NdbjLAnkA9PesDXwLe9huCpMRAGQOhFYxNKbtI0rCzS3gAAGf4gOuatsgIG3bjA6cY/x+lQWdws8A5wvQnPAq6v0Hr/jTRMm76mVdWyktv+VR39K4fUwkmsxxRct5ow2CD164rr/EWqLbRlEwSRjrVLwRozT3D6neoQP+WasOtWtjaEuWLkztQNqqGOSFAKnjFc/rdqBqhmZGZpUVQc4AK5PHcZ3c9uBxnObep+ILOymEJBnlPVVYBQe+T2qgfEX2mICaxxEQCDnLA/404+67mCpylrY8H8e6pJ4a8SaiiKi3N1MfNfrwRwPp0qqbrRV0sS6xBbpcSHCe+O5/H869E+LNpZw6fH4jjsPt7wY3Iq7mwO5HevnG7mj8XeKEaz3RWdynCBceUehA7dhXpQfMlI9KjUUoqL3R634f1B9Zkkt3kjRYIv8AR5nXhh/d+nauF8du5hF1EYv3LFcAn5T7Y6/5zXp2geG7PRdKhW86KMEnGen+c15x450doPELPYuogx+9KjeCOvA6VSauaxld6FfQ9blkkt4NSgW7tZgegOE7c8/Suq8NXV7p2uQR2KnKShjsGFkTI4P4d6zvhfoiX9/K6SpKhk83YAFyoxkc9MntXYz6heReJ4XFokaiTyQqqTgHrmh66DlLRo+gZb5Us7aeXckUgH1BxwK5X4iXkz+DdQOmsnmsoXJPIB44rpbS2j1HQGiDBt33SOzDpiuX8WFD4bvYbdRL5C/v484YcZIx64/pXJTSv8zw4S99HkNutzobWjusc9wpEpYtwBnv+tdVdanZ6hbXVwIAVZcyQAdSB+uKydL0y217SDeaeSbJjgq5+YY9PpXH2txJoF9cmN5mXzGXnkYPb6e9dlk9T2rKb8y3LN51l9se1j8iJwiY6rnPXj2/SvQtH16wtlt5N4lVAgVEO0dOmPrXjkV5dQzTPcTbopyGUEZQdcn2IyPXr2rqLvw7eQ3duRILqK4h82KePG0kc4GP5VbSe4TgpaM7D4h6lZkWzW5dxJJvZQcENzwfUcng8Zx6Vn3FzfXj2NvYttlDeUqkcc+/9a4ueQuUgMpEzHYyv/CQcfhXpXhvS2tdUtlMkV4zFELQ/N5QPGTj8vzqGlBE2jTieveF7VrPSraKQHzRGA5wBk9/61sfxZyfpUFkPkwpLIoCgnvVg4rzW7u54knd3E59ar3VpDclTKmWX7rDgirGQASe1Z17q9taD5y7+yLnP+eKEm9gTtqU9StTaQNK85a2HDFhlh6EVxPjbUBZ6ZK1qs20IChHOSf5cV28Or2WsW0sMDlJRyFlGMkc/j0rlPH0Qn0aWbYqiAh2ToRjofp1roorlkk1qXGTm0m9Dwq21VNQ1+aCLM05y0wY9W7D3I9KxtI+Hmo6p4nuNUiaRbKAgbiOVPcgenFdJJplzomspq+lRxkycMD90k9fccen+Fben+NhDO1q8br5py7fdIPfIHauzmaR7LTt7qKusaH4c0fRD/ZqSy6pKfvsuOT39OtVPDsGpWBI1hA9vgMCPusD3x7f0rr9c1e0lSyuIDDKqgj93hjj0/nSnUUd1he38qZ1IDTIcFf7w/8ArUuZ22JUmtyp4QvdQSDUfKiM1luO2QHhT2/DmtLRLW+uliW7uWS4urjayAYGB3HpwDXP6YJrXUmitWdI5TtEWMmR+/HYV6j4I8Of2eXvbrdJM4+QOD8g79e/Ss5tRuzKvNQV+rOtt7ZFiSKI4WNQoweorQACrtAAA4x0pkSlVzjBIH/6qcTycc+9cEnc8wQnjjv3qJyDuj5wRtyeKczD/DPH4U0nOc8/j/Ok9Ro4DUYpNG1J4peY2bej5+8Ce9WotTQqgJJbv2Gfx/z1rp9V0631S2EV4CdvKMDyPeseTwjZtGqRXU6YGMnk4/z/ACpWOhVIte8ZV9qgKMM5IGeeMf5965q5nnvJDHbxPI7t6evT/P0rsYPB0aThpbx5IhnK4AJ/GtO6vdK0CMJI8UQ6KoALE+4p2S3K9oo/AjJ8M+HI7CNLq4XfeMDxgjYPQCtd8HoAcjOD0H/1q5y58dW+8iKwnkT+9nmrmleJNL1ebyIJvLucf6qX5S30z1od2ZyjPdl9h8oBOTjPAx29P6dqKkmTAO/8e1FFn0I3LSklmBGF9R3NJcQx3EDwTglHGOBn8RTG6dzgde9OjYnGMcHHB4rnQGCLC+0yVjb5uIc/KRzwPb8KjF/fyExrbTHkHOOldIpfHyggZGBjH1qVJWK/Ke/XPJqk1vYvn7mDZeH3ubhJ9S+VFOfLJyT9al8Ua8mnRR2NkoM7gqFXogFaOo3LWumyzRYDY+XI7n/P6Vx+l2T3dw9xO252bkn/AD/nFUnfVlxXO7y2J9F0wuyz3G9pH5JbvmtiWxQRHAyD1GOn1q9ZQqI1AXgenSnXiqmS2Nv93pRdg5ts5aOZLG4eK5j821kG1lAyAa4rxL8O9L0vUH1rSyI7GciRlHSM57Y7Hniu21lFU5OOQWPv/npV/TAl3o/k3kUclu3y9eR/T0/rW1Oq4Oy2Zcm42mjyD4g+IVtdKliYqzxR7lIxnHpXmfhCPWdTY6hArSRtIdkUowAvH6+59q9a8cfBs3oaTT9W8uI/djnPA5yBkdaxvDPgLU7CFrW81i1t7aJsERHmQe+OK7oSi1ozdYimle5g6Rpd7/wk0l9bj7Hb5XzETnkdTj0717D4Ojt9Tmlms0dwoAUyd2/vCqsHhPTmEMiK9yYlAUgkIfc+tdVaRw6NAX2oGI4VF2qpPIwKmpOKRjVr+192H3nV2V/p+lWMVs8wDIoyADyaz7y60S9uXcRhblhtZyuA6+/qPwrmiJb6ZpDgjdg5XjOM4Ht9KV7MNEGSTcmPlYdB9K4FJp3M1hodTz7x5YXng5JUijUaReSbre4Q4WIn+An69K5fWYLqHRQrbTd53E9SV7ZFezzyWt7o82j65brNptyNpRvvc85B7f8A1q8m1jw3qvgm9862uZb/AEgD9xI43siH+B/XAxg16NGqqis9zqpVHD3Z/JnmU97cC+is0RpImAJLD7nT+oOfwr1FdRurS6sYdPZpCNoOwbggI5IHrVG4u9D8S3ottPje1cp+8PlZBOPX/JrU0fS9S0mZZLeFry1jzmRRwo9h+FbWaWqNpVYPdo697HR3ktUntoomdQQ7r8xbrk/U1oeANMltde1CSwkE8O4o3Pyk+nHt2/GuBjtL7XfFG93lYCLAEykbOTwoHNe5eAvDUeiafG5WSNyvMbHv3Yj1rnqPkjqzixFZRjyRd2zq4lCIqqAMelPJ/Cm561j6/qyWS+UCN7LubP8ACvrXBG8nZHnj7+8MkxihOQvcHrWfKVDfa53wPu4PBAPfn/PFeaeJviVFo08kWkmC4vsHeWO5VJ7n17fjWDc65qXjHw7fSS3eEtmBWGIbfM9efQZArshSZ1U8LOSu9EewSWWm32GgdDdxnf8AumBKt64B9KZqZe/ja3aMLFtKTF1+9714Yl7Fo0EN1oUEttrkKDeVkLKBj+JTwRz9ea9j+H3jG38V6Y1teNFbavDxPCpwHGPvL6jHUdqck4q61QVcLKlr0PPdc0S80ERrvWWzLELKxxt9Dn/OK5FLU6lq9zMZ7eMxcSNjbuX2+uK+htQ0u2kV7acLJaONwVucN3I9Oua5uy+H1hYalLdafNLiSIo8TgOv61SrRerZ0UsXZWluefeDNNsLO4ukS6Cxt88TSkBV9BnmugS/sPtLWax3OoXyjMRhUEA9ufTtW3D4F0mW7SW7aaYL85RPkAJHpiuy0TSbGzt3FtAqOf4+jEdsmlOrHcmpiYv4Tm/C2hTG++3asAt10iiAAC8d/fqDXdW6ANuO7av3QaihhZ3LSZA6VO5bIVQAuK5p1GzlnJzd2SE4JHp71GzADJPvwcCkJO3oM+ucYpm7v1PWsiUBck9qYGGTgjOADz/n3oPXbnjv3NNIDYPIPtQMVnwCc4A+Yk98d6Y5wpOeB36/jQVyOnXBwR0xz/8AXpCAAAeKLgZniPUl0vTZJPl8zB247cf/AFxXnelacdWujc3Ts7OSeSQR/n+tbvxPlcR2y/wliCB29B/OrXhNkNsvIyccdM//AKqFbc6Ye7DmQh0OBYzt5BHQfdx7e1ch4o0RYVLIpUodysvDKfavTXjUAbRgDnArm/Eiq9swk5IJAAPXFDbWqCFR3I/A3iCTWNKeG9bdeWp2OcY3DHB/nRXJeCGMXi1xDzDNEQ+O2DxRVSs9TOrFKR61t+fGecH6+1KMdOBx27//AFvalIx+Bz0z+lO/i4YnAwcHp7Vy3JAHDZPY8j29T/ninDsBuBA798U0525PTkdP6elPXnHammIq6zA1xpU6IPnA3D1NcnouoBBskyvPOeDXcpgANwfbFc74g8PedJ9qsCY5f4oxwCO+KtaqzNacktGa9rcIYxjn05qtfOpQZJIGcY/l/wDXrl47uewl8u9jaFlAB3qcH6evpVqbUjMhC5YtxwelOzTsX7LW6K0vmahepbW4YsxwMdfc10eu6Pa2ugxRvfLZvC2/zP7xx0//AFU7wTpjQ+ZezR7XcYXcOfrXIeN777dr5iV8xwgjb7+wpqTTuugOPtpci2Mp2kljMXnS3EQIbLtz16gelb9legR+XdWlvIACM7ASR2/z71S0+BSV+7lSMnqRWlc2xWEjaOvAJpOpJu7Zs6cEuVJGg1yEtMxIEAXgAe3arGlx2ev28ttI4FzGM7Oh6cGs+wkUoUdD9cdKo3ok0ueK808YniIYY7jnIP4Zo5myPZ9I6M25NOls7jyp92wnIPX/AD0qzPLCkWd+7Axxz9a2C8WtaEk8IBV13qV5we4/OudkaP7MxCZccYPOOMdPShN7mUW5bnO3t0GcrGhxyMngn+n4V0U+gmXwTI7Z+0YDpk/w5GRz2K54rHsrc6rraW6qMAruH4c12fjGcWWgtDFn58IAOu3v+lXGbg00Ov71qfc4rTLxbKFY4LWMRgdkHP6e1btvdkxhnRYzndjp/n/9dZNnbYUAggY4xx27VcmjbaVCABsE+w/ClKbluzVwjskSNq7W03n2kEDyhSFZhjJ+vb/CpB46ngkX7XYhovlDtG3IP8RA7jOce361prRSg6YPHTnPv+lZl5aFkUjO7bk543DjqKm99xKlTe6PSdH1ax1eAy2E6yhThlPDIfQjqK+dPih40t7jxVPpDag1vFI5kZgp3sB/COwHFeg6Sk2mXklxZMUk8tjxyG+tfMMlhqvivxtfatqq+VY21xJamQDBJUtwPfPU13YOK96REMPy1o21R6Hcx6bcTxXllD5sITaUiUgnHZs1R8KeJbGy1+e3lkdWmk2/YolPbgAY6dM//rqX4c3+lWj6npeoTuodQLfy8+h+b8elGkaBF4c8WNcvMk128wbzuCCCRt/kOP1rsstj0G+hJ4qkvhrc8UkEkMNyuViPJQdwPrXM22nanpfjQQtc3FoxIuIHGcnpgA+n+e9fRWpeErLVrJbu6mZ7sx/fQ8k+v+fWvFNX0qbUvGVvYq7H+FXJ+cAdPy/zmojJPYinUVRWZ7v4C8UxeINPaw1WaNtQtlzIQD8/ON2PyrrPs9xb7mjG6MnPBzn9etePfDPwfd+HfHsdxNdNt8to5A3LOCARn6e1e6xkxycnCtyR2B9vSuKvaMvd6nmV4KE/dKMUDccZPdsY/GrccAX5mOO+B0q1gY47d6Q/dzzj2Fc/MzG5EAD0GM9sUhUY6fSngAKRx9PWkORnFFxkbID/AL2e4qNkYnO7AA6VNxg8fUUMO34UrjImAx2H4YAFROpDDAGM1YYbuhOPcd/6UwJ8528ew9aLgRMpDbhk8Y9Mc9aacdSc/wCFSlcscEBe3t/9aopnhiYebIkYP95h1x+tF9RnLfEbTpLzw80sIDS23znHXbXCeH9Wa0KMr8EcE8Y9RXsimOZH2mOaMjBAIIrgPEngItM1zoUoTcxYwvnb/wABPakjpo1ElySLKeIoJYfvgE9hmuT8Sa/C8hh38Z5YcbfT60Dwl4i3gNDAO2TL/njNbGgeCFt7hbnWpFmljOUhU5RT2J9apRXUv93DVMh+HulvH5mo3MTReYv7pWXlV65ort2KohVAAAOB09KKU583Q5pPmd2WmAAG/txk9/YU5cEfLkD73Oc89PpS5K4OD3pjozIyoQCe455//X61zEj8ZYDjPXg8/wCelSKmXHzEY/hHes3TLaK1muBBFIvmPvclt2Sfr0q3qV0bHTppwOe3uatR1sg3MvXdfWyY21mm+46MxGQv1965+SfVLx/Na8mBHOA2Bn04pdNtzduXlIZz8zEnnJP/ANfpXVWtim37gOeSen+ela6LQ6fdpow4Nau0D2+q2gurZTtDuAC3TJHfj1PWt7Q4tBuSHskQS9djnkfhST6csiHoQPQVz19YGzkS6gLLIjb1x1z6UvQn3ZrTQ9EAOMAYA4AA/SvGNZjNv4jvlkB3GQnnnIJ7fnXruk3q39hFcDhmXDjPRu9cx488OvdumpWKlpkyssY6uO2PelF3TRNCXJO0jC06WEKFJAYthcc5PcY79605ZFlQgEHjoK4+0vFBIYYccEE4Kn6VswXuFGOCOCM8+3tS1TOyUOpeHyuMq3UkjOCKsCITw5IK5GSD2xVVWEihlwcnGKYl1IGEargtxj+7yeaRNjp/B8v2awuLZt2EYsgI6Z5Nc3qMwSZwD8p788dP061pQSvbQMqI7yHIKqPvn6VHp/hTUL6V5NRZbWNuw5c/0q1ruYrlhJybLXw9ti73F4ysApKLn69R9aPG84m1S3teCqKGYdMH/wDUa63S7CHTbRbe3DbAScsck5rg/FCyw+I5TKM7hmMnOMU1qZ05e0q8xLaFCwCgNjA//X7damIHm4HGOCetR6a/mSYcgZ4AyM9epI/p+tWJF2XDKR/u5bg+1Te5u9zQgshLb7sYboMVh6irmQGNQwP3vf0rdifagByBwSN2M+x9arXNlLIrSKN23J6daV0RF2epgyoBliRkc5255x6V81/FLU7nSLnxBpkkcsNyl4JoGXIWSJ/mDD1x0zX05PGyg5B6AHnqP6iuK8aeArTxhHMzuiagIwsOAQhUD+LkliTn5hjgKMcbj2YSooStLZm0m7XX9f1ueNfDt7e/i/t+Mxtf2xEUkD5KsD/ieteheItEi1O1ivXjazmBUpsPB57+/Ncx8NvDz6BrurWTwrLLACskPUHn+H3wetdJrHiHTLu4GnI7woFCqrjaVOegz0r0XdOyOiN2lcueJdb1nTLK2ghZo4FAUzRksvoB2rF0GzvP7QbU4ZfOnkB3ShR+7xwAMcj37100EEh8NSNKGuLWYlUIOSp7Gk8ByfZFmsI40+0M564xzxx3/wD11nsm0hq0U2iz4SuJpPEWlq1xLNPM7GQuNwTg5HXkV7vG2+NSDw3rzXl3hrw+dL8Uxk4MwDS7QM4z7+ma9LilBvEUkbiO1cVdptWPNxck5KxdGBwOtI3JwM5HWn4oPr2965kclyHnkYP5UhHPIz/X/wCtUjcKMA9fypBnvnj1oHcjJOB1+tJznBXj/PFSY55pDxz+uaYxhBz3z7Ux3WOJnkOEUZyalI49QKyvEJYWG1c9eeO1K40r6HKa7rFzevIsTSRW2cALkZ/Hv1rPGmNOoZi0m7nlj19OavawipbRRxjBZhgDt7/rXQ6Vp+20Qkgnb24OaOlzqclBaHDS2t1YTiWwnlt5VPADcHvyK6vw54jXVme2uk8nUEGQFOBIPUVLrNoPL4XZ6g4wfUfyP41xF8slrLFeQEpNA4ZCvX6fl2pX5tGPSovM9JlDAngnHOBzn2AqqwKjJxnHU96sxSC6tYp1zh1DYHaoGxgdPyx71FjnK7jCNyfw+lFEoPRXziiqV+iA5vUvFd2900OlwRGJSV81+c4Hp6VHb+KNUhGbmKKVP48DBFVHhClEQZzxhec10kWh/wCgBpQFcjOP6VFonU1CKs0a+lXdvqFmtxaMoDffHdT6VS8Xlk0RioJXILH2rA0q4bRteUc+RKdrj9M13VxAk8UkMq5RgQRjPH+e9VFckjGceSSa2OK8NTAeWWIJx3IGP8+tdjZAMpI5yfXrXnt1E+j6qbWQfLklGPQitzTtZYACXB5xx19/6VUlY0qQ5tYnXHDpyCCRzgViaxs8tt3DYIOTzUi6qrp99c/57VlajqCkeWvMh5wB/nn2qUZwg0zW8FsRb3QOdm8EZGPx9RXRoSDz6cj0rM8PWf2HTI0K4lf53rQHbA/+t/8AXpMym7yZia74V0zWXMrJ9nuiCBLFwffI71gN4AuUyIdSBAOQHTt/Wu4WJFd5ADubliKkGM8ngfhT52VGrOOiZyVl4NmRx9puwV55VeuTXRWWj2FkqKkCs/Te4yx+pq6CMGlHBOOwNJybJlUlLdjkSOMAxxqvbgAcU/PGe/8AOkxz79MVnarq9npa5uHzJgkRjljS1M0uZ2RpA56VkeJtIXV7IBMC5jOY2P8AI1zl34yvXz9jtEVezMc5qbTvGL+aq6jCqqf4oxyPrVpuKNo0KkfeRhP9p06cQXUMkLg9COPqD0IrVik+2WiMjLvwADn7wrtMWmp2iPtiuIHGVJAIqtDodhCxMcG0E5KhjjP0pO3Q0+sp/EtTlrS4kkJRlO8fKQf89K6ay86O18t485GcCrUtvaRAM4jix/EcDgVlzXj+Zttbm0kQ4+bzPU0JIlz9psjN1K3lJYeXhT3FVdOs3M7ySgxnH3j2xzWyL0Jzd3sGQcFI1yTx0qnq+rpdxRxWkLqEIbLAAnHp7VrFrqaKU7csUeO6JeS6Z4/1TUb+N54o3MR2LncCeuKq+O00S+1N7yO2MU0hDr8nU47D1/pXs8NvbazBcLIRb3ZHEkYwT/j0rznXPA2tT6uzTM13boB5csQAbjn5hXoRqRm7rQ3o1oqVp6NFXwJqUWpWT6EUZVZwy8fdz1A/GsPxVp1/4e1K8u7UtHEox5nVScV3+keFBb2rTWiymUghvMG1z9P1/X2q7Z6HDcW4+3Sb06vETuINDcVd9CpYiMJXi73K3wzGtR6c15qrtcXM6YiL9o+COe3eu+0mFI757q4u4gxXakIIwox3Pc1zglyiQRE+Ug2gD07fzpLjTRICZBkEenX3/n/nNcdSpzN2VjlnR53eTPQhgjg5+lN7Y6fjXmkSXukzifTpXjbI3Rsco49CP09a9A0XUo9V0+O5RdhOVdCclWHUVikYVaLp67ottkjIPtxSBMYHTv8AU08j86Q9Mj+VBlcZjgdfoMU3Hp/KpG59qaT83v7GkxoYfYj6YrM8QADTnzyAOea0gwZQUIIIyPpVbUYPtdlJGv3yMj61BcdGcPfNHutROcLvGWYV2ViALRdhyuOg/rXAawc4hkUK8bHcOhB9T71uaNqYjt1Rzg7QDz1+mf8AP1qntY6akG1dGrrThYdoOGAzn2/rXD6mu4MOnHXPOK3r+7DK3zA98Gsuztm1LUUjAbb95z2I96ILUcFyK7Oq0VCuj2gcDiMYOTxUs3VuST6f57VZ2qkaIg4XGMf56VVmyyjLOBngDKnj1HofQ8Gm9Wc1yuTuAyM/5/xxRRMcQyycnCE4PHQGipbaLjG5V0bSVtkE91+8lIyFA+7WjfXSW9vmZwHI+5nmszWNdhsh5UXz3BHcHAHrmuWuJpZXMly7O3UDPSlGPVmkYSm7sfqMhu76IR4Llx/kV6PGNkSg4yFAPGK4LwtZtfaqs748iHn8e3H4112qavFYKSwLyk/cHY9etU90FbVqKJtR0+01OIR3aBvRx1H0rmZvCNxHcN9m1DEOz7skfViT3z2A/UVHd6zqjuXilWNDyFABwKgOu6xFkM8T9vmXv6U05JDjColoy4PDGpnBFzGRj7wHStzRNBSwbzbxxPKBhBj5R/8AXrG0zxdKbyODVbZY0kIXzIznB+nXFdkcOQQ2R1zii5FSU1pIeJN2Cep6cU4fNkDJHbjrWTrmsw6SgUDfOwwFxx9c1zT6xqd1h0uTEPRR09qhpkQpSkro7wEZOBwODSg4Pfg964iPW9Us2DTSx3CgjKsvNdVpOoQalbCa3J3ZwwIIwaTQSpuOpeB6Yzkc89aeP8/57UzIHelUcfz9qdjIh1O+j02wkuZuiL0B6nsK83t3k1W8ae5YFnOeRn3x9MV0fxFldLS0jzhWck474HpWd4URC6b89AR6gfWqSsjroRUYOZr2mjqUUMuB6evHUVS1fSAsLcADjPFdtEAI1yMA/pWbrMYW3Y8j3GKq9zOFZuRyHg3VJNP1ddPkO62uDhR/cfk/rXoVxKIIJJWxhQTycZry63UHxLaFeSJVP69673xU5XSyq9XYKKVrjxEE5q3U5fUp5NXvDJMCIF+VVycdv696kFqsWBsUDIBIGMe1NtZXSEiJl80qwR2XK7u2R1IzyfWtKPzJbNUncNJsHmMFwrNjkgdh7VXob/DotiiyKgUqFGTwc/4/5FPW1kddxGARkduPX6ZrT0OC0V3hlgQTZ3J3GKl1+9W2hKoCCeMjoP8AOKCPaNy5Ujn9MmaPXrVCP9Y2GXOa7qSHbGRbhUbGBkVzXhLTWlf+0Lnn/nkp7ep/lWtr+pGxtysRxcOPlyMgVb00MKz56nLErDSb0Mf9Jixzj5OBVDWbJNM0+CGMbmdyXbHU+prOW91bckj3T4zlgG+6Mfr2rRur+Zo4ftiq8TL86nr7kEUObejKjQlCSd7lDSbcNfxKdvJ4B55/z/KuwWyi2YAB4781zdxZGOEvDINhO9HA5GK6TSbkXdjHIT+8wA/sai1wryekkc9f2oBcKGV1OcAY9ai8Jym21O4tgSEmHmKO2R1/GtLWlMd4ztlldQQAeRjtWDbSeRq9q6gbTIAce/8AhSW5ovfps7sn6ZpMj1pHzuYFSAByxxg+vv8A/r+tAHcYx2OKGcQ3n2rPv9UtrGMgncw/gX+VTapO0NsQhwz9D6Vzo08S5J+Y+pP41NjanBPWQybxmsZO/T5WXHZ+T9Ku6X4s0rUXEYlFvPnhJvlz+JrJn08EYUgkYOe+P8axNR0pGB3IjDqPU9/wpJHSqVOWx3WsaFaaqBKf3U5HEid/wrk7nw5qtlIRAFuIjj5g2CfqKz9E1298P3KR3TvNpp4ZXO4x+6nrjPavTd6SxrJG2VYcEjsar1Ilz0XbocFb+HdSmaPzwI0dgG2gE4zznngYPX/61dTp9lBpsIigXOPvE9z61ekIx8+c54HXOPeq77WGWyqkbs+3rQ5GcpuW5Xw6IQ8rzc4EkgUMw752gD9PWmsCrHcDnHIrL1PxBbWshVIzNIOCTwP5Vm/8JWiuDLZMFJ/hfP50LYFTk9bG7c5a2lXuyMPrx0oqrp+p2eqRubN23DIKMpBHbrRSaBe7oz//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Blood smear showing large lymphoblasts with prominent nucleoli and light blue cytoplasm, as seen in acute lymphocytic leukemia (ALL) of the French American British (FAB) L-2 morphologic type.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Baehner, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_54_42848=[""].join("\n");
var outline_f41_54_42848=null;
var title_f41_54_42849="Calculator: Revised International Prognostic Scoring System (IPSS-R) in myelodysplastic syndrome";
var content_f41_54_42849=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"MyeloDysplasiaRevised_form\" name=\"MyeloDysplasiaRevised_form\" onreset=\"rrclr();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Revised International Prognostic Scoring System (IPSS-R) in myelodysplastic syndrome",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_main\">",
"     <div id=\"calc_input\">",
"      <center>",
"       <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Cytogenetics",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"MyeloDysplasiaRevised_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Very good: -Y, del(11q) (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"MyeloDysplasiaRevised_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Good: Normal, del(5q), del(12p), del(20q), double including del(5q) (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"MyeloDysplasiaRevised_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Intermediate: del(7q), +8, +19, i(17q), any other single or double independent clones (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"MyeloDysplasiaRevised_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Poor: -7, inv(3)/t(3q)/del(3q), double including -7/del(7q), complex: 3 abnormalities (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"MyeloDysplasiaRevised_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Very poor: Complex: &gt;3 abnormalities (4 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Percentage of Bone Marrow Blasts",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"MyeloDysplasiaRevised_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           &le;2 percent (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"MyeloDysplasiaRevised_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           &gt;2 to &lt;5 percent (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"MyeloDysplasiaRevised_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           5 to 10 percent (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"MyeloDysplasiaRevised_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           &gt;10 percent (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Hemoglobin",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"MyeloDysplasiaRevised_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           &ge;10 g/dL (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"MyeloDysplasiaRevised_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           8 to &lt;10 g/dL (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"MyeloDysplasiaRevised_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           &lt;8 g/dL (1.5 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Platelets",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"MyeloDysplasiaRevised_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           &ge;100,000/microL (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"MyeloDysplasiaRevised_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           50,000-100,000/microL (0.5 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"MyeloDysplasiaRevised_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           &lt;50,000/microL (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Absolute neutrophil count",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"MyeloDysplasiaRevised_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           &ge;800/microL (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"MyeloDysplasiaRevised_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           &lt;800/microL (0.5 points)",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"     </div>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <div id=\"calc_result\">",
"      <span class=\"medCalcFontCCTabBold\">",
"       Total Criteria Point Count:",
"      </span>",
"      <input name=\"cctotal\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <input name=\"reset\" type=\"reset\" value=\"Reset Form\"/>",
"      </center>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"       <tr>",
"        <td bgcolor=\"#eeeeee\" width=\"1%\">",
"         <br/>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <span class=\"medCalcFontTitleBox\">",
"          IPSS-R Interpretation",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"        <tr id=\"rr1_1\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           Score &lt;=1.5:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           Very low risk: median overall survival 8.8 years with &gt;14.5 years to 25% AML evolution",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_2\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           Score &gt;1.5  and &lt;=3:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           Low risk: median overall survival 5.3 years with 10.8 years to 25% AML evolution",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_3\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           Score &gt;3  and &lt;=4.5:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           Intermediate risk: median overall survival 3 years with 3.2 years to 25% AML evolution",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_4\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           Score &gt;4.5  and &lt;=6:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           High risk: median overall survival 1.6 years with 1.4 years to 25% AML evolution",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_5\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           Score &gt;6:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           Very high risk: median overall survival 0.8 years with 0.7 years to 25% AML evolution",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"     </div>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"     </span>",
"    </div>",
"    <div id=\"calc_notes\">",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       This scoring system was applied to an initial group of 7012 patients with primary MDS by the French-American-British classification who had at least two months of stable blood counts, &le;30 percent bone marrow blasts and &le;19 percent peripheral blood blasts, and who were observed until progression to AML transformation or death (did not receive disease-modifying agents for MDS). Patients could be stratified into five groups with estimated overall survival and progression to AML as described above.",
"      </li>",
"      <li>",
"       AML: acute myeloid leukemia; MDS: myelodysplastic syndrome.",
"      </li>",
"     </ul>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Greenberg PL, Tuechler H, Schanz J, et. al. Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic  syndromes.",
"        <i>",
"         Blood",
"        </i>",
"        . 2012 Jun 27.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"   <script language=\"JavaScript1.1\" type=\"text/javascript\">",
"    &lt;!--",
"",
";",
"MyeloDysplasiaRevised_fx();",
"//--&gt;",
"   </script>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_54_42849=[" ",
"",
"var calctxt = '';",
"var xmltxt = '';",
"var htmtxt = '';",
"",
"",
"function MyeloDysplasiaRevised_fx() {",
"with(document.MyeloDysplasiaRevised_form){",
"",
"Score = 0.0;",
"doCalc = true;",
"",
"if (cc1[0].checked){",
"Score = Score + 0;",
"}",
"if (cc1[1].checked){",
"Score = Score + 1;",
"}",
"if (cc1[2].checked){",
"Score = Score + 2;",
"}",
"if (cc1[3].checked){",
"Score = Score + 3;",
"}",
"if (cc1[4].checked){",
"Score = Score + 4;",
"}",
"if (cc2[0].checked){",
"Score = Score + 0;",
"}",
"if (cc2[1].checked){",
"Score = Score + 1;",
"}",
"if (cc2[2].checked){",
"Score = Score + 2;",
"}",
"if (cc2[3].checked){",
"Score = Score + 3;",
"}",
"if (cc3[0].checked){",
"Score = Score + 0;",
"}",
"if (cc3[1].checked){",
"Score = Score + 1;",
"}",
"if (cc3[2].checked){",
"Score = Score + 1.5;",
"}",
"if (cc4[0].checked){",
"Score = Score + 0;",
"}",
"if (cc4[1].checked){",
"Score = Score + 0.5;",
"}",
"if (cc4[2].checked){",
"Score = Score + 1;",
"}",
"if (cc5[0].checked){",
"Score = Score + 0;",
"}",
"if (cc5[1].checked){",
"Score = Score + 0.5;",
"}",
"Score = Math.round(Score * 100) / 100;",
"cctotal.value = Score;",
"",
"if (doCalc){",
"rrclr();",
"if (Score <=1.5){ document.getElementById('rr1_1').bgColor = '#cccccc';",
"}",
"if ((Score >1.5 ) && (Score <=3)){ document.getElementById('rr1_2').bgColor = '#cccccc';",
"}",
"if ((Score >3 ) && (Score <=4.5)){ document.getElementById('rr1_3').bgColor = '#cccccc';",
"}",
"if ((Score >4.5 ) && (Score <=6)){ document.getElementById('rr1_4').bgColor = '#cccccc';",
"}",
"if (Score >6){ document.getElementById('rr1_5').bgColor = '#cccccc';",
"}",
"",
"}",
"}",
"}",
"",
"",
"",
"",
"function rrclr(){",
"document.getElementById('rr1_1').bgColor = \"\";",
"document.getElementById('rr1_2').bgColor = \"\";",
"document.getElementById('rr1_3').bgColor = \"\";",
"document.getElementById('rr1_4').bgColor = \"\";",
"document.getElementById('rr1_5').bgColor = \"\";",
"}",
"",
"",
""].join("\n");
var outline_f41_54_42849=null;
var title_f41_54_42850="ARF lateral view anal rectal fistulas";
var content_f41_54_42850=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F76507&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F76507&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 483px\">",
"   <div class=\"ttl\">",
"    Anal rectal fistulas, lateral view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 463px; height: 507px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this lateral view of anal rectal fistulas, a superficial fistula has been included. It is not a component of the original Parks' classification. This figure also illustrates the potential pathways of trans-sphincteric fistulas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_54_42850=[""].join("\n");
var outline_f41_54_42850=null;
var title_f41_54_42851="Pegaptanib: Drug information";
var content_f41_54_42851=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pegaptanib: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/19/22835?source=see_link\">",
"    see \"Pegaptanib: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F206719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Macugen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2973204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Macugen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F206733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Ophthalmic Agent;",
"     </li>",
"     <li>",
"      Vascular Endothelial Growth Factor (VEGF) Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F206720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      AMD:",
"     </b>",
"     Intravitreous injection: 0.3 mg into affected eye every 6 weeks",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F206721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjustment not required with renal impairment; information not available for patients requiring hemodialysis.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F206704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Macugen&reg;: 0.3 mg/0.09 mL (0.09 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F206693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F206707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For ophthalmic intravitreal injection only. Attach a 30 gauge",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     inch needle to the medication syringe. Depress plunger to expel excess air and medication (refer to product labeling for detailed instructions). Adequate anesthesia and a topical broad spectrum antibiotic should be administered prior to the procedure.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F206706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of neovascular (wet) age-related macular degeneration (AMD)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14188872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Pegaptanib may be confused with peginesatide, pegaspargase, pegfilgrastim, peginterferon, pegvisomant",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F206731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     10% to 40%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Anterior chamber inflammation, blurred vision, cataract, conjunctival hemorrhage, corneal edema, eye discharge, eye irritation, eye pain, intraocular pressure increased, ocular discomfort, punctate keratitis, visual acuity decreased, visual disturbance, vitreous floaters, vitreous opacities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Carotid artery occlusion (1% to 5%), cerebrovascular accident (1% to 5%), chest pain (1% to 5%), transient ischemic attack (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (6% to 10%), headache (6% to 10%), vertigo (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Contact dermatitis (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Diabetes mellitus (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (6% to 10%), nausea (6% to 10%), dyspepsia (1% to 5%), vomiting (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary retention (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthritis (1% to 5%), bone spur (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blepharitis (6% to 10%), conjunctivitis (6% to 10%), photopsia (6% to 10%), vitreous disorder (6% to 10%), allergic conjunctivitis (1% to 5%), conjunctival edema (1% to 5%), corneal abrasion (1% to 5%), corneal deposits (1% to 5%), corneal epithelium disorder (1% to 5%), endophthalmitis (1% to 5%), eye inflammation (1% to 5%), eye swelling (1% to 5%), eyelid irritation (1% to 5%), meibomianitis (1% to 5%), mydriasis (1% to 5%), periorbital hematoma (1% to 5%), retinal edema (1% to 5%), vitreous hemorrhage (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Hearing loss (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Urinary tract infection (6% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchitis (6% to 10%), pleural effusion (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Contusion (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis, anaphylactoid reaction, angioedema, hypersensitivity, iatrogenic traumatic cataract, endophthalmitis, retinal detachment",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F206710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pegaptanib or any component of the formulation; ocular or periocular infection",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F206695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Endophthalmitis/retinal detachment: Intravitreous injections may be associated with endophthalmitis and retinal detachments. Proper aseptic injection techniques should be used and patients should be instructed to report any signs of infection (eg, eye pain or redness, photophobia, blurred vision) immediately.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Rare hypersensitivity reactions (including anaphylaxis) have been associated with use, occurring within several hours of use; monitor closely. Equipment and appropriate personnel should be available for monitoring and treatment of anaphylaxis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intraocular pressure: Following intravitreal injection, intraocular pressure may increase. Onset is seen within 30 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thromboembolic events: Thromboembolic events (eg, nonfatal stroke/MI, vascular death) have been reported following intravitreal administration of other VEGF inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Safety and efficacy have not been established with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Safety and efficacy have not been established in patients requiring hemodialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Concurrent administration in both eyes: Safety and efficacy for administration into both eyes concurrently have not been studied.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegloticase: May diminish the therapeutic effect of Pegaptanib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F206700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F206712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not reported in animal studies. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F206723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Macugen Intraocular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.3 mg (0.09 mL): $1194.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F206702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intraocular pressure (within 30 minutes and 2-7 days after injection); signs of infection/inflammation (for first week following injection); retinal perfusion, endophthalmitis, visual acuity",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4301439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Macugen (AT, BE, BG, BR, CH, CO, CZ, DE, DK, EE, FI, FR, GB, GR, HK, HN, IE, IL, IT, MT, NL, NO, NZ, PE, PH, PL, PT, RU, SE, SG, SK, TH, TR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F206694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pegaptanib is an apatamer, an oligonucleotide covalently bound to polyethylene glycol, which can adopt a three-dimensional shape and bind to vascular endothelial growth factor (VEGF). Pegaptanib binds to extracellular VEGF, inhibiting VEGF from binding to its receptors and thereby suppressing neovascularization and slowing vision loss.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F206709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Slow systemic absorption following intravitreous injection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Metabolized by endo- and exonucleases",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Plasma: 6-14 days",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Gragoudas ES, Adamis AP, Cunningham ET, et al, &ldquo;Pegaptanib for Neovascular Age-Related Macular Degeneration,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 351(27):2805-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/54/42851/abstract-text/15625332/pubmed\" id=\"15625332\" target=\"_blank\">",
"        15625332",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10182 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-382E3F64B8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_54_42851=[""].join("\n");
var outline_f41_54_42851=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206719\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2973204\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206733\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206720\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062246\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206721\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206704\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206693\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206707\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206706\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14188872\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206731\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206710\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206695\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299828\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222174\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206700\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206712\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206723\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323629\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206702\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4301439\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206694\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206709\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10182\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10182|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/19/22835?source=related_link\">",
"      Pegaptanib: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_54_42852="Polymyalgia rheumatica and giant cell (temporal) arteritis";
var content_f41_54_42852=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   Patient information: Polymyalgia rheumatica and giant cell (temporal) arteritis (Beyond the Basics)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/54/42852/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/54/42852/contributors\">",
"     Gene G Hunder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/54/42852/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/54/42852/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/54/42852/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/54/42852/contributors\">",
"     Jerry M Greene, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/54/42852/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are linked inflammatory conditions that affect different parts of the body. They are frequently discussed together because:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Polymyalgia rheumatica occurs in about 50 percent of people with giant cell arteritis.",
"     </li>",
"     <li>",
"      Approximately 15 to 30 percent of people with polymyalgia rheumatica have giant cell arteritis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some people with one disorder later develop symptoms of the other.",
"   </p>",
"   <p>",
"    More detailed information about polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) is available elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13832?source=see_link\">",
"     \"Clinical manifestations and diagnosis of polymyalgia rheumatica\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34599?source=see_link\">",
"     \"Diagnosis of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     POLYMYALGIA RHEUMATICA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common symptoms of polymyalgia rheumatica (PMR) are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aching and morning stiffness in the shoulder, hips, neck, and upper body. Some people have trouble getting dressed (eg, fastening a bra, putting on a shirt or jacket, or pulling on stockings).",
"     </li>",
"     <li>",
"      Swelling or stiffness in the larger joints, such as the knees, or, occasionally, in the small joints of the hands and feet",
"     </li>",
"     <li>",
"      Swelling in the hands, wrists, ankles, or the tops of the feet. Swelling in the wrist can lead to numbness, tingling, and pain in the hands (called carpal tunnel syndrome).",
"     </li>",
"     <li>",
"      Feeling of tiredness, poor appetite, weight loss, or fever",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Polymyalgia rheumatica diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A combination of approaches is used to diagnose polymyalgia rheumatica, including an exam, lab tests, and imaging tests (x-ray, MRI, etc). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13832?source=see_link\">",
"     \"Clinical manifestations and diagnosis of polymyalgia rheumatica\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most people who are diagnosed with PMR:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Are age 50 years or older when symptoms begin.",
"     </li>",
"     <li>",
"      Have aching and morning stiffness (lasting 30 minutes or more) on both sides of the body, persisting for at least one month and involving at least two of the following three areas: neck or upper body, shoulders or upper arms, and hips or upper thighs.",
"     </li>",
"     <li>",
"      Have an elevated level of inflammation, which can be measured with a blood test (such as the erythrocyte sedimentation rate).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Polymyalgia rheumatica treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymyalgia rheumatica responds quickly to medicines that reduce inflammation, particularly glucocorticoids (also called steroids).",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?27/36/28230?source=see_link\">",
"     Prednisone",
"    </a>",
"    and",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/10/39072?source=see_link\">",
"     prednisolone",
"    </a>",
"    are two commonly used glucocorticoids.",
"   </p>",
"   <p>",
"    During your treatment, it is very important to call your doctor or nurse if you develop any new symptoms that could be caused by giant cell arteritis, such as a change in vision, headaches, jaw or arm pain or weakness, or a new cough. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Giant cell arteritis symptoms'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most people feel better after the first few doses of a glucocorticoid. Your doctor or nurse will gradually decrease the dose every two to four weeks to find the minimum dose that is needed to prevent symptoms. Most people need to take glucocorticoids for one to two years, although some people require an even longer course of treatment.",
"   </p>",
"   <p>",
"    Glucocorticoids can have serious side effects when taken for long periods of time. Side effects can include weight gain, weakening of the bones, and diabetes. Taking the lowest possible dose for the shortest possible time can help to lower the chance of these side effects.",
"   </p>",
"   <p>",
"    As the dose of the glucocorticoid is reduced, it is common to develop stiffness and pain. Decreasing the dose slowly can minimize these symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     GIANT CELL ARTERITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Giant cell arteritis, also called GCA or temporal arteritis, is a type of blood vessel inflammation that damages medium- and large-sized arteries. The most commonly affected arteries are those that start in the neck and travel into the head.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     How are polymyalgia rheumatica and giant cell arteritis related?",
"    </span>",
"    &nbsp;&mdash;&nbsp;About one-half of people with giant cell arteritis have polymyalgia rheumatica. About 15 to 30 percent of people with polymyalgia rheumatic have giant cell arteritis. It is not clear why the conditions often occur together.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Giant cell arteritis symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of giant cell arteritis tend to come on slowly. The most common symptoms include headaches, jaw or arm pain or weakness, difficulty seeing clearly, or a new cough. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/33/18969?source=see_link\">",
"     \"Clinical manifestations of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other symptoms can include developing a fever (usually less than 101&ordm;F or 38&ordm;C), feeling tired, and losing weight.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Headache &mdash; The pain, which may be mild or severe, tends to be located over the temples but may be in the front or back of the skull (",
"      <a class=\"graphic graphic_figure graphicRef65142 \" href=\"mobipreview.htm?6/47/6897\">",
"       figure 1",
"      </a>",
"      ). Some people also notice tenderness in the scalp.",
"     </li>",
"     <li>",
"      Jaw pain or weakness (claudication) &mdash; Nearly one-half of people with giant cell arteritis suffer from jaw pain which develops while chewing food. This is also called jaw claudication. Claudication develops because of inadequate blood flow to the muscles involved in chewing.",
"     </li>",
"     <li>",
"      Vision loss &mdash; About 20 percent of people with giant cell arteritis develop partial or complete blindness. Changes in vision may be a first sign of GCA. Vision loss usually begins suddenly with difficulty seeing out of one eye. If untreated, vision in the second eye can also be affected. It is rare, however, to become completely blind in both eyes.",
"     </li>",
"     <li>",
"      Arm claudication &mdash; Arm claudication causes pain in the arm, especially when moving the arm. It can develop when the arteries to the arm are narrowed.",
"     </li>",
"     <li>",
"      Upper respiratory complaints &mdash; About 10 percent of people with giant cell arteritis develop a dry cough or a sore throat.",
"     </li>",
"     <li>",
"      Thoracic aortic aneurysms &mdash; A thoracic aortic aneurysm occurs when the main artery that carries blood from the heart, the aorta, develops a weak spot and balloons outward (",
"      <a class=\"graphic graphic_figure graphicRef59752 \" href=\"mobipreview.htm?28/10/28834\">",
"       figure 2",
"      </a>",
"      ). This does not cause symptoms. However, aneurysms can be life threatening if they burst.",
"      <br/>",
"      <br/>",
"      People with giant cell arteritis are usually tested for this type of aneurysm with a once-yearly chest x-ray. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/7/10361?source=see_link\">",
"       \"Management and outcome of thoracic aortic aneurysm\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Giant cell arteritis diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Your doctor or nurse might perform tests for GCA if you have some of the symptoms listed above. He or she will perform an exam and will order some blood tests. If the blood tests show signs of GCA, you will need a biopsy of one or both arteries in the temples (",
"    <a class=\"graphic graphic_figure graphicRef65142 \" href=\"mobipreview.htm?6/47/6897\">",
"     figure 1",
"    </a>",
"    ), and you may need imaging tests (eg, x-ray, ultrasound, or MRI).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Giant cell arteritis treatment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Glucocorticoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoid (also called steroid) treatment is usually recommended once the diagnosis of giant cell arteritis is strongly suspected, even if it has not been proven by biopsy.",
"   </p>",
"   <p>",
"    Glucocorticoid treatment may be continued, even if artery biopsies performed later reveal no evidence of arteritis. This is especially true if your doctor strongly suspects that you have giant cell arteritis. If there is no evidence of arteritis on biopsy and if your doctor is not convinced you have giant cell arteritis, he or she might recommend decreasing the dose of glucocorticoids or stopping them completely. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34217?source=see_link\">",
"     \"Treatment of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many people continue taking glucocorticoids for one to two years and, occasionally, for even longer. The dose of glucocorticoids can begin to be tapered once the disease begins to go into remission. This is done slowly and carefully so that symptoms of giant cell arteritis do not recur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?41/59/42934?source=see_link\">",
"     Methotrexate",
"    </a>",
"    is a medicine that was originally designed to treat cancer. When used in much lower doses, methotrexate works to reduce inflammation. It is sometimes used along with glucocorticoids to treat giant cell arteritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Antiplatelet treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/12/6342?source=see_link\">",
"     Aspirin",
"    </a>",
"    is a medication sometimes recommended for people with giant cell arteritis who have an increased risk of blood clots. Aspirin inhibits the clumping of platelets; platelets are tiny cell fragments in the blood that have a role in blood clotting. Under normal circumstances, platelets clump together and help form blood clots to stop bleeding when needed.",
"   </p>",
"   <p>",
"    There is some evidence that people with giant cell arteritis who take low-dose",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/12/6342?source=see_link\">",
"     aspirin",
"    </a>",
"    have a lower risk of vision loss related to blockage of blood flow in blood vessels of the eye. Based upon these observations and upon the relatively small risk of low-dose aspirin, most experts recommend that everyone with giant cell arteritis take low-dose aspirin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     LONG-TERM OUTLOOK",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Polymyalgia rheumatica",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most people, polymyalgia rheumatica tends to run its course over months to years, and glucocorticoid therapy can eventually be stopped.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Giant cell arteritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Giant cell arteritis also tends to run its course over several months to several years. However, giant cell arteritis can reappear for no reason during the first year or two after it is diagnosed. The dose of glucocorticoids can eventually be reduced and then stopped in most patients. A small group of people with giant cell arteritis have more chronic disease and require a low dose of glucocorticoids for a number of years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     WHERE TO GET MORE INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"   </p>",
"   <p>",
"    This article will be updated as needed on our web site (",
"    <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"     www.uptodate.com/patients",
"    </a>",
"    ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12644176\">",
"    <span class=\"h2\">",
"     Patient level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12644191\">",
"    <span class=\"h3\">",
"     The Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/24/42369?source=see_link\">",
"     Patient information: Polymyalgia rheumatica and giant cell arteritis (The Basics)",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12644199\">",
"    <span class=\"h3\">",
"     Beyond the Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    This topic currently has no corresponding Beyond the Basics content.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Professional level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13832?source=see_link\">",
"     Clinical manifestations and diagnosis of polymyalgia rheumatica",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/33/18969?source=see_link\">",
"     Clinical manifestations of giant cell (temporal) arteritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34599?source=see_link\">",
"     Diagnosis of giant cell (temporal) arteritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34217?source=see_link\">",
"     Treatment of giant cell (temporal) arteritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/41/40598?source=see_link\">",
"     Treatment of polymyalgia rheumatica",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/7/10361?source=see_link\">",
"     Management and outcome of thoracic aortic aneurysm",
"    </a>",
"    <br/>",
"   </p>",
"   <p>",
"    The following organizations also provide reliable health information.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Library of Medicine",
"      <br/>",
"      (",
"      <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/polymyalgiarheumatica.html\">",
"       www.nlm.nih.gov/medlineplus/polymyalgiarheumatica.html",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      National Institute of Arthritis and Musculoskeletal and Skin Disease",
"      <br/>",
"      (",
"      <a class=\"external\" href=\"file://www.niams.nih.gov/\">",
"       www.niams.nih.gov",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      American College of Rheumatology",
"      <br/>",
"      (",
"      <a class=\"external\" href=\"file://www.rheumatology.org/practice/clinical/patients/index.asp\">",
"       file://www.rheumatology.org/practice/clinical/patients/index.asp",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42852/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42852/abstract/1\">",
"      Rodriguez-Valverde V, Sarabia JM, Gonz&aacute;lez-Gay MA, et al. Risk factors and predictive models of giant cell arteritis in polymyalgia rheumatica. Am J Med 1997; 102:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42852/abstract/2\">",
"      Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002; 347:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42852/abstract/3\">",
"      Brooks RC, McGee SR. Diagnostic dilemmas in polymyalgia rheumatica. Arch Intern Med 1997; 157:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42852/abstract/4\">",
"      Foroozan R, Deramo VA, Buono LM, et al. Recovery of visual function in patients with biopsy-proven giant cell arteritis. Ophthalmology 2003; 110:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42852/abstract/5\">",
"      Matteson EL, Gold KN, Bloch DA, Hunder GG. Long-term survival of patients with giant cell arteritis in the American College of Rheumatology giant cell arteritis classification criteria cohort. Am J Med 1996; 100:193.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 576 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-9843F0D5B8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_54_42852=[""].join("\n");
var outline_f41_54_42852=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      POLYMYALGIA RHEUMATICA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Polymyalgia rheumatica diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Polymyalgia rheumatica treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      GIANT CELL ARTERITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      How are polymyalgia rheumatica and giant cell arteritis related?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Giant cell arteritis symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Giant cell arteritis diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Giant cell arteritis treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Glucocorticoid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Antiplatelet treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      LONG-TERM OUTLOOK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Polymyalgia rheumatica",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Giant cell arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      WHERE TO GET MORE INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12644176\">",
"      Patient level information",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12644191\">",
"      - The Basics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12644199\">",
"      - Beyond the Basics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Professional level information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/576\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PI/576|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/47/6897\" title=\"figure 1\">",
"      Temporal arteritis PI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/10/28834\" title=\"figure 2\">",
"      Thoracic aneurysm PI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13832?source=related_link\">",
"      Clinical manifestations and diagnosis of polymyalgia rheumatica",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/33/18969?source=related_link\">",
"      Clinical manifestations of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34599?source=related_link\">",
"      Diagnosis of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/7/10361?source=related_link\">",
"      Management and outcome of thoracic aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/24/42369?source=related_link\">",
"      Patient information: Polymyalgia rheumatica and giant cell arteritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34217?source=related_link\">",
"      Treatment of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/41/40598?source=related_link\">",
"      Treatment of polymyalgia rheumatica",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_54_42853="Black widow spider ventral surface";
var content_f41_54_42853=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F78920&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F78920&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Black widow spider ventral surface",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard S Vetter, MS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_54_42853=[""].join("\n");
var outline_f41_54_42853=null;
var title_f41_54_42854="Rosuvastatin: Pediatric drug information";
var content_f41_54_42854=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rosuvastatin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"    see \"Rosuvastatin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/3/1077?source=see_link\">",
"    see \"Rosuvastatin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F13842378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      HMG-CoA Reductase Inhibitors and Risk of Increased Blood Glucose Concentrations and Diabetes",
"     </span>",
"     <span class=\"collapsible-date\">",
"      January 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Health Canada has notified healthcare professionals of updates to the product monographs of HMG-CoA reductase inhibitors (aka, &ldquo;statins&rdquo;) marketed in Canada regarding the risk of increased blood glucose concentrations and a small increased risk of diabetes mellitus following administration of these agents. The risk appears to be greatest in patients already at risk for diabetes (eg, patients with increased blood glucose concentration, hypertriglyceridemia, obesity, hypertension).  However, Health Canada continues to acknowledge that the benefits of statin therapy far outweigh the risk of dysglycemia. It is recommended that clinicians carefully monitor the use of statins in patients at high risk of developing diabetes mellitus.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For additional information, please refer to file://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/16949a-eng.php.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F219522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Crestor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F219523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Rosuvastatin;",
"     </li>",
"     <li>",
"      CO Rosuvastatin;",
"     </li>",
"     <li>",
"      Crestor&reg;;",
"     </li>",
"     <li>",
"      Jamp-Rosuvastatin;",
"     </li>",
"     <li>",
"      Mylan-Rosuvastatin;",
"     </li>",
"     <li>",
"      PMS-Rosuvastatin;",
"     </li>",
"     <li>",
"      RAN&trade;-Rosuvastatin;",
"     </li>",
"     <li>",
"      Sandoz-Rosuvastatin;",
"     </li>",
"     <li>",
"      Teva-Rosuvastatin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1035352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antilipemic Agent, HMG-CoA Reductase Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1035388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"      see \"Rosuvastatin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Doses should be individualized according to the baseline LDL-cholesterol levels, the recommended goal of therapy, and patient response; adjustments should be made at intervals of 4 weeks or more.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     A lower, conservative dosing regimen may be necessary in patient populations predisposed to myopathy, including patients of Asian descent or concurrently receiving other lipid-lowering agents (eg, gemfibrozil, niacin, fibric acid derivatives), amiodarone, atazanavir/ritonavir, cyclosporine, lopinavir/ritonavir, or indinavir (see conservative, maximum adult doses below).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Heterozygous familial hypercholesterolemia:",
"     </b>",
"     Children and Adolescents 10-17 years: Oral: 5-20 mg once daily; may titrate dose at 4-week intervals; maximum daily dose: 20 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Homozygous familial hypercholesterolemia:",
"     </b>",
"     Limited data available: Children and Adolescents (&ge;8 years and &ge;32 kg): Oral: Initial dose: 20 mg once daily; titrate at 6-week intervals to 40 mg once daily. Although higher doses have been used (ie, 80 mg/day), additional benefit has not been reported. Dosing based on an open-label, forced-titration study of 44 patients (n=8 pediatric patients &ge;8 years) which reported 72% of patients responded to rosuvastatin treatment (Marias, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Hyperlipidemia, mixed dyslipidemia, hypertriglyceridemia, primary dysbetalipoproteinemia, slowing progression of atherosclerosis:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Initial dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     General dosing: 10 mg once daily; 20 mg once daily may be used in patients with severe hyperlipidemia (LDL &gt;190 mg/dL) and aggressive lipid targets",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Conservative dosing: Patients requiring less aggressive treatment or predisposed to myopathy (including patients of Asian descent): 5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Titration: After 2 weeks, may be increased by 5-10 mg once daily; dosing range: 5-40 mg/day; maximum daily dose: 40 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Note:",
"     </b>",
"     The 40 mg dose should be reserved for patients who have not achieved goal cholesterol levels on a dose of 20 mg/day, including patients switched from another HMG-CoA reductase inhibitor.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Homozygous familial hypercholesterolemia (FH):",
"     </b>",
"     Initial: 20 mg once daily; maximum dose: 40 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment with concomitant medications:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Atazanavir/ritonavir  or lopinavir/ritonavir: Initiate rosuvastatin at 5 mg once daily; rosuvastatin dose should not exceed 10 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cyclosporine: Rosuvastatin dose should not exceed 5 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gemfibrozil: Avoid concurrent use; if unable to avoid concurrent use, initiate rosuvastatin at 5 mg once daily; rosuvastatin dose should not exceed 10 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Mild to moderate impairment: No dosage adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     and not receiving hemodialysis: Initial: 5 mg once daily; do not exceed 10 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustments in hepatic impairment:",
"     </b>",
"     There are no dosage adjustments provided in the manufacturer labeling; systemic exposure may be increased in patients with liver disease; use is contraindicated in patients with active liver disease or unexplained transaminase elevations.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F219497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Crestor&reg;: 5 mg, 10 mg, 20 mg, 40 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F219484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1035393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food; may be taken at any time of the day.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1035374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store between 20&deg;C and 25&deg;C (68&deg;F to 77&deg;F). Protect from moisture.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1035353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to dietary therapy to reduce elevated total-C, LDL-C, and apo-B levels in patients with heterozygous familial hypercholesterolemia (HeFH) [FDA approved in ages 10-17 years (girls &ge;1 year postmenarche)]. Adjunct to dietary therapy for hyperlipidemias to reduce elevations in total cholesterol (TC), LDL-C, apo-B, nonHDL-C, and triglycerides (TG) in patients with primary hypercholesterolemia (elevations of 1 or more components are present in Fredrickson type IIa, IIb, and IV hyperlipidemias) (FDA approved in adults); treatment of hypertriglyceridemia (FDA approved in adults); treatment of primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia) (FDA approved in adults); treatment of homozygous familial hypercholesterolemia (FH) (FDA approved in adults); to slow progression of atherosclerosis as an adjunct to diet to lower TC and LDL-C (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7914388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Rosuvastatin may be confused with atorvaSTATin, nystatin, pitavastatin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F219548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, constipation, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased (&gt;3 times ULN)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, CPK increased, myalgia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Alkaline phosphatase increased, amnesia (reversible),  AST increased, bilirubin increased, blood glucose increased, cataracts, cognitive impairment (reversible), confusion (reversible), depression, diabetes mellitus (new onset), GGT increased, glycosylated hemoglobin (Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     ) increased,  gynecomastia, hematuria (microscopic), hepatic failure, hepatitis, hyperglycemia, hypersensitivity reactions (including angioedema, pruritus, rash, urticaria), insomnia, jaundice, memory disturbance (reversible), memory impairment (reversible), myoglobinuria, myositis, myopathy, nightmares, pancreatitis, proteinuria (dose related), renal failure, rhabdomyolysis, thyroid function test abnormalities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adverse reactions reported with other HMG-CoA reductase inhibitors (not necessarily reported with rosuvastatin therapy) include a hypersensitivity syndrome (symptoms may include anaphylaxis, angioedema, arthralgia, erythema multiforme, eosinophilia, hemolytic anemia, immune-mediated necrotizing myopathy (IMNM), interstitial lung disease, lupus syndrome, photosensitivity, polymyalgia rheumatica, positive ANA, purpura, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria, vasculitis)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1035358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to rosuvastatin or any component; active liver disease; unexplained persistent elevations of hepatic serum transaminases (&gt;3 times ULN); pregnancy; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F9922285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rosuvastatin significantly increases INR in patients on warfarin. INR should be monitored before starting rosuvastatin and frequently during therapy. Transient proteinuria and hematuria have been reported; consider dose reduction if finding persists. Use caution in patients with conditions or on medications that reduce steroidogenesis (eg, ketoconazole, spironolactone, cimetidine). Increases in Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     and fasting blood glucose have been reported with HMG-CoA reductase inhibitors; however, the benefits of statin therapy far outweigh the risk of dysglycemia. Secondary causes of hyperlipidemia should be ruled out prior to therapy; has not been studied in conditions where the major abnormality is elevation of chylomicrons (hyperlipoproteinemia Types I or V). Use caution in patients with severe renal impairment not receiving dialysis; dosage adjustment required.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Although rare, reversible cognitive impairment (including confusion, forgetfulness, amnesia, and memory loss) can occur with HMG-CoA reductase inhibitors. These cognitive symptoms have been reported at variable times during therapy (1 day to years after initiation) and are reversible with discontinuation; resolution usually occurs within ~3 weeks. Cases have not been associated with fixed or progressive dementia; nor have they been associated with age, specific HMG-CoA reductase inhibitor, dose, or concomitant medication use.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1035359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients receiving HMG-CoA reductase inhibitors have developed rhabdomyolysis with or without acute renal failure and/or myopathy; patients should be monitored closely; risk is dose-related and is increased with concurrent use of other lipid-lowering medications (eg, fibric acid derivatives or niacin at doses &gt;1 g/day) or large quantities of grapefruit juice (&gt;1 quart/day).  With concurrent use of cyclosporine, lopinavir/ritonavir, or atazanavir/ritonavir; dosage reductions of rosuvastatin recommended. Ensure patient is on the lowest effective rosuvastatin dose in all circumstances. Discontinue in any patient in which CPK levels are markedly elevated (&gt;10 times ULN) or if myopathy is suspected/diagnosed; monitoring of CPK may be warranted, but may not prevent severe myopathy. The manufacturer recommends temporary discontinuation for elective major surgery, acute medical or surgical conditions, or in any patient experiencing an acute or serious condition predisposing to renal failure (eg, sepsis, hypotension, trauma, uncontrolled seizures). However, based upon current evidence, HMG-CoA reductase inhibitor therapy should be continued in the perioperative period unless risk outweighs cardioprotective benefit. Use caution in patients with renal impairment, inadequately treated hypothyroidism, and those taking other drugs associated with myopathy (eg, colchicine); these patients are predisposed to myopathy. Patients should be instructed to report unexplained muscle pain, tenderness, weakness, or brown urine.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     An autoimmune-mediated myopathy (IMNM), has been reported (rarely) with HMG-CoA reductase inhibitor therapy; presents as proximal muscle weakness with elevated CPK levels, which persists despite discontinuation of HMG-CoA reductase inhibitor therapy; additionally, muscle biopsy may show necrotizing myopathy with limited inflammation; immunosuppressive therapy (eg, corticosteroids, azathioprine) may be used for treatment. Hematuria (microscopic) and proteinuria have been observed; more commonly reported in patients receiving rosuvastatin 40 mg daily. Typically, transient and not associated with a decrease in renal function. Consider dosage reduction if unexplained hematuria and proteinuria persists.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Postmarketing reports of fatal and nonfatal hepatic failure are rare; if serious hepatotoxicity with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment, interrupt therapy. If an alternate etiology is not identified, do not restart rosuvastatin. Liver enzyme tests should be obtained at baseline and as clinically indicated; routine periodic monitoring of liver enzymes is not necessary. Use with caution in patients with history of heavy alcohol use or a previous history of liver disease.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F219537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (minor), CYP3A4 (minor), SLCO1B1;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F219491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May decrease the metabolism of HMG-CoA Reductase Inhibitors. Management: Dose of HMG-CoA reductase inhibitor may need to be reduced (limit simvastatin adult maximum dose to 20 mg/day, limit lovastatin adult maximum dose to 40 mg/day).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bezafibrate: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Bezafibrate may increase the serum concentration of HMG-CoA Reductase Inhibitors. More specifically, bezafibrate may increase the serum concentration of fluvastatin Management: Monitor patients closely for myopathy with concomitant use of bezafibrate and HMG-CoA reductase inhibitors. Concomitant use is contraindicated in patients predisposed to myopathy and alternative therapy should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Rosuvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Rosuvastatin. Management: Limit rosuvastatin to 5 mg/day in patients who are also receiving cyclosporine.  Canadian labeling contraindicates concomitant use of rosuvastatin with cyclosporine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DAPTOmycin: HMG-CoA Reductase Inhibitors may enhance the adverse/toxic effect of DAPTOmycin. Specifically, the risk of skeletal muscle toxicity may be increased.  Management: Consider temporarily stopping HMG-CoA reductase inhibitor therapy prior to daptomycin.  If used together, regular (i.e., at least weekly) monitoring of CPK concentrations is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May increase the serum concentration of Rosuvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of Rosuvastatin. Management: According to eltrombopag prescribing information, consideration should be given to a preventative 50% reduction in rosuvastatin adult dose when starting this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibrate: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibric Acid: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Specifically, the risk for muscle toxicities, including rhabdomyolysis may be significantly increased. Management: Avoid concurrent use of HMG-CoA reductase inhibitors (statins) with fusidic acid if possible.  If treatment with fusidic acid is necessary, consider temporarily stopping the statin.  With any concurrent use monitor patients closely for statin toxicity.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gemfibrozil: May enhance the myopathic (rhabdomyolysis) effect of Rosuvastatin. Gemfibrozil may increase the serum concentration of Rosuvastatin. Management: If possible, avoid concomitant use of rosuvastatin with gemfibrozil. If concomitant can not be avoided, limit rosuvastatin to 10 mg/day (US recommendation) or 20 mg/day (Canadian recommendation).  Monitor for signs/symptoms of rhabdomyolysis.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Rosuvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: HMG-CoA Reductase Inhibitors may decrease the serum concentration of Lanthanum.  Management: Administer HMG-CoA reductase inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacin: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Management: This is of greatest concern with niacin doses of 1 g or greater daily.  Avoid simvastatin 80 mg in combination with niacin 1 g or greater in Chinese patients. Canadian labeling contraindicates use of niacin with rosuvastatin 40 mg.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacinamide: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: HMG-CoA Reductase Inhibitors may enhance the hepatotoxic effect of Pazopanib. Specifically, the risk for increased serum transaminase concentrations may be increased.  Management: Simvastatin is specifically implicated in this interaction.  There is a lack of data regarding the risk with other statins, but caution appears warranted with any statins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Rosuvastatin. Management: Start with the lowest possible rosuvastatin dose and monitor for signs/symptoms of toxicity. In adult patients receiving atazanavir/ritonavir or lopinavir/ritonavir, initiate rosuvastatin at a 5 mg/day and do not exceed a dose of 10 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Rosuvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trabectedin: HMG-CoA Reductase Inhibitors may enhance the myopathic (rhabdomyolysis) effect of Trabectedin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): HMG-CoA Reductase Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F219493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F219506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cholesterol biosynthesis may be important in fetal development. Contraindicated in pregnancy. Administer to women of childbearing potential only when conception is highly unlikely and patients have been informed of potential hazards.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1035395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pediatric  patients: Baseline: ALT, AST, and creatine phosphokinase levels (CPK); fasting lipid panel (FLP) and repeat ALT and AST should be checked after 4 weeks of therapy; if no myopathy symptoms or laboratory abnormalities, then monitor FLP, ALT, and AST every 3-4 months during the first year and then every 6 months thereafter (NHLBI, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults: Baseline CPK (recheck CPK in any patient with symptoms suggestive of myopathy; discontinue therapy if markedly elevated); baseline liver function tests (LFTs) and repeat when clinically indicated thereafter. Patients with elevated transaminase levels should have a second (confirmatory) test and frequent monitoring until values normalize; discontinue if increase in ALT/AST is persistently &gt;3 times ULN (NCEP, 2002).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Lipid panel (total cholesterol, HDL, LDL, triglycerides):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     ATP III recommendations (NCEP, 2002): Baseline; 6-8 weeks after initiation of drug therapy; if dose increased, then at 6-8 weeks until final dose determined. Once treatment goal achieved, follow-up intervals may be reduced to every 4-6 months. Lipid panel should be assessed at least annually, and preferably at each clinic visit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Manufacturer's recommendation: Analyze lipid panel at initiation and every 2-4 weeks during therapy.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1035376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acts as a selective, competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the rate-limiting step in cholesterol biosynthesis",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F9922286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Within 1 week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effect: 4 weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1035378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     In pediatric patients (10-17 years of age), maximum serum concentration and AUC have been shown to be similar to adult values.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 134 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 88%, mostly to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic (10%), via CYP2C9; N-desmethyl rosuvastatin, one-sixth to one-half the HMG-CoA reductase activity of the parent compound",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~20% (high first-pass extraction by liver); increased in Asian patients (twofold increase in median exposure)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~19 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 3-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Feces (90%), primarily as unchanged drug",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1035399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/3/1077?source=see_link\">",
"      see \"Rosuvastatin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Report severe and unresolved gastric upset, any vision changes, muscle pain and weakness, changes in color of urine or stool, yellowing of skin or eyes, and any unusual bruising.  Avoid alcohol consumption. Female patients of childbearing age must be counseled to use two effective forms of contraception simultaneously, unless absolute abstinence is the chosen method; this drug may cause severe fetal defects.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Daniels SR, Greer FR, and Committee on Nutrition, \"Lipid Screening and Cardiovascular Health in Childhood,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 122(1):198-208.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/54/42854/abstract-text/18596007/pubmed\" id=\"18596007\" target=\"_blank\">",
"        18596007",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III),&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2001, 285(19):2486-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/54/42854/abstract-text/11368702/pubmed\" id=\"11368702\" target=\"_blank\">",
"        11368702",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marais AD, Raal FJ, Stein EA, et al, \"A Dose-Titration and Comparative Study of Rosuvastatin and Atorvastatin in Patients With Homozygous Familial Hypercholesterolaemia,\"",
"      <i>",
"       Atherosclerosis",
"      </i>",
"      , 2008, 197(1):400-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/54/42854/abstract-text/17727860/pubmed\" id=\"17727860\" target=\"_blank\">",
"        17727860",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McCrindle BW, Urbina EM, Dennison BA, et al, \"Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents: A Scientific Statement From the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, With the Council on Cardiovascular Nursing,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 115(14):1948-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/54/42854/abstract-text/17377073/pubmed\" id=\"17377073\" target=\"_blank\">",
"        17377073",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Heart, Lung, and Blood Institute, \"Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents,\" Clinical Practice Guidelines, 2011, National Institutes of Health. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf%20\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15562 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-CEC8CE9A1B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_54_42854=[""].join("\n");
var outline_f41_54_42854=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13842378\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219522\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219523\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1035352\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1035388\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219497\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219484\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1035393\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1035374\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1035353\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7914388\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219548\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1035358\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9922285\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1035359\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219537\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219491\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219493\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219506\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1035395\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1035376\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9922286\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1035378\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1035399\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15562\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15562|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=related_link\">",
"      Rosuvastatin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/3/1077?source=related_link\">",
"      Rosuvastatin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_54_42855="Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis";
var content_f41_54_42855=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/54/42855/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/54/42855/contributors\">",
"     Harold N Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/54/42855/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/54/42855/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/54/42855/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/54/42855/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/54/42855/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic glucocorticoid excess, either endogenous (ie, Cushing's syndrome) or exogenous, can lead to osteoporosis and fractures. The pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis will be reviewed here. The prevention and treatment of glucocorticoid-induced osteoporosis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids increase bone resorption and reduce bone formation (",
"    <a class=\"graphic graphic_algorithm graphicRef67048 \" href=\"mobipreview.htm?12/13/12510\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42855/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The risk of bone loss is most pronounced in the first few months of use, followed by slower but steady loss of bone with continued use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42855/abstract/2\">",
"     2",
"    </a>",
"    ]. Most agents that increase bone loss, such as thyroxine or sustained elevation of PTH, accelerate not only bone resorption but also formation, albeit to a lesser extent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42855/abstract/3\">",
"     3",
"    </a>",
"    ]. Because glucocorticoids accelerate resorption while inhibiting formation, their use is associated with early rapid bone loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42855/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. With chronic use, osteoclast mediated bone resorption slows and suppression of bone formation becomes the predominant skeletal effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42855/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Glucocorticoid therapy increases the risk of fracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42855/abstract/2,9\">",
"     2,9",
"    </a>",
"    ]. Vertebral fractures, in particular, occur early after exposure, during the rapid phase of bone loss.",
"   </p>",
"   <p>",
"    As in other target tissues, glucocorticoids exert their effects on gene expression via cytoplasmic glucocorticoid type 2 receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42855/abstract/10\">",
"     10",
"    </a>",
"    ]. In adult bone, functional glucocorticoid receptors are found in",
"    <span class=\"nowrap\">",
"     pre-osteoblast/stromal",
"    </span>",
"    cells, osteoblasts (the cells that produce bone matrix), but not in osteoclasts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42855/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Instead, glucocorticoids stimulate osteoclast proliferation by suppressing synthesis of osteoprotegerin, an inhibitor of osteoclast differentiation from hematopoietic cells of the macrophage lineage, and by stimulating production of the receptor activator of nuclear factor kappa-B (RANK), which is required for osteoclastogenesis. High glucocorticoid levels also stimulate RANKL synthesis by",
"    <span class=\"nowrap\">",
"     pre-osteoblast/stromal",
"    </span>",
"    cells, supporting osteoclast differentiation and net bone resorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42855/abstract/12\">",
"     12",
"    </a>",
"    ]. In addition, glucocorticoids increase bone resorption by decreasing secretion of androgens and estrogens, mediated primarily by inhibition of gonadotropin secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42855/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/5/34906?source=see_link&amp;anchor=H593827#H593827\">",
"     \"Normal skeletal development and regulation of bone formation and resorption\", section on 'Osteoclasts'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With long-term use, the predominant effect of glucocorticoids on the skeleton is reduced bone formation. The decline in bone formation is mediated by direct inhibition of osteoblast proliferation and differentiation and by an increase in the apoptosis rates of mature osteoblasts and osteocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42855/abstract/1,17-20\">",
"     1,17-20",
"    </a>",
"    ]. This apoptosis may also explain the tendency of glucocorticoids to cause osteonecrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42855/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, glucocorticoids alter parathyroid hormone (PTH) secretory dynamics (reduce tonic secretion and increase the amount released as pulses) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42855/abstract/22\">",
"     22",
"    </a>",
"    ], antagonize the anabolic action of PTH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42855/abstract/18,23\">",
"     18,23",
"    </a>",
"    ], and inhibit production of insulin-like growth factor-I (IGF-I) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42855/abstract/2,17,20\">",
"     2,17,20",
"    </a>",
"    ] and testosterone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42855/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. The reduction in bone formation is associated with a decrease in the mineral apposition rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42855/abstract/24\">",
"     24",
"    </a>",
"    ] and in serum and urine biochemical markers of bone formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42855/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/5/34906?source=see_link&amp;anchor=H593737#H593737\">",
"     \"Normal skeletal development and regulation of bone formation and resorption\", section on 'Osteoblasts'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Glucocorticoids also decrease intestinal calcium absorption, in part by opposing the action of vitamin D, and by decreasing the expression of calcium channels in the duodenum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42855/abstract/2,27-29\">",
"     2,27-29",
"    </a>",
"    ]. In addition, glucocorticoids increase renal calcium excretion by decreasing calcium reabsorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42855/abstract/26,28,30\">",
"     26,28,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Effect of low-dose glucocorticoid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of fracture is related to the dose and duration of glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42855/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. Although lower doses are less harmful than higher doses, there is controversy as to whether there is any dose of glucocorticoid that does not accelerate bone loss. The relationship between glucocorticoid dose and fracture risk is complicated by the observation that the disease for which the glucocorticoids are being given (eg, rheumatoid arthritis, inflammatory bowel disease) may itself lead to loss of bone and fracture. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/32/18954?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis\", section on 'Osteopenia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/54/30569?source=see_link\">",
"     \"Metabolic bone disease in inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A case-control study compared adults with rheumatoid arthritis who had been treated with a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (mean dose 8 mg daily for a mean duration of 6.9 years) to control patients with rheumatoid arthritis who had not received prednisone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42855/abstract/31\">",
"     31",
"    </a>",
"    ]. There was an increased rate of fractures, particularly in the spine, hips, and ribs, in patients taking steroids (25 versus 15 percent). Other studies in patients with rheumatoid arthritis have shown a fracture risk of 34 to 58 percent in patients receiving prolonged prednisone therapy at doses of 5 to 8.6 mg daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42855/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. A retrospective cohort study in 244,235 oral glucocorticoid users in the United Kingdom General Practice Research Database showed a dose-dependent relationship between chronic glucocorticoid use and fracture risk, with high doses (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    7.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or greater) having the highest risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42855/abstract/9\">",
"     9",
"    </a>",
"    ]. However, low doses of glucocorticoids (prednisolone less than 2.5",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    were also associated with increased fracture risk.",
"   </p>",
"   <p>",
"    The effect of glucocorticoid replacement therapy on bone mineral density in patients with adrenal insufficiency is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42855/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. In cross sectional studies of adults with Addison&rsquo;s disease receiving long-term replacement therapy, bone mineral density was lower in men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42855/abstract/37\">",
"     37",
"    </a>",
"    ] and women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42855/abstract/36\">",
"     36",
"    </a>",
"    ] with Addison&rsquo;s disease than in the reference population. In one study, the degree of bone loss was inversely related to the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    dose per kilogram [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42855/abstract/37\">",
"     37",
"    </a>",
"    ]. The men who lost bone received a mean hydrocortisone dose of 16.4",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    per day. This is approximately 1.6 times estimated daily production rate in normal subjects, suggesting they were slightly overtreated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/47/42745?source=see_link\">",
"     \"Treatment of adrenal insufficiency in adults\"",
"    </a>",
"    .) In another cross-sectional study of 32 adults treated with glucocorticoids since childhood for 21-hydroxylase deficiency, bone density was significantly lower at the femoral neck than in the reference population, likely due to slight overtreatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42855/abstract/38\">",
"     38",
"    </a>",
"    ]. Although fracture data are not available, these studies highlight the importance of avoiding excessive doses of replacement glucocorticoids.",
"   </p>",
"   <p>",
"    The sparse data that has been published on alternate-day",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    therapy suggests that this regimen is not protective of bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42855/abstract/39-41\">",
"     39-41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Effect of inhaled glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled glucocorticoids are partially absorbed and have systemic effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42855/abstract/42\">",
"     42",
"    </a>",
"    ]. Studies have not found consistent results regarding the impact of inhaled glucocorticoids on risk of osteoporosis and of osteoporotic fracture. This could relate to the fact that patients randomized to inhaled glucocorticoids tend to need fewer courses of systematic glucocorticoids, so that a mild direct deleterious effect of high-dose inhaled glucocorticoids could be masked by the benefit of reducing the need for systemic glucocorticoids. Topical therapy (eg, inhaled glucocorticoids) is preferred over enteral or parenteral glucocorticoids whenever possible. This topic is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7114?source=see_link&amp;anchor=H11#H11\">",
"     \"Major side effects of inhaled glucocorticoids\", section on 'Osteoporosis'",
"    </a>",
"    .)&nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2397063\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of glucocorticoid-induced osteoporosis are the same as those of other causes of osteoporosis. Most often, there are no clinical manifestations until there is a fracture. There is a substantial increase in fracture risk in patients receiving chronic glucocorticoid therapy, occurring in as many as 30 to 50 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42855/abstract/2,43\">",
"     2,43",
"    </a>",
"    ]. The fractures occur within three to six months of initiating treatment. Vertebral fractures are most common and are often asymptomatic. These are diagnosed as an incidental finding on chest or abdominal x-ray. In patients who have a symptomatic vertebral fracture, there is often no history of preceding trauma. The typical symptomatic patient presents with acute back pain after sudden bending, coughing, or lifting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/55/11128?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnosis and evaluation of osteoporosis in postmenopausal women\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/7/14458?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and treatment of osteoporotic thoracolumbar vertebral compression fractures\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fracture risk correlates with the dose and duration of therapy, but fractures occur at higher bone mineral density levels in women taking glucocorticoids than in women with postmenopausal osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42855/abstract/2,9,43,44\">",
"     2,9,43,44",
"    </a>",
"    ]. In a meta-analysis of seven prospective cohort studies evaluating the relationship between glucocorticoid use and fracture, the risks of any osteoporotic fracture and hip fracture were significantly higher among those with a history of glucocorticoid use compared to those with no history (risk ratios 1.66 and 2.25 for osteoporotic and hip fracture, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42855/abstract/44\">",
"     44",
"    </a>",
"    ]. The increased risk persisted after adjustment of bone mineral density. The increased risk of fracture in patients taking glucocorticoids declines rapidly in the first year off therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42855/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2397070\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any patient taking any dose of glucocorticoid with an anticipated duration of &ge;3 months requires an evaluation. The goal of the evaluation is to identify patients at high risk for fracture who would benefit from intervention. Osteoporosis fracture risk assessment is reviewed in detail separately and briefly below. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link\">",
"     \"Osteoporotic fracture risk assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348100952\">",
"    <span class=\"h2\">",
"     Fracture risk assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of fracture risk in patients taking glucocorticoids should include evaluation of bone mineral density (BMD), clinical risk factors for fracture, and measurement of serum 25-hydroxyvitamin D. In addition to glucocorticoid exposure, advancing age, prior history of fragility fracture, low body mass index (BMI), parental history of hip fracture, frequent falls, cigarette smoking, and excess alcohol intake are risk factors that have been demonstrated to be predictive of fracture. These risk factors are easily discernible from a routine history and physical examination.",
"   </p>",
"   <p>",
"    We suggest measurement of BMD (DXA) of the hip and spine in adults over 30 years of age taking any dose of glucocorticoid with anticipated duration of &ge;3 months. Patients with a history of a fracture or with osteoporosis on baseline BMD (T-score &le;-2.5) should be evaluated to exclude secondary causes of osteoporosis, including vitamin D deficiency, hyperparathyroidism, or hypogonadism (",
"    <a class=\"graphic graphic_table graphicRef62821 \" href=\"mobipreview.htm?1/57/1948\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef51140 \" href=\"mobipreview.htm?7/36/7756\">",
"     table 2",
"    </a>",
"    ). The evaluation for secondary causes of osteoporosis is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/55/11128?source=see_link&amp;anchor=H14#H14\">",
"     \"Diagnosis and evaluation of osteoporosis in postmenopausal women\", section on 'Evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/23/36213?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical manifestations, diagnosis, and evaluation of osteoporosis in men\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who do not have osteoporosis on baseline BMD or a history of fracture, we also measure serum 25-hydroxyvitamin D. Vitamin D supplementation is recommended for patients initiating or receiving any dose of glucocorticoids for any duration. For patients with normal baseline serum 25-hydroxyvitamin D levels, supplementation with 800 International",
"    <span class=\"nowrap\">",
"     Units/day",
"    </span>",
"    is adequate. However, patients with low baseline serum 25-hydroxyvitamin D levels will require higher doses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=see_link\">",
"     \"Treatment of vitamin D deficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348100959\">",
"    <span class=\"h2\">",
"     Vertebral imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vertebral fracture is the most common type of fracture in patients taking glucocorticoids, but they are often asymptomatic. The presence of a vertebral fracture is a strong predictor of future fractures of all types [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42855/abstract/45,46\">",
"     45,46",
"    </a>",
"    ] and is an indication for pharmacologic therapy. Thus, the identification of a previously undetected vertebral fracture may be useful in making a decision to treat with pharmacologic therapy or to monitor. In a patient who already has an indication for pharmacologic therapy (ie, prior fracture, osteoporosis on bone mineral density), we do not typically obtain radiographic imaging of the spine. For patients in whom the decision to treat or monitor is not obvious (eg, low bone mass [T-score between -1.0 and -2.5], no known prior fracture, but strong family history of osteoporosis), we obtain imaging of the spine. Imaging may be performed with conventional radiography or with vertebral fracture assessment (VFA), a component of the DXA instrument. The benefit of using VFA is that a patient does not require a separate appointment for vertebral imaging. It can be performed at the same time as bone mineral density study. VFA compares favorably with spine radiographs in detecting moderate and severe vertebral fractures, but it does not perform as well for diagnosing mild vertebral fractures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42583?source=see_link&amp;anchor=H21#H21\">",
"     \"Overview of dual-energy x-ray absorptiometry\", section on 'Vertebral fracture assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348101135\">",
"    <span class=\"h2\">",
"     Other imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advanced methods of measuring volumetric bone mineral density, including high resolution microCT and microMRI, allow noninvasive three-dimensional evaluation of bone architecture. While these methods have provided insight into the skeletal changes that occur with chronic glucocorticoid exposure, they do not have a role in the clinical evaluation of patients with glucocorticoid-induced osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42855/abstract/47\">",
"     47",
"    </a>",
"    ]. They are used only for research.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3556708\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucocorticoids increase bone resorption, reduce bone formation, decrease intestinal calcium absorption, and increase renal calcium excretion. Glucocorticoid therapy is associated with an appreciable risk of bone loss, which is most pronounced in the first few months of use. In addition, glucocorticoids increase fracture risk, and fractures occur at higher bone mineral density values than occur in postmenopausal osteoporosis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The increased risk of fracture has been reported with doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      &nbsp;or its equivalent as low as 2.5 to 7.5 mg daily. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Effect of low-dose glucocorticoid therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations of glucocorticoid-induced osteoporosis are the same as those of other causes of osteoporosis. Most often, there are no clinical manifestations until there is a fracture. (See",
"      <a class=\"local\" href=\"#H2397063\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Any patient taking any dose of glucocorticoid with an anticipated duration of &ge;3 months requires an evaluation, which includes assessment of clinical risk factors for fracture, bone mineral density (DXA) of the hip and spine, and measurement of serum 25-hydroxyvitamin D. Additional laboratory evaluation depends upon the results of the initial bone mineral density study. (See",
"      <a class=\"local\" href=\"#H2397070\">",
"       'Evaluation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/55/11128?source=see_link\">",
"       \"Diagnosis and evaluation of osteoporosis in postmenopausal women\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/23/36213?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and evaluation of osteoporosis in men\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The prevention and treatment of glucocorticoid-induced osteoporosis are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link\">",
"       \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/1\">",
"      Manolagas SC, Weinstein RS. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 1999; 14:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/2\">",
"      Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007; 18:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/3\">",
"      Mosekilde L, Melsen F. A tetracycline-based histomorphometric evaluation of bone resorption and bone turnover in hyperthyroidism and hyperparathyroidism. Acta Med Scand 1978; 204:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/4\">",
"      Reid IR, Heap SW. Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy. Arch Intern Med 1990; 150:2545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/5\">",
"      Gennari C, Imbimbo B. Effects of prednisone and deflazacort on vertebral bone mass. Calcif Tissue Int 1985; 37:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/6\">",
"      Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990; 112:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/7\">",
"      Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999; 42:2309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/8\">",
"      Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 2000; 15:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/9\">",
"      Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/10\">",
"      Feldman D, Dziak R, Koehler R, Stern P. Cytoplasmic glucocorticoid binding proteins in bone cells. Endocrinology 1975; 96:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/11\">",
"      Abu EO, Horner A, Kusec V, et al. The localization of the functional glucocorticoid receptor alpha in human bone. J Clin Endocrinol Metab 2000; 85:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/12\">",
"      Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001; 142:5050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/13\">",
"      MacAdams MR, White RH, Chipps BE. Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med 1986; 104:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/14\">",
"      Crilly R, Cawood M, Marshall DH, Nordin BE. Hormonal status in normal, osteoporotic and corticosteroid-treated postmenopausal women. J R Soc Med 1978; 71:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/15\">",
"      Pearce G, Tabensky DA, Delmas PD, et al. Corticosteroid-induced bone loss in men. J Clin Endocrinol Metab 1998; 83:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/16\">",
"      Odell WD. Testosterone treatment of men treated with glucocorticoids. Arch Intern Med 1996; 156:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/17\">",
"      Canalis E, Avioli L. Effects of deflazacort on aspects of bone formation in cultures of intact calvariae and osteoblast-enriched cells. J Bone Miner Res 1992; 7:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/18\">",
"      Rubin MR, Bilezikian JP. Clinical review 151: The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence. J Clin Endocrinol Metab 2002; 87:4033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/19\">",
"      Pereira RM, Delany AM, Canalis E. Cortisol inhibits the differentiation and apoptosis of osteoblasts in culture. Bone 2001; 28:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/20\">",
"      Pereira RM, Carvalho JF, Canalis E. Glucocorticoid-induced osteoporosis in rheumatic diseases. Clinics (Sao Paulo) 2010; 65:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/21\">",
"      Weinstein RS, Nicholas RW, Manolagas SC. Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab 2000; 85:2907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/22\">",
"      Bonadonna S, Burattin A, Nuzzo M, et al. Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects. Eur J Endocrinol 2005; 152:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/23\">",
"      Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998; 102:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/24\">",
"      Bressot, C, Meunier, PJ, Chapuy, MC, et al. Histomorphometric profile, pathophysiology, and reversibility of corticosteroid-induced osteoporosis. Metab Bone Dis Rel Res 1979; 1:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/25\">",
"      Mitchell DR, Jackson TW, Lyles KW. Effects of short-term administration of glucocorticoids on bone metabolism in healthy elderly men. J Am Geriatr Soc 1991; 39:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/26\">",
"      Nielsen HK, Thomsen K, Eriksen EF, et al. The effects of high-dose glucocorticoid administration on serum bone gamma carboxyglutamic acid-containing protein, serum alkaline phosphatase and vitamin D metabolites in normal subjects. Bone Miner 1988; 4:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/27\">",
"      Hahn TJ, Halstead LR, Baran DT. Effects off short term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man. J Clin Endocrinol Metab 1981; 52:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/28\">",
"      Wajchenberg BL, Pereira VG, Kieffer J, Ursic S. Effect of dexamethasone on calcium metabolism and 47Ca kinetics in normal subjects. Acta Endocrinol (Copenh) 1969; 61:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/29\">",
"      Huybers S, Naber TH, Bindels RJ, Hoenderop JG. Prednisolone-induced Ca2+ malabsorption is caused by diminished expression of the epithelial Ca2+ channel TRPV6. Am J Physiol Gastrointest Liver Physiol 2007; 292:G92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/30\">",
"      Suzuki Y, Ichikawa Y, Saito E, Homma M. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism 1983; 32:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/31\">",
"      McDougall R, Sibley J, Haga M, Russell A. Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls. J Rheumatol 1994; 21:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/32\">",
"      Michel BA, Bloch DA, Fries JF. Predictors of fractures in early rheumatoid arthritis. J Rheumatol 1991; 18:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/33\">",
"      Lems WF, Jahangier ZN, Jacobs JW, Bijlsma JW. Vertebral fractures in patients with rheumatoid arthritis treated with corticosteroids. Clin Exp Rheumatol 1995; 13:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/34\">",
"      Suliman AM, Freaney R, Smith TP, et al. The impact of different glucocorticoid replacement schedules on bone turnover and insulin sensitivity in patients with adrenal insufficiency. Clin Endocrinol (Oxf) 2003; 59:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/35\">",
"      Peacey SR, Guo CY, Robinson AM, et al. Glucocorticoid replacement therapy: are patients over treated and does it matter? Clin Endocrinol (Oxf) 1997; 46:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/36\">",
"      Florkowski CM, Holmes SJ, Elliot JR, et al. Bone mineral density is reduced in female but not male subjects with Addison's disease. N Z Med J 1994; 107:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/37\">",
"      Zelissen PM, Croughs RJ, van Rijk PP, Raymakers JA. Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann Intern Med 1994; 120:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/38\">",
"      J&auml;&auml;skel&auml;inen J, Voutilainen R. Bone mineral density in relation to glucocorticoid substitution therapy in adult patients with 21-hydroxylase deficiency. Clin Endocrinol (Oxf) 1996; 45:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/39\">",
"      R&uuml;egsegger P, Medici TC, Anliker M. Corticosteroid-induced bone loss. A longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography. Eur J Clin Pharmacol 1983; 25:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/40\">",
"      Gluck OS, Murphy WA, Hahn TJ, Hahn B. Bone loss in adults receiving alternate day glucocorticoid therapy. A comparison with daily therapy. Arthritis Rheum 1981; 24:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/41\">",
"      Dore RK. How to prevent glucocorticoid-induced osteoporosis. Cleve Clin J Med 2010; 77:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/42\">",
"      Geddes DM. Inhaled corticosteroids: benefits and risks. Thorax 1992; 47:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/43\">",
"      van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002; 13:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/44\">",
"      Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004; 19:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/45\">",
"      Cauley JA, Hochberg MC, Lui LY, et al. Long-term risk of incident vertebral fractures. JAMA 2007; 298:2761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/46\">",
"      Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004; 35:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42855/abstract/47\">",
"      Kalpakcioglu BB, Engelke K, Genant HK. Advanced imaging assessment of bone fragility in glucocorticoid-induced osteoporosis. Bone 2011; 48:1221.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2032 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-46FA143880-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_54_42855=[""].join("\n");
var outline_f41_54_42855=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3556708\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Effect of low-dose glucocorticoid therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Effect of inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2397063\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2397070\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H348100952\">",
"      Fracture risk assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H348100959\">",
"      Vertebral imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H348101135\">",
"      Other imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3556708\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2032\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2032|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?12/13/12510\" title=\"algorithm 1\">",
"      Glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2032|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/57/1948\" title=\"table 1\">",
"      Laboratory evaluation postmenopausal osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/36/7756\" title=\"table 2\">",
"      Lab eval men osteo",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/7/14458?source=related_link\">",
"      Clinical manifestations and treatment of osteoporotic thoracolumbar vertebral compression fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/23/36213?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/55/11128?source=related_link\">",
"      Diagnosis and evaluation of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7114?source=related_link\">",
"      Major side effects of inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/54/30569?source=related_link\">",
"      Metabolic bone disease in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/5/34906?source=related_link\">",
"      Normal skeletal development and regulation of bone formation and resorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=related_link\">",
"      Osteoporotic fracture risk assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42583?source=related_link\">",
"      Overview of dual-energy x-ray absorptiometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/32/18954?source=related_link\">",
"      Overview of the systemic and nonarticular manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/47/42745?source=related_link\">",
"      Treatment of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=related_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_54_42856="Diagnosis of sickle cell syndromes";
var content_f41_54_42856=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of sickle cell syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/54/42856/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/54/42856/contributors\">",
"     Elliott P Vichinsky, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/54/42856/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/54/42856/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/54/42856/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/54/42856/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/54/42856/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/54/42856/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaso-occlusive phenomena and hemolysis are the clinical hallmarks of sickle cell disease (SCD). Vaso-occlusion results in recurrent painful episodes and a variety of serious organ system complications that can lead to life-long disabilities and even death. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42170?source=see_link\">",
"     \"Overview of the clinical manifestations of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemoglobin S results from the substitution of a valine for glutamic acid as the sixth amino acid of the beta globin chain, which produces a hemoglobin tetramer",
"    <span class=\"nowrap\">",
"     (alpha2/beta",
"    </span>",
"    S2) that is poorly soluble when deoxygenated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/1\">",
"     1",
"    </a>",
"    ]. The polymerization of deoxyhemoglobin (Hb) S is essential to vaso-occlusive phenomena [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/1\">",
"     1",
"    </a>",
"    ]. The polymer assumes the form of an elongated rope-like fiber which usually aligns with other fibers, resulting in distortion of erythrocytes into the classic crescent or sickle shape and a marked decrease in red cell deformability.",
"   </p>",
"   <p>",
"    Hemoglobin S polymerization is a primary determinant of the severity of sickle cell disease. Polymerization is affected by the presence or absence of other hemoglobin mutations occurring with hemoglobin S as well as the concentration of fetal hemoglobin within the red cell. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/25/30104?source=see_link\">",
"     \"Sickle hemoglobin polymer: Structure and functional properties\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, polymerization alone does not account for the pathophysiology of SCD. Subsequent changes in red cell membrane structure and function, disordered cell volume control, and increased adherence to vascular endothelium also play an important role [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Hemolysis generates reactive oxygen species and free plasma hemoglobin. This free plasma hemoglobin is a powerful scavenger of nitric oxide whose deficiency plays an important role in the pathology of sickle cell disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27082?source=see_link&amp;anchor=H18#H18\">",
"     \"Pulmonary complications of sickle cell disease\", section on 'Pulmonary hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of patients with SCD will be reviewed here. The treatment and prognosis of SCD and the features of the variant sickle cell syndromes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39946?source=see_link\">",
"     \"Overview of the management of sickle cell disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/5/5209?source=see_link\">",
"     \"Variant sickle cell syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF DIAGNOSTIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals and methods of diagnosis of SCD vary with the age of the patient. DNA based testing is used for prenatal diagnosis. The diagnostic methods used after birth are those that separate hemoglobin species according to amino acid composition (hemoglobin electrophoresis or thin layer isoelectric focusing), solubility testing, and examination of the peripheral blood smear. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11768?source=see_link\">",
"     \"Fetal blood sampling\"",
"    </a>",
"    .) Characterization of adult hemoglobins in the fetal and newborn periods can be difficult because of the predominance of Hb F, which confounds detection of Hb S by solubility testing.",
"   </p>",
"   <p>",
"    Clinical manifestations of SCD are not present at birth, and usually begin to become apparent after the first few months of life as the concentration of Hb S rises and Hb F declines. Sickled cells can be seen in the peripheral blood of children with SCD at three months of age and moderately severe hemolytic anemia is apparent by four months of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PRENATAL TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sickle hemoglobin diseases (ie, sickle cell anemia, hemoglobin SC disease, sickle cell beta thalassemia) are chronic, debilitating and sometimes fatal. The severe clinical nature of these diseases, particularly SCD and sickle cell beta (0) thalassemia, and the absence of curative therapy are the primary stimulants for the development of fetal sampling and DNA-based diagnostic methodology. Couples at risk should be offered hemoglobinopathy testing early in pregnancy and the opportunity for prenatal diagnosis where appropriate.",
"   </p>",
"   <p>",
"    Currently, fetal DNA samples are obtained by chorionic villus sampling at 8 to 10 weeks gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/4\">",
"     4",
"    </a>",
"    ]. Preimplantation diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/5,6\">",
"     5,6",
"    </a>",
"    ] and testing fetal cells isolated from the maternal circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/7,8\">",
"     7,8",
"    </a>",
"    ] are not yet in routine use. Although these latter strategies are costly with limited availability, reproductive centers in the United States and Europe are developing protocols for pre-implantation diagnosis of sickle cell disorders that utilize very small amounts of DNA from single cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The many social and ethical issues that must be faced by the patient and physician in making decisions about prenatal testing for the hemoglobinopathies and the sampling methods that may be used are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/26/24999?source=see_link\">",
"     \"Prenatal testing for the hemoglobinopathies and thalassemias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Development of the polymerase chain reaction (PCR) for amplifying DNA sequences of interest in vitro allowed testing of minute quantities of DNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. It also motivated the development of several new methods for detecting the sickle cell gene such as restriction analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/13,14\">",
"     13,14",
"    </a>",
"    ], allele specific hybridization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/15\">",
"     15",
"    </a>",
"    ], reverse dot blotting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/16\">",
"     16",
"    </a>",
"    ], and allele specific fluorescence PCR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/17\">",
"     17",
"    </a>",
"    ]. PCR-based diagnosis for Hb SC disease can be made using specific molecular methods for detecting the Hb C gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/18,19\">",
"     18,19",
"    </a>",
"    ], while the diagnosis of sickle cell-beta thalassemia can be made using reverse dot blot methodology to screen the many African-American beta thalassemia mutations, as well as the Hb S and Hb C mutations, in a single hybridization reaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/60/968?source=see_link\">",
"     \"Laboratory diagnosis of the hemoglobinopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     NEWBORN SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with SCD generally are healthy at birth and develop symptoms only when fetal hemoglobin levels decline later in infancy or early childhood.",
"   </p>",
"   <p>",
"    The goals of newborn screening include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early recognition of affected infants",
"     </li>",
"     <li>",
"      Early medical intervention to reduce morbidity and mortality, particularly from bacterial infections",
"     </li>",
"     <li>",
"      Institution of regular and ongoing comprehensive care through a multidisciplinary sickle cell clinic, in collaboration with the primary care physician, whenever feasible",
"     </li>",
"     <li>",
"      Access for families of children with SCD to accurate information about the diagnosis, clinical manifestations, treatment options, and age-appropriate anticipatory guidance toward the management of these emerging issues.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an example of the effectiveness of these programs, the use of prophylactic penicillin and the provision of comprehensive medical care have reduced the mortality of SCD during the first five years of life from approximately 25 percent to less than 3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The magnitude of the problem in the United States is demonstrated by the frequency of carrier conditions for hemoglobinopathies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Data obtained in California from 1998 to 2006 found that the genetic trait for sickle cell",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      thalassemia occurred in one in 75 California births [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/27,28\">",
"       27,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The gene frequency is much higher in the African-American population: 4 percent for hemoglobin S, 1.5 percent for hemoglobin C, and 4 percent for beta-thalassemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/29\">",
"       29",
"      </a>",
"      ]. The Hispanic population is also at risk for sickle cell disease. At least 1 in 180 Hispanic births have sickle cell trait. In California, 12.5 percent of Hemoglobin",
"      <span class=\"nowrap\">",
"       S/beta",
"      </span>",
"      thalassemia births occurred in the Hispanic population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These frequencies predict the occurrence of 4000 to 5000 pregnancies per year at risk for sickle cell disease in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although there have been advances in the diagnosis and management of SCD in high income countries, much remains to be learned about the optimum implementation of newborn screening programs and medical management of patients in low income countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/30\">",
"     30",
"    </a>",
"    ]. For example, a strategy that utilized a team of specially trained midwives at two large maternity services in Cotonou, Republic of Benin, resulted in almost 80 percent of women informed of the risk for SCD agreeing to testing of their offspring. Eighty-five percent of offspring testing positive enrolled in a sickle cell program, and more than 80 percent of these infants were still followed by the program at five years. The mortality rate for this cohort of children under five years of age with SCD was 10 times lower than the general rate recorded in the Republic of Benin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Types of screening programs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, two programs have been used for newborn screening: selective screening of infants of high-risk parents, and universal testing of newborns. At present, universal testing seems preferable due to its economy and superiority of detection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]; this approach has been endorsed by a consensus panel convened by the National Institutes of Health [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/35\">",
"     35",
"    </a>",
"    ]. Although a cost-effectiveness analysis found that targeted screening of African-American newborns for SCD is cost-effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/36\">",
"     36",
"    </a>",
"    ], universal screening identifies more infants with disease and prevents more deaths. The advantages of this approach can be illustrated by two observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Targeted screening missed 20 percent of African-American newborns with sickle cell disease born in Georgia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The number of sickle cell diagnoses doubled when screening was changed from targeted to universal in Connecticut [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As of 2008, screening for sickle cell disease in newborns is mandated in all 50 states and the District of Columbia, regardless of birth setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/39\">",
"     39",
"    </a>",
"    ]. In fact, the importance of NewBorn Screening (NBS) Programs is being increasingly recognized worldwide. Due to changes in immigrant migration patterns, several European and African countries are initiating NBS programs. These programs face logistical and economic challenges for comprehensive implementation and patient outreach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, any high risk infant should have documentation of newborn screen results by one to two months of age so that confirmatory testing, if necessary, can be performed, and parental education, penicillin prophylaxis, and referral for comprehensive care can be implemented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The methods for implementation of newborn screening programs vary somewhat from state to state. In Texas, as an example, \"heel stick\" filter paper screen is performed within 72 hours of life, with a second screen required at one to two weeks. Testing is by isoelectric focusing and abnormal specimens are confirmed by repeat testing, or by DNA analysis (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Hemoglobin patterns'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Abnormal results are reported to the Newborn Screening Program (NBS), data are maintained on a computer registry, and case management services are initiated to assure medical follow-up. In a review of newborn screen outcomes from 1992 to 1998, 2,292,698 live births were recorded in Texas and 94 percent had specimens collected. The overall prevalence of SCD by ethnic group per 10,000 live births was: 29.91 African American, 0.11 white, 0.29 Hispanic, and 2.47",
"    <span class=\"nowrap\">",
"     other/unknown",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/42\">",
"     42",
"    </a>",
"    ]. Despite these measures, other states have reported gaps in compliance with early medical intervention, parental education, and provision of comprehensive health services [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In California, a two-tier approach to universal NBS is used. First, NBS is performed on dried blood spots utilizing high performance liquid chromatography (HPLC). Abnormal hemoglobin findings are then referred to the Hemoglobin Reference Laboratory (HRL), where additional testing, including DNA sequencing may then be performed for final confirmation. With this approach, of approximately 530,000 annual NBS, approximately 2118 samples were referred for HRL over an eight-year period. Hemoglobin genotypes included: sickle hemoglobinopathies (32 percent), alpha thalassemia conditions (24 percent), beta thalassemia conditions (4 percent), and other hemoglobin variants, including traits (41 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/28,44\">",
"     28,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite high percentages of NBS completions by states and high rates of follow-up testing where abnormal findings were detected, there are ongoing problems with timely follow-up and implementation of comprehensive care. One study suggests that there is a wide variation in stakeholder notification (physician, PCP, hospital, families, hematologists), which can lead to alteration in early intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/45\">",
"     45",
"    </a>",
"    ]. Other states have reported gaps in compliance with early medical intervention, parental education, and provision of comprehensive health services [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Methodology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended approach to neonatal testing is to obtain blood samples by heel stick or cord blood and spot the sample onto filter paper for stable transport and subsequent electrophoresis, thin-layer isoelectric focusing, or HPLC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. A requirement for tests used in newborn screening is the capability to distinguish among hemoglobins F, S, A, and C. There are two problems that can occur with the prenatal tests. Solubility testing may not be valid because of the large amount of Hb F present in fetal blood. In addition, neonatal blood transfusion can impair detection of SCD with newborn screening, allowing for possible SCD-related morbidity before the diagnosis is made [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hemoglobin patterns",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to convention, the patterns of hemoglobins present are described in descending order according to the quantities detected (",
"    <a class=\"graphic graphic_table graphicRef51810 \" href=\"mobipreview.htm?10/51/11069\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     FS pattern",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newborns with homozygous sickle cell anemia have predominantly Hb F with a small amount of Hb S and no Hb A, the FS pattern. An FS pattern is also found in newborns who have sickle cell-beta (O) thalassemia, sickle cell-hereditary persistence of fetal hemoglobin, and, because Hb D and Hb G have the same electrophoretic mobility as Hb S, sickle cell-hemoglobin D disease and sickle cell-hemoglobin G disease. Family studies are confirmatory; in the newborn with sickle cell-beta (O) thalassemia, for example, one parent has sickle cell trait and the other beta thalassemia minor. When family members are not available, the diagnosis is established by DNA-based testing or repeat hemoglobin analysis at three to four months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     FAS and FSA patterns",
"    </span>",
"    &nbsp;&mdash;&nbsp;The newborn with sickle cell trait will have Hb F, Hb A, and Hb S, the FAS pattern. The quantity of Hb A is greater than that of Hb S. If the quantity of Hb S exceeds that of Hb A, the FSA pattern, the presumptive diagnosis is sickle cell-beta (+) thalassemia. It may not be possible to distinguish FAS and FSA patterns in newborns; thus, DNA-based testing or repeat hemoglobin testing at age three to six months is recommended.",
"   </p>",
"   <p>",
"    In the future, PCR-based diagnosis from blood spotted onto a filter paper may be used to detect sickle cell genes directly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     OLDER CHILDREN AND ADULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The purpose of correct diagnosis in this age group is to identify patients who need therapy for sickle cell disease and counseling for the disease or the trait. Despite newborn screening, many patients with sickle cell disease may be undiagnosed, in part due to immigration of young, unscreened patients from other countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/50\">",
"     50",
"    </a>",
"    ]. The \"sickle cell prep\" using metabisulfite or dithionite is no longer in routine clinical use and is of historical interest only.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Methodology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of the sickle cell syndromes can be made with several methods:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cellulose acetate electrophoresis at pH 8.4 is a standard method of separating Hb S from other hemoglobin variants. However, Hb S, G, and D have the same electrophoretic mobility with this method (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef68806 \" href=\"mobipreview.htm?8/51/9023\">",
"       image 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Citrate agar electrophoresis at pH 6.2 separates Hb S from Hb D and G, which co-migrate with Hb A in this system.",
"     </li>",
"     <li>",
"      Thin layer isoelectric focusing is a highly accurate and cost effective tool for the diagnosis of sickle or other hemoglobin variants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/34\">",
"       34",
"      </a>",
"      ]. The bands on isoelectric focusing are sharper than those on electrophoresis and can distinguish some hemoglobins not seen on standard electrophoresis. Isoelectric focusing is more complicated because it is also sensitive to the presence of methemoglobin and glycosylated hemoglobins.",
"     </li>",
"     <li>",
"      HPLC is a highly precise technique for identification and quantification of hemoglobins and can be fully automated. In California and a growing number of states, newborn samples are screened with high performance liquid chromatography (HPLC). This automated technique is able to detect most hemoglobin variants by their different retention times. It is highly sensitive and specific and provides both quantitative and qualitative interpretation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/28\">",
"       28",
"      </a>",
"      ]. Major disadvantages are the initial cost of the apparatus and reagents.",
"     </li>",
"     <li>",
"      A solubility test such as the Sickledex&reg; also distinguishes Hb D and G from Hb S as only Hb S precipitates using this test.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the combination of cellulose acetate electrophoresis with either citrate agar electrophoresis or a solubility test allows a definitive diagnosis of a sickle cell syndrome. Alternatively, thin-layer isoelectric focusing will separate Hb S, D, and G and can replace the two electrophoretic methods. Even with thin-layer isoelectric focusing, it is still necessary to use a confirmatory solubility test for Hb S.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2374771\">",
"    <span class=\"h3\">",
"     Hemoglobin A2 measurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement and interpretation of levels of the minor hemoglobin, hemoglobin A2 (Hb A2), valuable for the diagnosis of concomitant beta thalassemia, requires some expertise. With many laboratory techniques, Hb A2 levels are influenced by closely migrating hemoglobin variants. Of importance, using HPLC and electrophoresis modalities, Hb A2 is overestimated in the presence of Hb S, while severe iron deficiency reduces the Hb A2 level; this is a particular problem in pregnant women who may be thalassemia carriers. When Hb S is not present, microcolumn chromatography or HPLC accurately quantifies Hb A2. Electrophoresis with scanning densitometry does not accurately quantitate Hb A2 levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5964937\">",
"    <span class=\"h3\">",
"     High levels of fetal hemoglobin",
"    </span>",
"    &nbsp;&mdash;&nbsp;DNA testing may be useful in selected cases where high concentrations of fetal hemoglobin (Hb F) raise the possibility of hereditary persistence of fetal hemoglobin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Findings in sickle cell disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chronic hemolysis of sickle cell disease is usually associated with a mild to moderate anemia (hematocrit 20 to 30 percent), reticulocytosis of 3 to 15 percent (accounting for high or high-normal mean corpuscular volume [MCV]), unconjugated hyperbilirubinemia, and elevated serum LDH and low serum haptoglobin. The peripheral blood smear reveals sickled red cells (",
"    <a class=\"graphic graphic_picture graphicRef64449 \" href=\"mobipreview.htm?1/42/1703\">",
"     picture 1",
"    </a>",
"    ), polychromasia indicative of reticulocytosis, and Howell-Jolly bodies reflecting hyposplenia (",
"    <a class=\"graphic graphic_picture graphicRef60588 \" href=\"mobipreview.htm?38/45/39638\">",
"     picture 2",
"    </a>",
"    ). The red cells are normochromic unless there is coexistent thalassemia or iron deficiency. If the age-adjusted MCV is not elevated, the possibility of sickle cell-beta thalassemia, coincident alpha thalassemia, or iron deficiency should be considered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29418?source=see_link\">",
"     \"Approach to the adult patient with anemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Hb F level is usually slightly to moderately elevated and Hb A is absent (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68806 \" href=\"mobipreview.htm?8/51/9023\">",
"     image 1",
"    </a>",
"    ). The amount of Hb F is a function of the number of reticulocytes that contain Hb F, the extent of selective survival of Hb F-containing reticulocytes to become mature Hb F-containing erythrocytes, and the amount of Hb F per red cell. Each variable is separately regulated and the expression of each shows interpatient variability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/53\">",
"     53",
"    </a>",
"    ]. In some patients with SCD alone, values are as high (1 to 4 percent) as the modest elevations seen in heterocellular hereditary persistence of fetal hemoglobin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/5/5209?source=see_link\">",
"     \"Variant sickle cell syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, certain beta globin haplotypes appear to be related to factors that regulate production of Hb F. As examples, the Arab-Indian and Senegal haplotypes are associated with higher levels of Hb F (over 20 percent in some cases), probably due to linkage with important gamma globin regulatory sequences in the locus control region [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. In one study of Senegalese patients, the mean Hb F was 8.2 percent, and approximately one-half of patients had a benign form of sickle cell anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39434?source=see_link\">",
"     \"Clinical variability in sickle cell anemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A comprehensive analysis of the clinical laboratory data collected from 2600 subjects from the Cooperative Study of Sickle Cell Disease found the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/57\">",
"     57",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with SCD, mean white blood cell (WBC) counts were higher than normal, particularly in those under the age of 10, and mean platelet counts were elevated, particularly in those under the age of 18. Mean WBC and platelet counts were not elevated in Hb SC disease or sickle cell-beta (+) thalassemia.",
"     </li>",
"     <li>",
"      Mean serum bilirubin concentrations were higher in SCD than in Hb SC disease or sickle cell-beta (+) thalassemia due to the greater hemolytic rate. The serum bilirubin rose after the first decade, possibly due to chronic hepatobiliary dysfunction. Serum aminotransferase concentrations were often elevated, particularly in adults with SCD, but mean levels were normal. Serum alkaline phosphatase was elevated in all genotypes until puberty, suggesting an origin from bone rather than the liver.",
"     </li>",
"     <li>",
"      Serum creatinine concentrations were low in all genotypes until 18 years of age, when males experienced a rise apparently related to increasing muscle mass. The low serum creatinine was in part due to an initial elevation in glomerular filtration rate. Serum creatinine increased with age in all genotypes, presumably due to declining renal function. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6202?source=see_link\">",
"       \"Renal manifestations of sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Diagnostic patterns in other sickle cell syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several of the sickle cell syndromes may have similar results with electrophoresis or isoelectric focusing. Additional information from examination of the peripheral smear often helps to separate the sickle cell diseases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/5/5209?source=see_link\">",
"     \"Variant sickle cell syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Solubility tests are positive in both sickle cell disease and sickle cell trait, but sickled forms occur on the peripheral smear only in the sickle cell diseases.",
"     </li>",
"     <li>",
"      The diagnosis of Hb SC disease is straightforward; nearly equal amounts of Hb S and Hb C are detected (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef68806 \" href=\"mobipreview.htm?8/51/9023\">",
"       image 1",
"      </a>",
"      ). Target cells predominate and sickled cells are rare on the peripheral smear. Those that are present may be canoe-shaped (",
"      <a class=\"graphic graphic_picture graphicRef71393 \" href=\"mobipreview.htm?42/19/43318\">",
"       picture 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Results from electrophoresis or thin-layer isoelectric focusing are similar in SCD and sickle cell-beta (0) thalassemia as nearly all the hemoglobin consists of Hb S, with no Hb A evident. Differences in the levels of Hb F and Hb A2 and in the peripheral blood smear may be useful in distinguishing these syndromes (",
"      <a class=\"graphic graphic_table graphicRef64715 \" href=\"mobipreview.htm?17/56/18316\">",
"       table 2",
"      </a>",
"      ). In SCD, both sickled and target cells are seen; red cell indices are generally normal. In sickle cell-beta (0) thalassemia, sickled cells, target cells, and hypochromic microcytic discocytes are prominent. If one parent does not have sickle cell trait, this is a useful indicator of the presence of sickle cell-beta (0) thalassemia in the child, rather than sickle cell disease.",
"     </li>",
"     <li>",
"      Sickle cell-beta (+) thalassemia and sickle cell trait both have substantial amounts of both Hb A and Hb S. Sickle cell trait is not associated with anemia or microcytosis and has a Hb A fraction that exceeds 50 percent along with 35 to 45 percent Hb S (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef68806 \" href=\"mobipreview.htm?8/51/9023\">",
"       image 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/58\">",
"       58",
"      </a>",
"      ]. Sickle cell-beta (+) thalassemia is associated with anemia, microcytosis, and an Hb A fraction that ranges between 5 and 30 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/59\">",
"       59",
"      </a>",
"      ]. Sickle cell trait in combination with alpha thalassemia can be suspected when there is less than 35 percent Hb S (",
"      <a class=\"graphic graphic_table graphicRef70184 \" href=\"mobipreview.htm?16/17/16667\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/37/16984?source=see_link&amp;anchor=H5#H5\">",
"       \"Introduction to hemoglobin mutations\", section on 'Positively charged beta chain mutants'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are some sickle cell disease variants that are uncommon yet important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/5/5209?source=see_link\">",
"     \"Variant sickle cell syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sickle",
"      <span class=\"nowrap\">",
"       cell/hemoglobin",
"      </span>",
"      D-Punjab (D-Los Angeles) and",
"      <span class=\"nowrap\">",
"       Sickle/Hemoglobin",
"      </span>",
"      O-Arab are moderate to severe diseases characterized by anemia, reticulocytosis, and often, macrocytosis.",
"     </li>",
"     <li>",
"      Sickle",
"      <span class=\"nowrap\">",
"       cell/hemoglobin",
"      </span>",
"      C-Harlem is slightly milder than sickle cell anemia with a similar blood film.",
"     </li>",
"     <li>",
"      Sickle",
"      <span class=\"nowrap\">",
"       cell/hemoglobin",
"      </span>",
"      Lepore, also a moderately severe disease, is more characterized by microcytosis and a blood smear comparable to",
"      <span class=\"nowrap\">",
"       sickle/beta",
"      </span>",
"      thalassemia.",
"     </li>",
"     <li>",
"      Sickle",
"      <span class=\"nowrap\">",
"       cell/hereditary",
"      </span>",
"      persistence of fetal hemoglobin is usually asymptomatic or extremely mild. Mild anemia and reticulocytosis may be noted. The electrophoresis may be misread as sickle cell anemia with an elevated hemoglobin F. Definitive diagnosis requires family studies or DNA analysis.",
"     </li>",
"     <li>",
"      Sickle cell hemoglobin E is a clinically mild disease. The blood film shows targeting and variable microcytosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     COMPREHENSIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once an infant is diagnosed with SCD, there is an immediate obligation to implement a program of comprehensive care for the affected child and",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    family [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/41,61,62\">",
"     41,61,62",
"    </a>",
"    ]. Because of the protean manifestations of the acute and chronic complications of SCD, comprehensive care requires medical professionals with special expertise in this disease, together with access to multidisciplinary teams, including social workers, psychologists, nurses, genetic counselors, and nutritionists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Available guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for the comprehensive care of infants, children, and adolescents have been published [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/57\">",
"     57",
"    </a>",
"    ]. A comprehensive manual has been developed in collaboration with pediatricians and hematologists from nine states and supported in part by the Genetic Services Branch, Maternal and Child Health Bureau, HRSA (",
"    <a class=\"graphic graphic_table graphicRef58681 \" href=\"mobipreview.htm?13/63/14334\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/63\">",
"     63",
"    </a>",
"    ]. The manual represents a broad consensus, but does not represent an exclusive standard of care, and is not intended to replace a physician's best medical judgment or the experience of physicians with expertise in SCD.",
"   </p>",
"   <p>",
"    The manual is available on websites of the Mountain States Genetics Network (",
"    <a class=\"external\" href=\"file://www.mostgene.org\">",
"     www.mostgene.org",
"    </a>",
"    ), the Texas Department of Health (",
"    <a class=\"external\" href=\"file://www.dshs.state.tx.us/newborn/default.shtm\">",
"     file://www.dshs.state.tx.us/newborn/default.shtm",
"    </a>",
"    ), and the Georgia Comprehensive Sickle Cell Center (",
"    <a class=\"external\" href=\"file://scinfo.org/\">",
"     file://scinfo.org",
"    </a>",
"    ). This manual will undergo periodic review and revisions. Additional references are also available from NHLBI or other comprehensive sickle cell centers, and should serve as a framework for continued care of these children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39946?source=see_link\">",
"     \"Overview of the management of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17004686\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of sickle cell syndromes is important in three general settings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prenatal testing (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Prenatal testing'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Newborn screening, for early recognition of affected infants (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Newborn screening'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      For diagnosis of symptomatic children and adults with sickle cell disease and counseling of those with the trait (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Older children and adults'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Diagnosis of one of the sickle cell syndromes is generally made via electrophoresis, isoelectric focusing, high performance liquid chromatography (HPLC), polymerase chain reaction (PCR) techniques, or direct DNA testing. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Methodology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17004794\">",
"    <span class=\"h2\">",
"     Findings during the newborn period",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta globin production (which includes production of hemoglobins A and S) is not fully developed during the newborn period. Accordingly, only general patterns are available during the newborn period. If questions arise as to interpretation, the tests should be repeated at age three to six months, when beta globin production is complete. DNA testing can be performed if clinically indicated. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Hemoglobin patterns'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    These general patterns include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The normal newborn has only hemoglobin Hb F and Hb A at birth (the FA pattern)",
"     </li>",
"     <li>",
"      The newborn with sickle cell trait has hemoglobins F, A, and S, with more Hb A than Hb S (the FAS pattern)",
"     </li>",
"     <li>",
"      Presence of the FSA pattern (eg, more Hb S than Hb A) suggests sickle cell-beta(+) thalassemia",
"     </li>",
"     <li>",
"      Presence of the FS pattern (eg, no Hb A present) suggests either homozygous sickle cell disease or compound heterozygosity (eg, sickle cell-beta(0) thalassemia, sickle cell hereditary persistence of&nbsp;fetal hemoglobin) (see",
"      <a class=\"local\" href=\"#H8\">",
"       'FS pattern'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5964967\">",
"    <span class=\"h3\">",
"     Exceptions to the expected hemoglobin patterns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several newborns have undergone testing after transfusion of red cells, resulting in the wrong diagnosis. In such cases, sickle cell diagnosis should utilize DNA testing or be postponed for at least four months after transfusion. In very premature babies, Hb A may not be detected, resulting in misdiagnosis. In addition, very premature babies with sickle cell trait may be found to have Hb S levels greater than Hb A, resulting in the incorrect diagnosis of Hemoglobin",
"    <span class=\"nowrap\">",
"     S/Beta(+)",
"    </span>",
"    thalassemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42856/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17004860\">",
"    <span class=\"h2\">",
"     Findings in children and adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of cellulose acetate electrophoresis with either citrate agar electrophoresis or a solubility test allows for a definitive diagnosis of one of the sickle cell syndromes. The most common are described below. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Older children and adults'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Sickle cell trait",
"      </strong>",
"      &mdash; The usual pattern is to find &gt;50 percent HbA, 35 to 45 percent HbS and &lt;2 percent HbF. The presence of &lt;35 percent HbS suggests the presence of alpha thalassemia.",
"     </li>",
"     <li>",
"      <strong>",
"       Hemoglobin SC disease",
"      </strong>",
"      &mdash; Approximately equal amounts of HbS and HbC.",
"     </li>",
"     <li>",
"      <strong>",
"       Sickle cell beta(+) thalassemia",
"      </strong>",
"      &mdash; 5 to 30 percent HbA, increased HbA2, with the rest HbS. Target cells and hypochromic red cells are also present",
"     </li>",
"     <li>",
"      <strong>",
"       Sickle cell beta(0) thalassemia",
"      </strong>",
"      &mdash; Zero percent HbA, along with variable amounts of HbF and increased amounts of HbA2, with the remainder HbS. Target cells and hypochromic microcytic red cells are also present.",
"     </li>",
"     <li>",
"      <strong>",
"       Sickle cell disease",
"      </strong>",
"      &mdash; Zero percent HbA, &lt;2 percent HbF, normal amounts of HbA2, and the remainder HbS",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/1\">",
"      Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997; 337:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/2\">",
"      Kaul DK, Fabry ME, Costantini F, et al. In vivo demonstration of red cell-endothelial interaction, sickling and altered microvascular response to oxygen in the sickle transgenic mouse. J Clin Invest 1995; 96:2845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/3\">",
"      Gladwin MT, Vichinsky E. Pulmonary complications of sickle cell disease. N Engl J Med 2008; 359:2254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/4\">",
"      Shulman LP, Elias S. Amniocentesis and chorionic villus sampling. West J Med 1993; 159:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/5\">",
"      Lissens W, Sermon K. Preimplantation genetic diagnosis: current status and new developments. Hum Reprod 1997; 12:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/6\">",
"      Xu K, Shi ZM, Veeck LL, et al. First unaffected pregnancy using preimplantation genetic diagnosis for sickle cell anemia. JAMA 1999; 281:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/7\">",
"      Lamvu G, Kuller JA. Prenatal diagnosis using fetal cells from the maternal circulation. Obstet Gynecol Surv 1997; 52:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/8\">",
"      Cheung MC, Goldberg JD, Kan YW. Prenatal diagnosis of sickle cell anaemia and thalassaemia by analysis of fetal cells in maternal blood. Nat Genet 1996; 14:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/9\">",
"      Vrettou C, Traeger-Synodinos J, Tzetis M, et al. Real-time PCR for single-cell genotyping in sickle cell and thalassemia syndromes as a rapid, accurate, reliable, and widely applicable protocol for preimplantation genetic diagnosis. Hum Mutat 2004; 23:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/10\">",
"      Bermudez MG, Piyamongkol W, Tomaz S, et al. Single-cell sequencing and mini-sequencing for preimplantation genetic diagnosis. Prenat Diagn 2003; 23:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/11\">",
"      Saiki RK, Scharf S, Faloona F, et al. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 1985; 230:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/12\">",
"      Li HH, Gyllensten UB, Cui XF, et al. Amplification and analysis of DNA sequences in single human sperm and diploid cells. Nature 1988; 335:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/13\">",
"      Embury SH, Scharf SJ, Saiki RK, et al. Rapid prenatal diagnosis of sickle cell anemia by a new method of DNA analysis. N Engl J Med 1987; 316:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/14\">",
"      Chehab FF, Doherty M, Cai SP, et al. Detection of sickle cell anaemia and thalassaemias. Nature 1987; 329:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/15\">",
"      Saiki RK, Bugawan TL, Horn GT, et al. Analysis of enzymatically amplified beta-globin and HLA-DQ alpha DNA with allele-specific oligonucleotide probes. Nature 1986; 324:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/16\">",
"      Saiki RK, Walsh PS, Levenson CH, Erlich HA. Genetic analysis of amplified DNA with immobilized sequence-specific oligonucleotide probes. Proc Natl Acad Sci U S A 1989; 86:6230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/17\">",
"      Chehab FF, Kan YW. Detection of sickle cell anaemia mutation by colour DNA amplification. Lancet 1990; 335:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/18\">",
"      Fischel-Ghodsian N, Hirsch PC, Bohlman MC. Rapid detection of the hemoglobin C mutation by allele-specific polymerase chain reaction. Am J Hum Genet 1990; 47:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/19\">",
"      Kropp GL, Cornett PA, Leavitt AD, et al. Resolution of complex genotypes containing hemoglobin C genes using the allele-specific fluorescence polymerase chain reaction (abstract). Blood 1990; 76 (Suppl 1):257a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/20\">",
"      Gonzalez-Redondo JM, Stoming TA, Lanclos KD, et al. Clinical and genetic heterogeneity in black patients with homozygous beta-thalassemia from the southeastern United States. Blood 1988; 72:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/21\">",
"      Gonzalez-Redondo JM, Kutlar A, Kutlar F, et al. Molecular characterization of Hb S(C) beta-thalassemia in American blacks. Am J Hematol 1991; 38:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/22\">",
"      Sutcharitchan P, Saiki R, Huisman TH, et al. Reverse dot-blot detection of the African-American beta-thalassemia mutations. Blood 1995; 86:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/23\">",
"      Almeida AM, Henthorn JS, Davies SC. Neonatal screening for haemoglobinopathies: the results of a 10-year programme in an English Health Region. Br J Haematol 2001; 112:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/24\">",
"      Kaye CI, Committee on Genetics, Accurso F, et al. Newborn screening fact sheets. Pediatrics 2006; 118:e934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/25\">",
"      Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med 1986; 314:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/26\">",
"      Vichinsky E, Hurst D, Earles A, et al. Newborn screening for sickle cell disease: effect on mortality. Pediatrics 1988; 81:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/27\">",
"      Lorey FW, Arnopp J, Cunningham GC. Distribution of hemoglobinopathy variants by ethnicity in a multiethnic state. Genet Epidemiol 1996; 13:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/28\">",
"      Michlitsch J, Azimi M, Hoppe C, et al. Newborn screening for hemoglobinopathies in California. Pediatr Blood Cancer 2009; 52:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/29\">",
"      Motulsky AG. Frequency of sickling disorders in U.S. blacks. N Engl J Med 1973; 288:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/30\">",
"      Odame I. Developing a global agenda for sickle cell disease: report of an international symposium and workshop in Cotonou, Republic of Benin. Am J Prev Med 2010; 38:S571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/31\">",
"      Rahimy MC, Gangbo A, Ahouignan G, Alihonou E. Newborn screening for sickle cell disease in the Republic of Benin. J Clin Pathol 2009; 62:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/32\">",
"      Panepinto JA, Magid D, Rewers MJ, Lane PA. Universal versus targeted screening of infants for sickle cell disease: a cost-effectiveness analysis. J Pediatr 2000; 136:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/33\">",
"      Cronin EK, Normand C, Henthorn JS, et al. Organisation and cost-effectiveness of antenatal haemoglobinopathy screening and follow up in a community-based programme. BJOG 2000; 107:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/34\">",
"      Henthorn JS, Almeida AM, Davies SC. Neonatal screening for sickle cell disorders. Br J Haematol 2004; 124:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/35\">",
"      Consensus conference. Newborn screening for sickle cell disease and other hemoglobinopathies. JAMA 1987; 258:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/36\">",
"      Tsevat J, Wong JB, Pauker SG, Steinberg MH. Neonatal screening for sickle cell disease: a cost-effectiveness analysis. J Pediatr 1991; 118:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/37\">",
"      Harris MS, Eckman JR. Georgia's experience with newborn screening: 1981 to 1985. Pediatrics 1989; 83:858.",
"     </a>",
"    </li>",
"    <li>",
"     Landenberger G, State of Connecticut newborn experience 1987-1992, 1993, personal communication.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/39\">",
"      US Preventive Services Task Force. Screening for sickle cell disease in newborns: recommendation statement. Am Fam Physician 2008; 77:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/40\">",
"      Bain BJ. Neonatal/newborn haemoglobinopathy screening in Europe and Africa. J Clin Pathol 2009; 62:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/41\">",
"      Section on Hematology/Oncology Committee on Genetics, American Academy of Pediatrics. Health supervision for children with sickle cell disease. Pediatrics 2002; 109:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/42\">",
"      Strahan JE, Canfield MA, Drummond-Borg LM, Neill SU. Ethnic and gender patterns for the five congenital disorders in Texas from 1992 through 1998. Tex Med 2002; 98:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/43\">",
"      Centers for Disease Control and Prevention (CDC). Update: newborn screening for sickle cell disease--California, Illinois, and New York, 1998. MMWR Morb Mortal Wkly Rep 2000; 49:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/44\">",
"      Hoppe CC. Newborn screening for hemoglobin disorders. Hemoglobin 2011; 35:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/45\">",
"      Kavanagh PL, Wang CJ, Therrell BL, et al. Communication of positive newborn screening results for sickle cell disease and sickle cell trait: variation across states. Am J Med Genet C Semin Med Genet 2008; 148C:15.",
"     </a>",
"    </li>",
"    <li>",
"     Schneider RG. Laboratory identification of hemoglobin variants in the newborn. In: Genetic Disease - Screening and Management, Carter TP, Wiley AM (Eds), Liss, New York 1986. p.137.",
"    </li>",
"    <li>",
"     National Committee for Clinical Laboratory Standards (NCCLS): Blood collection on filter paper for neonatal screening programs. NCCLS 1988; vol 5, #14 Publication LA4-T.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/48\">",
"      Reed W, Lane PA, Lorey F, et al. Sickle-cell disease not identified by newborn screening because of prior transfusion. J Pediatr 2000; 136:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/49\">",
"      Jinks DC, Minter M, Tarver DA, et al. Molecular genetic diagnosis of sickle cell disease using dried blood specimens on blotters used for newborn screening. Hum Genet 1989; 81:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/50\">",
"      Peters M, Fijnvandraat K, van den Tweel XW, et al. One-third of the new paediatric patients with sickle cell disease in The Netherlands are immigrants and do not benefit from neonatal screening. Arch Dis Child 2010; 95:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/51\">",
"      Ryan K, Bain BJ, Worthington D, et al. Significant haemoglobinopathies: guidelines for screening and diagnosis. Br J Haematol 2010; 149:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/52\">",
"      Bhardwaj U, Zhang YH, Jackson DS, et al. DNA diagnosis confirms hemoglobin deletion in newborn screen follow-up. J Pediatr 2003; 142:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/53\">",
"      Dover GJ, Boyer SH, Charache S, Heintzelman K. Individual variation in the production and survival of F cells in sickle-cell disease. N Engl J Med 1978; 299:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/54\">",
"      Nagel RL, Ranney HM. Genetic epidemiology of structural mutations of the beta-globin gene. Semin Hematol 1990; 27:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/55\">",
"      Oner C, Dimovski AJ, Altay C, et al. Sequence variations in the 5' hypersensitive site-2 of the locus control region of beta S chromosomes are associated with different levels of fetal globin in hemoglobin S homozygotes. Blood 1992; 79:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/56\">",
"      Diop S, Thiam D, Cisse M, et al. New results in clinical severity of homozygous sickle cell anemia, in Dakar, Senegal. Hematol Cell Ther 1999; 41:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/57\">",
"      West MS, Wethers D, Smith J, Steinberg M. Laboratory profile of sickle cell disease: a cross-sectional analysis. The Cooperative Study of Sickle Cell Disease. J Clin Epidemiol 1992; 45:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/58\">",
"      Bunn HF. Subunit assembly of hemoglobin: an important determinant of hematologic phenotype. Blood 1987; 69:1.",
"     </a>",
"    </li>",
"    <li>",
"     Bunn, HF, Forget, BG. Hemoglobin: Molecular, Genetic and Clinical Aspects, WB Saunders, Philadelphia 1986.",
"    </li>",
"    <li>",
"     Bain BJ. Haemoglobinopathy Diagnosis, 2nd ed, Blackwell, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/61\">",
"      Rahimy MC, Gangbo A, Ahouignan G, et al. Effect of a comprehensive clinical care program on disease course in severely ill children with sickle cell anemia in a sub-Saharan African setting. Blood 2003; 102:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/62\">",
"      Okpala I, Thomas V, Westerdale N, et al. The comprehensiveness care of sickle cell disease. Eur J Haematol 2002; 68:157.",
"     </a>",
"    </li>",
"    <li>",
"     Lane PA. Sickle cell disease in children and adolescents: Diagnosis, guidelines for comprehensive care, and care paths and protocols for management of acute and chronic complications. The Sickle Cell Disease Core Consortium, by permission, 2003.",
"    </li>",
"    <li>",
"     The management of sickle cell disease, 4th ed. National Heart, Lung, and Blood Institute. National Institutes of Health, NIH Publication No. 02-2117, June 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42856/abstract/65\">",
"      Steinberg MH. Management of sickle cell disease. N Engl J Med 1999; 340:1021.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7113 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-0970125B04-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_54_42856=[""].join("\n");
var outline_f41_54_42856=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17004686\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF DIAGNOSTIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRENATAL TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NEWBORN SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Types of screening programs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Methodology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hemoglobin patterns",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - FS pattern",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - FAS and FSA patterns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      OLDER CHILDREN AND ADULTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Methodology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2374771\">",
"      - Hemoglobin A2 measurement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5964937\">",
"      - High levels of fetal hemoglobin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Findings in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Diagnostic patterns in other sickle cell syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      COMPREHENSIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Available guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17004686\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17004794\">",
"      Findings during the newborn period",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5964967\">",
"      - Exceptions to the expected hemoglobin patterns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17004860\">",
"      Findings in children and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7113\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7113|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?8/51/9023\" title=\"diagnostic image 1\">",
"      Hemoglobin electrophoresis at alkaline pH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7113|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/42/1703\" title=\"picture 1\">",
"      Sickle cell anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/45/39638\" title=\"picture 2\">",
"      Howell-Jolly bodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/19/43318\" title=\"picture 3\">",
"      Hemoglobin SC disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7113|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/51/11069\" title=\"table 1\">",
"      Sickle cell diagnostic test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/56/18316\" title=\"table 2\">",
"      Hgb electrophoresis patterns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/17/16667\" title=\"table 3\">",
"      Sickle trait alpha thalassemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/63/14334\" title=\"table 4\">",
"      Sickle cell full evaluation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39434?source=related_link\">",
"      Clinical variability in sickle cell anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11768?source=related_link\">",
"      Fetal blood sampling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/37/16984?source=related_link\">",
"      Introduction to hemoglobin mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/60/968?source=related_link\">",
"      Laboratory diagnosis of the hemoglobinopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42170?source=related_link\">",
"      Overview of the clinical manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39946?source=related_link\">",
"      Overview of the management of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/26/24999?source=related_link\">",
"      Prenatal testing for the hemoglobinopathies and thalassemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27082?source=related_link\">",
"      Pulmonary complications of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6202?source=related_link\">",
"      Renal manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/25/30104?source=related_link\">",
"      Sickle hemoglobin polymer: Structure and functional properties",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/5/5209?source=related_link\">",
"      Variant sickle cell syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_54_42857="Acute otitis media in children: Prevention of recurrence";
var content_f41_54_42857=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute otitis media in children: Prevention of recurrence",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/54/42857/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/54/42857/contributors\">",
"     Jerome O Klein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/54/42857/contributors\">",
"     Stephen Pelton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/54/42857/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/54/42857/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/54/42857/contributors\">",
"     Ellen M Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/54/42857/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/54/42857/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/54/42857/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention is an important part of the management strategy for the child with severe and recurrent acute otitis media (AOM) and the child who is at risk for severe and recurrent AOM.",
"   </p>",
"   <p>",
"    The prevention of AOM will be reviewed here. Other topics related to otitis media are presented separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29642?source=see_link\">",
"       \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/35/8760?source=see_link\">",
"       \"Acute otitis media in children: Diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/0/21514?source=see_link\">",
"       \"Acute otitis media in children: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/40/22153?source=see_link\">",
"       \"Otitis media with effusion (serous otitis media) in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/62/32743?source=see_link\">",
"       \"External otitis: Pathogenesis, clinical features, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/10/12456?source=see_link\">",
"       \"External otitis: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20216?source=see_link\">",
"       \"Malignant (necrotizing) external otitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent acute otitis media (AOM) is usually defined as &ge;3 distinct and well-documented episodes of AOM within six months or &ge;4 episodes within 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Infants who have their first episode before six months of age or who have siblings with severe and recurrent AOM are at highest risk for severe and recurrent AOM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a cohort of 698 children followed from shortly after birth until age three years, 17 percent had &ge;3 episodes of acute otitis media (AOM) by one year of age and 46 percent had &ge;3 episodes by three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/4\">",
"     4",
"    </a>",
"    ]. These data precede the introduction of pneumococcal conjugate vaccine. Current estimates suggest a reduced prevalence but definitive data are not available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     OVERVIEW OF APPROACH",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52372127\">",
"    <span class=\"h2\">",
"     Interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific interventions that may be used in the prevention of recurrent acute otitis media (AOM) include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Identification and treatment of underlying predisposing conditions (eg, exposure to tobacco smoke)",
"     </li>",
"     <li>",
"      Parental education",
"     </li>",
"     <li>",
"      Breast feeding",
"     </li>",
"     <li>",
"      Administration of influenza virus",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pneumococcal conjugate vaccines",
"     </li>",
"     <li>",
"      Antibiotic prophylaxis",
"     </li>",
"     <li>",
"      Surgery (myringotomy and placement of tympanostomy tubes)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These interventions, discussed below, are typically approached in a stepwise fashion, beginning with identification of underlying conditions, parental education and vaccine administration, and then, if indicated, chemoprophylaxis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52372134\">",
"    <span class=\"h2\">",
"     Factors influencing choice",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decisions regarding strategies for prevention of recurrent AOM are made on a case-by-case basis. Factors to be considered in the decision include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age of the child &ndash; Children younger than two years appear to receive the most benefit from antibiotic prophylaxis.",
"     </li>",
"     <li>",
"      Age at first episode &ndash; Infants who have their first episode of AOM before six months of age are at risk for severe and recurrent AOM.",
"     </li>",
"     <li>",
"      Time of year &ndash; The child who has already had several episodes of AOM by late fall (ie, November in the northern hemisphere) is likely to have many more before the end of the winter, whereas the child who has recurrent episodes by late spring (ie, May in the northern hemisphere) could have fewer additional infections during the late spring and summer.",
"     </li>",
"     <li>",
"      Attendance in large-group day care &ndash; Children in this setting are likely to have more respiratory infections, some of which will be accompanied by AOM.",
"     </li>",
"     <li>",
"      Family history &ndash; The risk of AOM is increased in children whose other family members have AOM.",
"     </li>",
"     <li>",
"      The developmental status of the child, particularly language development.",
"     </li>",
"     <li>",
"      Underlying medical conditions that predispose to AOM (eg, cleft palate, immotile cilia syndrome, IgG deficiency).",
"     </li>",
"     <li>",
"      The effects of recurrent AOM on the quality of life for the child and family.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77986258\">",
"    <span class=\"h2\">",
"     Choice of intervention(s)",
"    </span>",
"    &nbsp;&mdash;&nbsp;When all factors are considered, the balance of risks and benefits will favor less aggressive interventions for some children and more aggressive interventions for others.",
"   </p>",
"   <p>",
"    Less aggressive interventions (including no intervention) may be warranted for children older than two years because the incidence of AOM declines after the second year of life. Less aggressive interventions include treatment of predisposing conditions, education, and provision of pneumococcal and influenza vaccines. (See",
"    <a class=\"local\" href=\"#H54646609\">",
"     'Treatment of predisposing conditions'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H6\">",
"     'Education'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H7\">",
"     'Vaccines'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We suggest more aggressive interventions (eg, antibiotic prophylaxis or tympanostomy tube placement) for children with recurrent otitis media and one or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age &lt;2 years (when optimal hearing is necessary for acquisition of language skills)",
"     </li>",
"     <li>",
"      Multiple risk factors, especially if the risk factor cannot be modified (eg, time of year, size of day care) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29642?source=see_link&amp;anchor=H4#H4\">",
"       \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\", section on 'Risk factors'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Underlying medical conditions that predispose to recurrent AOM",
"     </li>",
"     <li>",
"      Co-morbid conditions associated with developmental or language delays (the conductive hearing loss associated with middle ear effusion may persist for weeks to months after the acute signs of AOM have resolved and may add additional burden in children with existing delays or deficits)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the ultimate decision about whether to use a more aggressive intervention and which intervention to use is made on a case-by-case basis after discussion of the potential benefits and risks with the caregivers.",
"   </p>",
"   <p>",
"    The choice of antibiotic prophylaxis or tympanostomy tube placement is influenced by the level of concern about antibiotic-resistant bacteria in the nasopharynx, language development, the risks of surgery and anesthesia, and the values and preferences of the family. For children who have had frequent breakthrough episodes of AOM while receiving antibiotic prophylaxis and continue to warrant more aggressive prevention strategies, we suggest tympanostomy tube placement. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Antibiotic prophylaxis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H21\">",
"     'Tympanostomy tubes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The 2013 American Academy of Pediatrics (AAP) and American Academy of Family Physicians (AAFP) clinical practice guideline for the diagnosis and management of acute otitis media in children 6 months through 12 years of age recommends that clinicians not prescribe prophylactic antibiotics, but &ldquo;may offer&rdquo; tympanostomy tubes to prevent recurrent AOM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/7\">",
"     7",
"    </a>",
"    ]. The 2013",
"    <span class=\"nowrap\">",
"     AAP/AAFP",
"    </span>",
"    guideline does not apply to children with underlying conditions that may alter the natural course of AOM (eg, anatomic abnormalities, genetic conditions with craniofacial abnormalities, immune deficiencies, or cochlear implants), whereas this topic review does not make such exclusions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54646609\">",
"    <span class=\"h1\">",
"     TREATMENT OF PREDISPOSING CONDITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in the prevention of recurrent acute otitis media (AOM) is identification, and treatment if warranted, of underlying conditions that predispose the child to recurrent AOM. Such conditions include immune deficiencies",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anatomic abnormalities.",
"   </p>",
"   <p>",
"    Children who have had suppurative infections at multiple sites, including recurrent AOM, may have immunologic deficiencies. The most commonly identified immune abnormality in children with recurrent AOM is an IgG subclass deficiency. Children with recurrent AOM as their only manifestation of recurrent infection rarely have severe immunologic abnormalities. However, hypogammaglobulinemia, granulocyte defects, defective cell-mediated immunity, or HIV infection may present with recurrent AOM as part of the spectrum of either increased infections or infections that resolve more slowly than expected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30458?source=see_link\">",
"     \"Approach to the child with recurrent infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/60/13258?source=see_link&amp;anchor=H5#H5\">",
"     \"IgG subclass deficiency\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/48/24326?source=see_link&amp;anchor=H2#H2\">",
"     \"Primary humoral immune deficiencies: An overview\", section on 'Presentation of humoral immune deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with palatal clefts also are predisposed to the development of recurrent AOM. This includes children with craniofacial abnormalities that are associated with submucous palatal clefts, such as micrognathia and glossoptosis (seen in Robin sequence and similar syndromes). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/59/1977?source=see_link&amp;anchor=H3#H3\">",
"     \"Congenital anomalies of the jaw, mouth, oral cavity, and pharynx\", section on 'Jaw anomalies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EDUCATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Educating parents about ways to decrease exposure to risk factors and increase exposure to protective factors is an appropriate prevention strategy for all children with recurrent acute otitis media (AOM) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/7\">",
"     7",
"    </a>",
"    ]. Although the effectiveness of parental education in preventing recurrent AOM has not been proven, there is little risk of harm. The risk factors for AOM are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29642?source=see_link&amp;anchor=H4#H4\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specific",
"    <span class=\"nowrap\">",
"     risk/protective",
"    </span>",
"    factors to be discussed include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Day care &ndash; The fewer children in the day care group, the lower the exposure to respiratory pathogens and risk for AOM.",
"     </li>",
"     <li>",
"      Exposure to smoke &ndash; Children exposed to cigarette smoke in the home have more episodes of AOM than children in smoke-free homes; methods of home heating, such as wood or coal burning stoves, also may be a risk factor.",
"     </li>",
"     <li>",
"      Breastfeeding &ndash; Breastfeeding for at least three months protects against AOM during the first year of life. Although this knowledge may not prevent recurrent AOM in the index case, when family history suggests an increased risk of recurrent AOM, breastfeeding may help prevent recurrent AOM in subsequent children.",
"     </li>",
"     <li>",
"      Pacifiers &ndash; The use of pacifiers after six months of age increases the risk of recurrent AOM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     VACCINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The routine administration of pneumococcal conjugate vaccine and influenza vaccine during infancy provides only a modest reduction in the frequency of acute otitis media (AOM), but appears to decrease the need for placement of tympanostomy tubes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pneumococcal conjugate vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that infants and children be immunized with the 13-valent pneumococcal conjugate vaccine (PCV13) according to the routine childhood immunization schedule at ages 2, 4, 6 and 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/7,11\">",
"     7,11",
"    </a>",
"    ]. Although AOM is not specifically identified as \"an underlying medical condition\" requiring the supplemental dose of PCV13 through 71 months of age, we also suggest PCV13 for children younger than six years who continue to have recurrent episodes of AOM and have not previously received PCV13. The &ldquo;catch-up&rdquo; dose of PCV13 should be administered as soon as possible (provided that at least 8 weeks have passed since the last dose of PCV7). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7402?source=see_link&amp;anchor=H19#H19\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\", section on 'Supplemental dose'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In randomized trials, administration of the 7-valent pneumococcal conjugate vaccine (PCV7) beginning at age two months was associated with a modest reduction in AOM (6 to 8 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. However, the efficacy of prevention of culture-confirmed pneumococcal AOM caused by a vaccine serotype was 57 to 65 percent. In these and other randomized and observational studies, receipt of PCV7 was associated with fewer medical visits for AOM and fewer tympanostomy tube placements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/12,13,15-19\">",
"     12,13,15-19",
"    </a>",
"    ]. Several studies have noted an increase in AOM caused by pneumococcal serotypes not included in the vaccine (ie, &ldquo;replacement&rdquo; serotypes) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/12,20,21\">",
"     12,20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is assumed that the additional serotypes (particularly serotype 19A) in PCV13 will provide additional protection against AOM and recurrent AOM (",
"    <a class=\"graphic graphic_table graphicRef77274 \" href=\"mobipreview.htm?14/59/15293\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/22\">",
"     22",
"    </a>",
"    ]. However, continued monitoring is necessary to characterize the efficacy for prevention of vaccine serotype AOM and monitor for &ldquo;replacement&rdquo; serotypes.",
"   </p>",
"   <p>",
"    In countries where the pneumococcal conjugate vaccine is not part of the routine immunization schedule, we suggest pneumococcal conjugate vaccine for infants and young children at high-risk for recurrent AOM (ie, first episode of AOM at &lt;6 months of age, older siblings with severe and recurrent AOM). In a randomized trial, 96 infants with AOM onset at &lt;6 months of age were assigned to receive or not receive PCV7 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/23\">",
"     23",
"    </a>",
"    ]. Receipt of PCV7 was associated with a 26 percent reduction in AOM, a 36 percent reduction in emergency visits for suspected AOM, and a 50 percent reduction in placement of ventilation tubes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pneumococcal polysaccharide vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children older than two years who continue to have recurrent episodes of AOM, we suggest administration of the 23-valent pneumococcal polysaccharide (PPSV23) after completion of immunization with PCV13 to provide coverage for as broad a range of pneumococcal serotypes as possible (",
"    <a class=\"graphic graphic_table graphicRef77274 \" href=\"mobipreview.htm?14/59/15293\">",
"     table 1",
"    </a>",
"    ). PPSV23 should be administered at least 8 weeks after PCV13 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review of randomized controlled trials evaluating pneumococcal vaccination for AOM in children younger than 12 years found a moderate effect of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?4/12/4294?source=see_link\">",
"     pneumococcal polysaccharide vaccine",
"    </a>",
"    in the prevention of AOM in children older than 24 months who had documented AOM before vaccination (relative risk 0.74, 95% CI 0.62 to 0.90) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/24\">",
"     24",
"    </a>",
"    ]. No overall reduction in AOM is observed when immunization is initiated after the development of recurrent otitis media [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/24-27\">",
"     24-27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Influenza vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, annual influenza immunization is recommended for all children &ge;6 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/28\">",
"     28",
"    </a>",
"    ]. In countries where universal influenza immunization of infants is not routine, we suggest annual influenza vaccination for children who had recurrent episodes of AOM during the preceding winter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27946?source=see_link&amp;anchor=H7#H7\">",
"     \"Seasonal influenza vaccination in children\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a meta-analysis of randomized studies, the efficacy of influenza vaccination against AOM (of any cause) in healthy children younger than 18 years was 51 percent (95% CI 21-70 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/30\">",
"     30",
"    </a>",
"    ]. It is not surprising that influenza vaccine has only a modest impact on AOM episodes, because infection with other respiratory viruses, such as respiratory syncytial virus, parainfluenzae, and human metapneumovirus, appear to have a much greater association with AOM. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29642?source=see_link&amp;anchor=H19#H19\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\", section on 'Viruses'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/21/20824?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    (IIV) may be given to children 6 to 24 months of age, whereas either IIV or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/10/14502?source=see_link\">",
"     live attenuated influenza vaccine",
"    </a>",
"    (LAIV) may be given to children &ge;24 months. For children &ge;24 months with recurrent AOM, LAIV may be more beneficial than IIV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. In pooled analysis of two randomized trials, the relative efficacy of LAIV versus IIV in preventing influenza-associated AOM was 54 percent (95% CI 27-72 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27946?source=see_link&amp;anchor=H8#H8\">",
"     \"Seasonal influenza vaccination in children\", section on 'Choice of vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ANTIBIOTIC PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylaxis with a modified dose of an antimicrobial agent can be helpful in preventing recurrent acute otitis media (AOM) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. However, the protection afforded by prophylaxis is not sustained after discontinuation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H506976221\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic prophylaxis may be warranted for children who have had &ge;3 distinct and well-documented episodes within six months or &ge;4 episodes within 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/3,36\">",
"     3,36",
"    </a>",
"    ]. However, decisions regarding the use of antibiotic prophylaxis should be made on a case-by-case basis. The potential benefits (20 to 50 percent fewer episodes) must be balanced with the risk of development of nasopharyngeal colonization with antibiotic-resistant organisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/34,37\">",
"     34,37",
"    </a>",
"    ]. Additional factors that influence the decision to use antibiotic prophylaxis are discussed above. (See",
"    <a class=\"local\" href=\"#H52372134\">",
"     'Factors influencing choice'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Potential benefits",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a meta-analysis, of 14 randomized trials (1461 children) comparing long-term antibiotics (&gt;6 weeks) with placebo or no treatment for the prevention of acute and chronic suppurative otitis media, antibiotic prophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/34\">",
"     34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduced the occurrence of any episode of AOM (37 versus 56 percent; pooled risk ratio 0.65, 95% CI 0.53-0.79); approximately five children would need to be treated to prevent one child from experiencing AOM while on treatment.",
"     </li>",
"     <li>",
"      Reduced the number of episodes of AOM while on antibiotics from 3 to 1.5 per year (incidence rate ratio 0.51, 95% CI 0.39-0.66).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The protection afforded by prophylaxis does not persist after discontinuation of chemoprophylaxis. Many children in whom antibiotic prophylaxis is discontinued will have recurrence of frequent AOM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The findings of the meta-analysis must be interpreted with caution because the studies that were included had different entry criteria, used different drugs for different durations, and observed patients for various lengths of time. Most were conducted before the era of widespread penicillin-resistant pneumococci and the recommendation for routine immunization of infants with the pneumococcal conjugate vaccine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Antibiotic prophylaxis compared with tubes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the only trial comparing antibiotic prophylaxis and tympanostomy tube placement that excluded children with otitis media with effusion (OME), antibiotic prophylaxis was more effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/2\">",
"     2",
"    </a>",
"    ]. In this trial, 264 children 7 to 35 months of age with recurrent AOM (&ge;3 episodes within six months or &ge;4 episodes within 12 months) were randomly assigned to three groups:",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/49/34583?source=see_link\">",
"     amoxicillin",
"    </a>",
"    prophylaxis, myringotomy and tympanostomy tube placement, or placebo, and followed for two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/2\">",
"     2",
"    </a>",
"    ]. The average rate of new episodes of AOM was decreased in the amoxicillin group compared with the tympanostomy and placebo groups (0.6, 1.02, and 1.08 new episodes of AOM or otorrhea per child per year, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolonged use of antibiotic prophylaxis for AOM may result in the selection of resistant bacteria in the nasopharynx and subsequent respiratory tract infection with resistant pathogens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/34,37\">",
"     34,37",
"    </a>",
"    ]. The treatment of AOM and other upper respiratory infections caused by antibiotic-resistant organisms is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/0/21514?source=see_link&amp;anchor=H10#H10\">",
"     \"Acute otitis media in children: Treatment\", section on 'Antimicrobial therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/58/42921?source=see_link&amp;anchor=H3#H3\">",
"     \"Acute bacterial rhinosinusitis in children: Microbiology and treatment\", section on 'Empiric antibiotic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54646436\">",
"    <span class=\"h2\">",
"     Antibiotic choice and regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the decision is made to use antibiotic prophylaxis, we typically use",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/49/34583?source=see_link\">",
"     amoxicillin",
"    </a>",
"    40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    orally once per day unless the child has a penicillin allergy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/46/23274?source=see_link\">",
"     \"Allergy to penicillins\"",
"    </a>",
"    .) Sulfisoxazole 50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    orally once per day is an alternative. Cephalosporins usually are not used for prophylaxis because they have a broader spectrum and are more expensive.",
"   </p>",
"   <p>",
"    Antibiotic prophylaxis should be provided during the fall, winter, and early spring months, when respiratory infections are most prevalent, but for no longer than six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/36\">",
"     36",
"    </a>",
"    ]. In a small randomized trial, administration every day was more effective than administration only during upper respiratory infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54646443\">",
"    <span class=\"h2\">",
"     Breakthrough AOM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breakthrough episodes of AOM in the child who is currently on",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/49/34583?source=see_link\">",
"     amoxicillin",
"    </a>",
"    prophylaxis increases the likelihood of a beta-lactamase producing nontypeable",
"    <em>",
"     H. influenzae",
"    </em>",
"    or a penicillin-resistant pneumococcus. Our initial choice is",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/26/34214?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    90",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day amoxicillin and 6.4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of clavulanate in two divided doses.",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/19/312?source=see_link\">",
"     Ceftriaxone",
"    </a>",
"    50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intramuscularly once per day is an alternative. A single dose of ceftriaxone may be sufficient, but often a two- or three- dose regimen is necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/0/21514?source=see_link&amp;anchor=H10#H10\">",
"     \"Acute otitis media in children: Treatment\", section on 'Antimicrobial therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54646450\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;During chemoprophylaxis, children should be examined whenever they have signs or symptoms of acute AOM. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/35/8760?source=see_link&amp;anchor=H19#H19\">",
"     \"Acute otitis media in children: Diagnosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children without signs of acute AOM should be examined approximately every two months to determine the presence and duration of middle ear effusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/6\">",
"     6",
"    </a>",
"    ]. The management of persistent middle ear effusion is discussed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Tympanostomy tubes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myringotomy with placement of tympanostomy tubes permits drainage of the middle ear fluid, aeration of the middle ear space, and return of the middle ear mucosa to normal. An abscess does not form because the tube allows drainage of accumulated middle ear fluid. Nevertheless, recurrent infection may result in a mucositis that is usually identified by systemic signs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    otorrhea. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/56/3978?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of tympanostomy tube placement and medical care of children with tympanostomy tubes\", section on 'Tube otorrhea'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36457?source=see_link&amp;anchor=H10#H10\">",
"     \"Prevention and management of tympanostomy tube otorrhea in children\", section on 'Acute tympanostomy tube otorrhea'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of tympanostomy tubes in the prevention of recurrent acute otitis media (AOM) in otherwise healthy children has increased as the popularity of chemoprophylaxis has decreased due to concerns about antibiotic resistance among otopathogens. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Adverse effects'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H506976432\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tympanostomy tube placement may be warranted for children who have had &ge;3 distinct and well-documented episodes within six months or &ge;4 episodes within 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/3,36\">",
"     3,36",
"    </a>",
"    ]. Decisions regarding the placement of tympanostomy tubes for recurrent AOM must be individualized after consideration of the risks and benefits. (See",
"    <a class=\"local\" href=\"#H52372134\">",
"     'Factors influencing choice'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We suggest tympanostomy tube placement for children who warrant more aggressive prevention strategies and:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Have had breakthrough episodes of AOM while receiving prophylaxis, or",
"     </li>",
"     <li>",
"      Have declined antibiotic prophylaxis (because of parental concerns)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Potential benefits",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of five randomized trials of tympanostomy tubes versus no surgery in children with AOM or otitis media with effusion (OME) showed a mean absolute decrease in AOM incidence of 1.0 episode per child-year (95% CI 0.4-1.6) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/41\">",
"     41",
"    </a>",
"    ]. When the analysis was limited to trials of children with recurrent AOM, the mean absolute decrease in the incidence of AOM was 1.75 episodes per child-year (95% CI -0.44-3.93).",
"   </p>",
"   <p>",
"    A subsequent systematic review [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/42\">",
"     42",
"    </a>",
"    ] that included only two trials (both of which included children with OME) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/43,44\">",
"     43,44",
"    </a>",
"    ] found that insertion of tympanostomy tubes was associated with a mean of 1.5 fewer episodes of AOM in the six months after surgery.",
"   </p>",
"   <p>",
"    In a randomized trial published after the systematic review, 300 children (10 months to 2 years of age) with recurrent AOM (&ge;3 episodes in the previous six months) were randomly assigned to tympanostomy tubes, tympanostomy tubes plus adenoidectomy, or neither [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/45\">",
"     45",
"    </a>",
"    ]. Treatment failure (defined as two episodes of AOM in two months, three episodes in six months, or effusion for longer than two months) occurred in fewer patients in the tympanostomy tube groups (21 and 16 percent in the tympanostomy tube and tympanostomy",
"    <span class=\"nowrap\">",
"     tube/adenoidectomy",
"    </span>",
"    groups, respectively, versus 34 percent in controls). More children in the tympanostomy tube groups were AOM-free during the one year of follow-up (48 and 49 percent in the tympanostomy tube and tympanostomy",
"    <span class=\"nowrap\">",
"     tube/adenoidectomy",
"    </span>",
"    groups, respectively, versus 34 percent in controls). As discussed below, the combination of adenoidectomy and tympanostomy tubes did not provide any advantage over tympanostomy tubes alone. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Adenoidectomy or adenotonsillectomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Two trials included in the first meta-analysis compared tympanostomy tube placement with chemoprophylaxis and placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/2,46\">",
"     2,46",
"    </a>",
"    ]. However, only one excluded children with OME [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/2\">",
"     2",
"    </a>",
"    ]. This study, which is described in greater detail above, found antibiotic prophylaxis with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/49/34583?source=see_link\">",
"     amoxicillin",
"    </a>",
"    to be more effective than tympanostomy tube placement or placebo. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Antibiotic prophylaxis compared with tubes'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myringotomy and placement of tympanostomy tubes are surgical procedures and parents should be informed about the potential adverse events associated with anesthesia and surgery. Complications and sequelae of tympanostomy tubes include otorrhea, persistent perforation of the tympanic membrane, tympanosclerosis, focal atrophy of the tympanic membrane, and cholesteatoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/56/3978?source=see_link&amp;anchor=H23#H23\">",
"     \"Overview of tympanostomy tube placement and medical care of children with tympanostomy tubes\", section on 'Complications and sequelae'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Adenoidectomy or adenotonsillectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the decision is made to proceed with a first set of tympanostomy tubes, concurrent adenoidectomy is indicated only for patients with moderate to severe nasal obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/22/35178?source=see_link&amp;anchor=H11#H11\">",
"     \"Tonsillectomy and adenoidectomy in children\", section on 'Nasal obstruction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adenoidectomy, with or without tonsillectomy, does not appear to be an effective primary preventive measure for children with recurrent AOM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/45,47-49\">",
"     45,47-49",
"    </a>",
"    ]. Two randomized clinical trials run in parallel failed to demonstrate a substantial effect of adenoidectomy or adenotonsillectomy on the occurrence of AOM in patients 3 to 15 years of age with recurrent otitis media and no previous history of tympanostomy tubes, whether or not they had evidence of enlarged tonsils or adenoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relative merits of adenoidectomy at the time of tympanostomy tube placement in children with recurrent AOM (more than three episodes in the past six months) or chronic otitis media with effusion were evaluated in a prospective trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/50\">",
"     50",
"    </a>",
"    ]. A total of 217 children with no previous surgery (aged 12 to 48 months) were randomly assigned to adenoidectomy with insertion of tympanostomy tubes or insertion of tympanostomy tubes alone. There was no difference in the incidence of subsequent AOM between the two groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, adenoidectomy with or without tonsillectomy may be helpful in reducing the number of episodes of AOM in children who have recurrences after an initial placement of tympanostomy tubes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/51\">",
"     51",
"    </a>",
"    ]. A retrospective study suggested that adenoidectomy or adenoidectomy plus tonsillectomy at the time of tube reinsertion substantially reduced the incidence of subsequent hospitalizations and repeat tympanostomy tube insertion in patients &ge;2 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/22/35178?source=see_link&amp;anchor=H13#H13\">",
"     \"Tonsillectomy and adenoidectomy in children\", section on 'Otitis media'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     OTHER INTERVENTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Xylitol",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not suggest the use of xylitol to prevent recurrent acute otitis media in children. Although there is some evidence to suggest that xylitol may be beneficial, additional information is necessary before it can be routinely recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/53\">",
"     53",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    Xylitol is a five-carbon sugar alcohol that is used in place of sucrose as a sweetener. It has been shown to prevent dental caries by inhibiting the growth of",
"    <em>",
"     Streptococcus mutans",
"    </em>",
"    and has been studied as a means of preventing AOM in children attending day care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/54-56\">",
"     54-56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a meta-analysis of three randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/57-59\">",
"     57-59",
"    </a>",
"    ], two to three months of xylitol chewing gum, syrup, or lozenges prevented recurrent AOM among healthy children (mean age two to five years) attending day care (risk ratio 0.75, 95% CI 0.65-0.88) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/56\">",
"     56",
"    </a>",
"    ]. In individual studies, administration of xylitol five times per day was effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/57,58\">",
"     57,58",
"    </a>",
"    ], but three times per day was not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/59\">",
"     59",
"    </a>",
"    ]. In a separate randomized trial, xylitol syrup administered only during respiratory infections did not prevent AOM among children attending day care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the results of the meta-analysis are promising, it has several limitations. The mean ages in the study populations were older than the age of peak incidence of AOM. In addition, it is not clear that the study conditions (eg, administration of xylitol five times per day) could be replicated in \"the real world\". The optimal dose, dosing regimen, long-term benefits, and full range of adverse effects must be determined before xylitol can be recommended to prevent AOM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Antiadhesive oligosaccharide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of oligosaccharides may be helpful in the prevention of infection by inhibiting the binding of bacteria to epithelial cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. In an animal study, intratracheal administration of antiadhesive oligosaccharides was effective in decreasing pneumococcal load and subsequent bacteremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/64\">",
"     64",
"    </a>",
"    ]. However, in a randomized controlled trial, nasopharyngeal administration of oligosaccharides to children for three months did not affect nasopharyngeal carriage of",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    ,",
"    <em>",
"     Haemophilus influenzae",
"    </em>",
"    , or",
"    <em>",
"     Moraxella catarrhalis",
"    </em>",
"    or prevent AOM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/65\">",
"     65",
"    </a>",
"    ]. We do not suggest the administration of oligosaccharides to prevent recurrent AOM in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Probiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another strategy for the prevention of recurrent AOM involves recolonization of the nasopharynx with bacteria that can hinder the growth of pathogenic bacteria after treatment of AOM. This strategy was evaluated in a controlled trial in which 130 children (six months to six years) with recurrent AOM were randomly assigned to 10 days of treatment with alpha-streptococcal or placebo nasal spray after a 10-day course of oral antibiotic therapy for AOM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/66\">",
"     66",
"    </a>",
"    ]. A second 10-day course of the nasal spray was administered beginning on day 60. At the three-month follow-up, a greater proportion of children in the treatment group had had no recurrences of AOM and normal-appearing tympanic membranes (42 versus 22 percent).",
"   </p>",
"   <p>",
"    We do not suggest the administration of probiotics to prevent recurrent AOM in children. Alpha-streptococcal nasal spray is not commercially available. Other probiotic preparations that are commercially available have not been proven effective in the prevention of AOM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/67,68\">",
"     67,68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H80591100\">",
"    <span class=\"h2\">",
"     Other complementary therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly one-half of families of children with recurrent AOM may try complementary, holistic, or integrative therapies (eg, herbal remedies, homeopathy, nutritional supplements, such as zinc) to prevent recurrent AOM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/69\">",
"     69",
"    </a>",
"    ]. Although some of these interventions have been evaluated in clinical trials, methodologic limitations preclude definitive conclusions about their safety or efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/54/42857/abstract/7,68,70\">",
"     7,68,70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/9/20626?source=see_link\">",
"       \"Patient information: Ear tubes (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/16/15619?source=see_link\">",
"       \"Patient information: Ear infections (otitis media) in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recurrent acute otitis media (AOM) is defined as &ge;3 distinct and well-documented episodes within six months or &ge;4 episodes within 12 months. Infants who have their first episode of AOM before six months of age or who have siblings with severe and recurrent AOM are at risk for severe and recurrent AOM. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prevention strategies include identification and treatment of underlying conditions that predispose to recurrent AOM, parental education about the risk factors for AOM, vaccine administration, chemoprophylaxis, and tympanostomy tube placement. (See",
"      <a class=\"local\" href=\"#H52372127\">",
"       'Interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Factors that influence the choice of prevention strategy include the age of the child, the age at first episode of AOM, the time of year, day care attendance, family history, cognitive and language status, underlying conditions that predispose to AOM, and the effects of recurrent AOM on the quality of life for the child and family. (See",
"      <a class=\"local\" href=\"#H52372134\">",
"       'Factors influencing choice'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of predisposing conditions and parental education are reasonable strategies for all children with recurrent AOM. (See",
"      <a class=\"local\" href=\"#H54646609\">",
"       'Treatment of predisposing conditions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Education'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend administration of the pneumococcal conjugate vaccine (PCV) and annual influenza vaccine according to the routine childhood immunization schedule (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We suggest that children with recurrent AOM who are between two and six years of age and have not received any doses of the 13-valent PCV (PCV13), receive a dose of PCV13 (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We also suggest that children older than two years of age with recurrent AOM receive a dose of the 23-valent pneumococcal conjugate vaccine at least eight weeks after PCV13 (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Vaccines'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7402?source=see_link&amp;anchor=H19#H19\">",
"       \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\", section on 'Supplemental dose'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27946?source=see_link&amp;anchor=H7#H7\">",
"       \"Seasonal influenza vaccination in children\", section on 'Indications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest antibiotic prophylaxis or tympanostomy tube placement for children who are younger than two years of age, have multiple risk factors for recurrent AOM, have underlying medical conditions that predispose to AOM, or have known or suspected developmental or language delays (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, the ultimate decision about whether to use one of these more aggressive interventions and which intervention to use is made on a case-by-case basis after discussion of the potential benefits and risks with the caregivers. (See",
"      <a class=\"local\" href=\"#H77986258\">",
"       'Choice of intervention(s)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When the decision is made to use antibiotic prophylaxis, we typically use",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/49/34583?source=see_link\">",
"       amoxicillin",
"      </a>",
"      40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      orally once per day. Sulfisoxazole 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      orally once per day is an alternative. Antibiotic prophylaxis should be provided every day during the fall, winter, and early spring months. Children receiving chemoprophylaxis should be examined approximately every two months to determine the presence and duration of middle ear effusion. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Antibiotic prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tympanostomy tube placement is an alternative to antibiotic prophylaxis for children who warrant more aggressive prevention strategies and an option for those who have had breakthrough episodes of AOM while receiving antibiotic prophylaxis. (See",
"      <a class=\"local\" href=\"#H77986258\">",
"       'Choice of intervention(s)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Tympanostomy tubes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adenoidectomy is not an effective primary preventive measure for children with recurrent AOM but may be beneficial in those who continue to have recurrent AOM after extrusion of tubes and are undergoing repeat tympanostomy tube placement. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Adenoidectomy or adenotonsillectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not suggest xylitol, antiadhesive oligosaccharide, or probiotics for the prevention of recurrent AOM in children (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Other interventions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/1\">",
"      Bluestone CD. Role of surgery for otitis media in the era of resistant bacteria. Pediatr Infect Dis J 1998; 17:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/2\">",
"      Casselbrant ML, Kaleida PH, Rockette HE, et al. Efficacy of antimicrobial prophylaxis and of tympanostomy tube insertion for prevention of recurrent acute otitis media: results of a randomized clinical trial. Pediatr Infect Dis J 1992; 11:278.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Antimicrobial prophylaxis. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK (Ed), American Adademy of Pediatrics, Elk Grove Village, IL 2012. p.871.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/4\">",
"      Teele DW, Klein JO, Rosner B. Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. J Infect Dis 1989; 160:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/5\">",
"      Giebink GS. Otitis media prevention: non-vaccine prophylaxis. Vaccine 2000; 19 Suppl 1:S129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/6\">",
"      Klein JO. Nonimmune strategies for prevention of otitis media. Pediatr Infect Dis J 2000; 19:S89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/7\">",
"      Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media. Pediatrics 2013; 131:e964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/8\">",
"      Paradise JL. Antimicrobial prophylaxis for recurrent acute otitis media. Ann Otol Rhinol Laryngol Suppl 1992; 155:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/9\">",
"      Avanzini AM, Castellazzi AM, Marconi M, et al. Children with recurrent otitis show defective IFN gamma-producing cells in adenoids. Pediatr Allergy Immunol 2008; 19:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/10\">",
"      Uhari M, M&auml;ntysaari K, Niemel&auml; M. A meta-analytic review of the risk factors for acute otitis media. Clin Infect Dis 1996; 22:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/11\">",
"      Nuorti JP, Whitney CG, Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/12\">",
"      Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/13\">",
"      Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001; 344:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/14\">",
"      Taylor S, Marchisio P, Vergison A, et al. Impact of pneumococcal conjugate vaccination on otitis media: a systematic review. Clin Infect Dis 2012; 54:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/15\">",
"      Fireman B, Black SB, Shinefield HR, et al. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J 2003; 22:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/16\">",
"      Palmu AA, Verho J, Jokinen J, et al. The seven-valent pneumococcal conjugate vaccine reduces tympanostomy tube placement in children. Pediatr Infect Dis J 2004; 23:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/17\">",
"      Grijalva CG, Poehling KA, Nuorti JP, et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics 2006; 118:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/18\">",
"      Zhou F, Shefer A, Kong Y, Nuorti JP. Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004. Pediatrics 2008; 121:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/19\">",
"      Poehling KA, Szilagyi PG, Grijalva CG, et al. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics 2007; 119:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/20\">",
"      McEllistrem MC, Adams JM, Patel K, et al. Acute otitis media due to penicillin-nonsusceptible Streptococcus pneumoniae before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 2005; 40:1738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/21\">",
"      Pelton SI, Loughlin AM, Marchant CD. Seven valent pneumococcal conjugate vaccine immunization in two Boston communities: changes in serotypes and antimicrobial susceptibility among Streptococcus pneumoniae isolates. Pediatr Infect Dis J 2004; 23:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/22\">",
"      Cohen R, Levy C, Bingen E, et al. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J 2012; 31:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/23\">",
"      Gisselsson-Sol&eacute;n M, Melhus A, Hermansson A. Pneumococcal vaccination in children at risk of developing recurrent acute otitis media - a randomized study. Acta Paediatr 2011; 100:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/24\">",
"      Straetemans M, Sanders EA, Veenhoven RH, et al. Review of randomized controlled trials on pneumococcal vaccination for prevention of otitis media. Pediatr Infect Dis J 2003; 22:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/25\">",
"      American Academy of Pediatrics. Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics 2000; 106:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/26\">",
"      Hoberman A, Marchant CD, Kaplan SL, Feldman S. Treatment of acute otitis media consensus recommendations. Clin Pediatr (Phila) 2002; 41:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/27\">",
"      Veenhoven R, Bogaert D, Uiterwaal C, et al. Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study. Lancet 2003; 361:2189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/28\">",
"      Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/29\">",
"      Pappas DE, Owen Hendley J. Otitis media. A scholarly review of the evidence. Minerva Pediatr 2003; 55:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/30\">",
"      Manzoli L, Schioppa F, Boccia A, Villari P. The efficacy of influenza vaccine for healthy children: a meta-analysis evaluating potential sources of variation in efficacy estimates including study quality. Pediatr Infect Dis J 2007; 26:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/31\">",
"      Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007; 356:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/32\">",
"      Block SL, Heikkinen T, Toback SL, et al. The efficacy of live attenuated influenza vaccine against influenza-associated acute otitis media in children. Pediatr Infect Dis J 2011; 30:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/33\">",
"      Williams RL, Chalmers TC, Stange KC, et al. Use of antibiotics in preventing recurrent acute otitis media and in treating otitis media with effusion. A meta-analytic attempt to resolve the brouhaha. JAMA 1993; 270:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/34\">",
"      Leach AJ, Morris PS. Antibiotics for the prevention of acute and chronic suppurative otitis media in children. Cochrane Database Syst Rev 2011; :CD00401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/35\">",
"      Teele DW, Klein JO, Word BM, et al. Antimicrobial prophylaxis for infants at risk for recurrent acute otitis media. Vaccine 2000; 19 Suppl 1:S140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/36\">",
"      Dowell SF, Marcy SM, Phillips WR, et al. Otitis media--principles of judicious use of antimicrobial agents. Pediatrics 1998; 101 Suppl 1:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/37\">",
"      Brook I, Gober AE. Prophylaxis with amoxicillin or sulfisoxazole for otitis media: effect on the recovery of penicillin-resistant bacteria from children. Clin Infect Dis 1996; 22:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/38\">",
"      Berman S, Nuss R, Roark R, et al. Effectiveness of continuous vs. intermittent amoxicillin to prevent episodes of otitis media. Pediatr Infect Dis J 1992; 11:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/39\">",
"      Barnett ED, Teele DW, Klein JO, et al. Comparison of ceftriaxone and trimethoprim-sulfamethoxazole for acute otitis media. Greater Boston Otitis Media Study Group. Pediatrics 1997; 99:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/40\">",
"      Leibovitz E, Piglansky L, Raiz S, et al. Bacteriologic and clinical efficacy of one day vs. three day intramuscular ceftriaxone for treatment of nonresponsive acute otitis media in children. Pediatr Infect Dis J 2000; 19:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/41\">",
"      Rosenfeld RM. Surgical prevention of otitis media. Vaccine 2000; 19 Suppl 1:S134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/42\">",
"      McDonald S, Langton Hewer CD, Nunez DA. Grommets (ventilation tubes) for recurrent acute otitis media in children. Cochrane Database Syst Rev 2008; :CD004741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/43\">",
"      Gebhart DE. Tympanostomy tubes in the otitis media prone child. Laryngoscope 1981; 91:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/44\">",
"      El-Sayed Y. Treatment of recurrent acute otitis media chemoprophylaxis versus ventilation tubes. Aust J Otolaryngol 1996; 2:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/45\">",
"      Kujala T, Alho OP, Luotonen J, et al. Tympanostomy with and without adenoidectomy for the prevention of recurrences of acute otitis media: a randomized controlled trial. Pediatr Infect Dis J 2012; 31:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/46\">",
"      Gonzalez C, Arnold JE, Woody EA, et al. Prevention of recurrent acute otitis media: chemoprophylaxis versus tympanostomy tubes. Laryngoscope 1986; 96:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/47\">",
"      Paradise JL, Bluestone CD, Colborn DK, et al. Adenoidectomy and adenotonsillectomy for recurrent acute otitis media: parallel randomized clinical trials in children not previously treated with tympanostomy tubes. JAMA 1999; 282:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/48\">",
"      Koivunen P, Uhari M, Luotonen J, et al. Adenoidectomy versus chemoprophylaxis and placebo for recurrent acute otitis media in children aged under 2 years: randomised controlled trial. BMJ 2004; 328:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/49\">",
"      van den Aardweg MT, Schilder AG, Herkert E, et al. Adenoidectomy for otitis media in children. Cochrane Database Syst Rev 2010; :CD007810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/50\">",
"      Hammar&eacute;n-Malmi S, Saxen H, Tarkkanen J, Mattila PS. Adenoidectomy does not significantly reduce the incidence of otitis media in conjunction with the insertion of tympanostomy tubes in children who are younger than 4 years: a randomized trial. Pediatrics 2005; 116:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/51\">",
"      Paradise JL, Bluestone CD, Rogers KD, et al. Efficacy of adenoidectomy for recurrent otitis media in children previously treated with tympanostomy-tube placement. Results of parallel randomized and nonrandomized trials. JAMA 1990; 263:2066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/52\">",
"      Coyte PC, Croxford R, McIsaac W, et al. The role of adjuvant adenoidectomy and tonsillectomy in the outcome of the insertion of tympanostomy tubes. N Engl J Med 2001; 344:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/53\">",
"      Mitchell AA. Xylitol prophylaxis for acute otitis media: tout de suite? Pediatrics 1998; 102:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/54\">",
"      M&auml;kinen KK, Bennett CA, Hujoel PP, et al. Xylitol chewing gums and caries rates: a 40-month cohort study. J Dent Res 1995; 74:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/55\">",
"      Knuuttila ML, M&auml;kinen K. Effect of xylitol on the growth and metabolism of Streptococcus mutans. Caries Res 1975; 9:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/56\">",
"      Azarpazhooh A, Limeback H, Lawrence HP, Shah PS. Xylitol for preventing acute otitis media in children up to 12 years of age. Cochrane Database Syst Rev 2011; :CD007095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/57\">",
"      Uhari M, Kontiokari T, Niemel&auml; M. A novel use of xylitol sugar in preventing acute otitis media. Pediatrics 1998; 102:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/58\">",
"      Uhari M, Kontiokari T, Koskela M, Niemel&auml; M. Xylitol chewing gum in prevention of acute otitis media: double blind randomised trial. BMJ 1996; 313:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/59\">",
"      Hautalahti O, Renko M, Tapiainen T, et al. Failure of xylitol given three times a day for preventing acute otitis media. Pediatr Infect Dis J 2007; 26:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/60\">",
"      Tapiainen T, Luotonen L, Kontiokari T, et al. Xylitol administered only during respiratory infections failed to prevent acute otitis media. Pediatrics 2002; 109:E19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/61\">",
"      Beachey EH. Bacterial adherence: adhesin-receptor interactions mediating the attachment of bacteria to mucosal surface. J Infect Dis 1981; 143:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/62\">",
"      Zopf D, Roth S. Oligosaccharide anti-infective agents. Lancet 1996; 347:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/63\">",
"      Lingwood CA. Oligosaccharide receptors for bacteria: a view to a kill. Curr Opin Chem Biol 1998; 2:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/64\">",
"      Id&auml;np&auml;&auml;n-Heikkil&auml; I, Simon PM, Zopf D, et al. Oligosaccharides interfere with the establishment and progression of experimental pneumococcal pneumonia. J Infect Dis 1997; 176:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/65\">",
"      Ukkonen P, Varis K, Jernfors M, et al. Treatment of acute otitis media with an antiadhesive oligosaccharide: a randomised, double-blind, placebo-controlled trial. Lancet 2000; 356:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/66\">",
"      Roos K, H&aring;kansson EG, Holm S. Effect of recolonisation with \"interfering\" alpha streptococci on recurrences of acute and secretory otitis media in children: randomised placebo controlled trial. BMJ 2001; 322:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/67\">",
"      Hatakka K, Blomgren K, Pohjavuori S, et al. Treatment of acute otitis media with probiotics in otitis-prone children-a double-blind, placebo-controlled randomised study. Clin Nutr 2007; 26:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/68\">",
"      Bukutu C, Deol J, Vohra S. Complementary, holistic, and integrative medicine: therapies for acute otitis media. Pediatr Rev 2008; 29:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/69\">",
"      Marchisio P, Bianchini S, Galeone C, et al. Use of complementary and alternative medicine in children with recurrent acute otitis media in Italy. Int J Immunopathol Pharmacol 2011; 24:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/54/42857/abstract/70\">",
"      Gulani A, Sachdev HS. Zinc supplements for preventing otitis media. Cochrane Database Syst Rev 2012; 4:CD006639.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5998 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-B4DFEB0FC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_54_42857=[""].join("\n");
var outline_f41_54_42857=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      OVERVIEW OF APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52372127\">",
"      Interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52372134\">",
"      Factors influencing choice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H77986258\">",
"      Choice of intervention(s)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H54646609\">",
"      TREATMENT OF PREDISPOSING CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EDUCATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      VACCINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pneumococcal conjugate vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pneumococcal polysaccharide vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Influenza vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ANTIBIOTIC PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H506976221\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Potential benefits",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Antibiotic prophylaxis compared with tubes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H54646436\">",
"      Antibiotic choice and regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H54646443\">",
"      Breakthrough AOM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H54646450\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Tympanostomy tubes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H506976432\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Potential benefits",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Adenoidectomy or adenotonsillectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      OTHER INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Xylitol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Antiadhesive oligosaccharide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Probiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H80591100\">",
"      Other complementary therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5998\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5998|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/59/15293\" title=\"table 1\">",
"      Pneumococcal vaccines",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/58/42921?source=related_link\">",
"      Acute bacterial rhinosinusitis in children: Microbiology and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/35/8760?source=related_link\">",
"      Acute otitis media in children: Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29642?source=related_link\">",
"      Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/0/21514?source=related_link\">",
"      Acute otitis media in children: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/46/23274?source=related_link\">",
"      Allergy to penicillins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30458?source=related_link\">",
"      Approach to the child with recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/59/1977?source=related_link\">",
"      Congenital anomalies of the jaw, mouth, oral cavity, and pharynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/62/32743?source=related_link\">",
"      External otitis: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/10/12456?source=related_link\">",
"      External otitis: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/60/13258?source=related_link\">",
"      IgG subclass deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20216?source=related_link\">",
"      Malignant (necrotizing) external otitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/40/22153?source=related_link\">",
"      Otitis media with effusion (serous otitis media) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/56/3978?source=related_link\">",
"      Overview of tympanostomy tube placement and medical care of children with tympanostomy tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/16/15619?source=related_link\">",
"      Patient information: Ear infections (otitis media) in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/9/20626?source=related_link\">",
"      Patient information: Ear tubes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36457?source=related_link\">",
"      Prevention and management of tympanostomy tube otorrhea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/48/24326?source=related_link\">",
"      Primary humoral immune deficiencies: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27946?source=related_link\">",
"      Seasonal influenza vaccination in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/22/35178?source=related_link\">",
"      Tonsillectomy and adenoidectomy in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_54_42858="DEB1";
var content_f41_54_42858=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86594%7EDERM%2F86595%7EDERM%2F86596%7EDERM%2F86597%7EDERM%2F87097&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86594%7EDERM%2F86595%7EDERM%2F86596%7EDERM%2F86597%7EDERM%2F87097&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Recessive dystrophic epidermolysis bullosa (DEB)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 382px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large nonhealing erosions and ulcers in severe generalized recessive dystrophic epidermolysis bullosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Recessive dystrophic epidermolysis bullosa (DEB)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 384px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 608px\">",
"   <div class=\"ttl\">",
"    Recessive dystrophic epidermolysis bullosa (DEB)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 588px; height: 440px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large, nonhealing erosions and ulcers with partly impetiginized crusts in severe generalized recessive dystrophic EB.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Dominant dystrophic epidermolysis bullosa (DEB)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 382px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erosions, crusts, and atrophic scarring on knees in dominant dystrophic EB.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Recessive dystrophic epidermolysis bullosa (EB)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 574px; height: 381px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erosions, crusts, atrophic scarring, and milia formation in recessive dystrophic EB",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     <font color=\"black\">",
"      Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.",
"     </font>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_54_42858=[""].join("\n");
var outline_f41_54_42858=null;
var title_f41_54_42859="Pertussis CDC case definitions";
var content_f41_54_42859=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F80177&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F80177&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Centers for Disease Control and Prevention case definition for pertussis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        A clinical case is defined as a person:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Who has a cough illness lasting at least two weeks with one of the following: paroxysms of coughing, inspiratory \"whoop,\" or post-tussive vomiting, and without other apparent cause (as reported by a health professional)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        The laboratory criteria for diagnosis are:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The isolation of B. pertussis from a clinical specimen, or",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Positive polymerase chain (PCR) reaction assay for B. pertussis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        A confirmed case is defined as a person:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        With an acute cough illness of any duration who is culture positive from nasopharyngeal secretions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Who meets the clinical case definition (see text) with laboratory confirmation by PCR from nasopharyngeal secretions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Who meets the clinical case definition (see text) and is epidemiologically linked directly to a case confirmed by either culture or PCR from nasopharyngeal secretions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        A probable case is defined as a person:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Who meets the clinical case definition (see text) without laboratory confirmation or an epidemiologic link to a laboratory-confirmed case",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Centers for Disease Control and Prevention, Council of State and Territorial Epidemiologists. Pertussis-1997 Case Definition. Available at",
"     <a href=\"file://www.cdc.gov/osels/ph_surveillance/nndss/casedef/pertussis_1997.htm\" target=\"_blank\">",
"      file://www.cdc.gov/osels/ph_surveillance/nndss/casedef/pertussis_1997.htm",
"     </a>",
"     . 1997.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_54_42859=[""].join("\n");
var outline_f41_54_42859=null;
var title_f41_54_42860="Procedure table child endotracheal intubation";
var content_f41_54_42860=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F64481&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F64481&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Procedure summary: Endotracheal intubation in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Preparation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1. Preoxygenate the patient with 100 percent inspired oxygen.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Provide bag-mask ventilation as needed.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. Initiate continuous monitoring of heart rate, respiratory, pulse oximetry, and cycled noninvasive or intraarterial blood pressure.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. Assemble appropriately sized equipment*.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5. Test the laryngoscope blade light.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6. If applicable, inflate and deflate the cuff of the endotracheal tube to ensure no leak.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       7. Place a stylet in the endotracheal tube and put a slight \"hockey stick\" bend at the tip.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       8. If no concern for cervical spine trauma, position the patient in the sniffing position&bull;.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       9. Have an assistant provide manual inline stabilization for patients with concern for cervical spine trauma&Delta;.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Direct laryngoscopy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1. Open the patient's mouth using the scissor technique or, in patients without cervical spine restrictions, extending the head.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Insert the laryngoscope blade into the right side of the mouth along the base of the tongue while following the natural contour of the oropharynx.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. Sweep the tongue to the left side by advancing the laryngoscope into the midline of the hypopharynx.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. Advance the laryngoscope blade and identify the epiglottis.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       5. Visualize the glottic opening and vocal cords:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Straight blade - Position the tip of the blade under the epiglottis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Curved blade - Position the tip of the blade in the deepest portion of the vallecula",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6. Pull upward on the laryngoscope handle at a 45 degree angle to expose the glottic opening.",
"       <strong>",
"        DO NOT",
"       </strong>",
"       rock the laryngoscope handle backward as this will limit the ability to pass the endotracheal tube and typically causes injury to the upper gums, teeth, or lip.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Endotracheal tube placement",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1. While maintaining visualization of the glottic opening and vocal cords, advance the endotracheal tube horizontally from the right side of the mouth.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Once the endotracheal tube has passed approximately 1 to 2 cm through the vocal cords, remove the stylet.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. Confirm tracheal placement with capnography and clinical findings.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. Assess proper depth of insertion (eg, centimeter mark equal to 3 times the internal diameter of the endotracheal tube).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5. Secure the endotracheal tube.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6. Obtain chest radiograph to document proper endotracheal tube placement.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * See table \"Equipment sizing for pediatric endotracheal intubation\" and see table \"Age based formula for selecting endotracheal tube size (internal diameter in mm)\".",
"     <br>",
"      &bull; See figure \"Proper positioning for ventilation and intubation for children older than two years of age\".",
"      <br>",
"       &Delta; See figure \"Manual stabilization of the pediatric spine\".",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_54_42860=[""].join("\n");
var outline_f41_54_42860=null;
var title_f41_54_42861="Ventilatory threshold";
var content_f41_54_42861=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52387&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52387&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ventilatory threshold",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 356px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The ventilatory threshold is the intensity at which ventilation begins to rise in excess of VO",
"    <sub>",
"     2",
"    </sub>",
"    . It is best demonstrated by plotting VE/VO",
"    <sub>",
"     2",
"    </sub>",
"    and VE/VCO",
"    <sub>",
"     2",
"    </sub>",
"    on the same graph (as above). VE is the volume of gas expired (L/min), VO",
"    <sub>",
"     2",
"    </sub>",
"    is the volume of oxygen consumed (L/min), and VCO",
"    <sub>",
"     2",
"    </sub>",
"    is the volume of CO",
"    <sub>",
"     2",
"    </sub>",
"    produced (L/min). The ventilatory threshold is the point just before VE/VO",
"    <sub>",
"     2",
"    </sub>",
"    begins to rise without a similar rise in VE/VCO",
"    <sub>",
"     2",
"    </sub>",
"    .",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_54_42861=[""].join("\n");
var outline_f41_54_42861=null;
var title_f41_54_42862="Scrofuloderma ulcer";
var content_f41_54_42862=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F72008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F72008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scrofuloderma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 270px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A draining, ulcerated nodule is present on the flank.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of the Research Institute for Tropical Medicine, Philippines.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_54_42862=[""].join("\n");
var outline_f41_54_42862=null;
var title_f41_54_42863="Placement of endotracheal tube anterior view";
var content_f41_54_42863=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F58682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F58682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Placement of endotracheal tube anterior view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 348px; height: 472px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note that the tongue is swept to the left side by the curved blade.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_54_42863=[""].join("\n");
var outline_f41_54_42863=null;
